Heme oxygenase (HO)-1 induction prevents endoplasmic reticulum stress-mediated endothelial cell death and impaired angiogenic capacity induced by high glucose. by Maamoun, Hatem et al.
		
Heme	Oxygenase	(HO)-1	Induction	Prevents	
Endoplasmic	Reticulum	Stress-Mediated	
Endothelial	Cell	Death	and	Impaired	
Angiogenic	Capacity	Induced	by	High	Glucose	
	
PhD	thesis	
		
By	Hatem	Maamoun	
URN:	6027091	
	
	
Faculty	of	Medical	&	Health	Sciences	
School	of	Bioscience	and	Medicine	
	
2017	
Declaration of originality 
This thesis and the work to which it refers are the results of my own efforts. Any ideas, data, 
images or text resulting from the work of others (whether published or unpublished) are fully 
identified as such within the work and attributed to their originator in the text, bibliography or in 
footnotes. This thesis has not been submitted in whole or in part for any other academic degree or 
professional qualification. I agree that the University has the right to submit my work to the 
plagiarism detection service TurnitinUK for originality checks. Whether or not drafts have been 
so-assessed, the University reserves the right to require an electronic version of the final document 
(as submitted) for assessment as above.  
	
	
	
1	
	
Abstract 
Most diabetic cardiovascular complications are mediated by endothelial dysfunction 
and impaired angiogenesis. Endoplasmic Reticulum [ER] and oxidative stresses were shown 
to play a pivotal role in the development of endothelial dysfunction in diabetes. The 
cytoprotective effects of Hemeoxygenase-1 [HO-1] were extensively studied; however, its 
role in alleviating ER stress-induced endothelial dysfunction remains elusive. We aim here to 
test the role of HO-1 against high glucose-mediated ER stress response and endothelial 
dysfunction and understand the underlying mechanisms with special emphasis on oxidative 
stress, inflammation and cell death. 
Primary Human Umbilical Vein Endothelial cells [HUVECs] were harbored in 
culture medium containing high glucose (33 mM) for 5 days with 8 hrs intermittent recovery 
periods to mimic the diabetic milieu. Using a wide array of molecular biology techniques, we 
were able to show that this chronic and intermittent exposure of HUVECs to high glucose 
significantly increased mRNA and protein expression of key ER stress markers namely, 
binding immunoglobulin protein [BiP], activation transcription factor-4 [ATF-4], CCAAT-
enhancer-binding protein homologous protein [CHOP], and phosphorylated eukaryotic 
initiation factor2α [p-eIF-2α].  In addition, there was a significant elevation in ROS 
associated with significant increased phosphorylation of p47phox regulatory subunit of 
NADPH oxidase [NOX]. Moreover, inflammatory and apoptotic responses were also elicited, 
featured mainly by significant increase in phosphorylation/activation of IκB kinase [IKK] and 
c-Jun, and upregulation of IL-6, whereas apoptosis was featured by showing significantly 
increased caspase3/7 activity and  cell death. Vascular endothelial growth factor-A [VEGF-
A] expression, Nitric Oxide [NO] production, and tube formation capacity were also 
significantly inhibited by high glucose. Pre-treatment by HO-1 inducer Cobalt protoporphyrin 
IX  [CoPP] significantly abolished all the observed effects with high glucose. 
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Altogether, to the best of our knowledge we present for the first time the role of HO-1 
induction as a potential antagonist to ER stress response against high glucose mediated 
endothelial dysfunction and impaired angiogenesis.  
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1 Introduction 
Endothelial dysfunction generally refers to structural and functional impairment of 
endothelium with reduction in NO bioavailability and aberrant angiogenesis being two major 
hallmarks in such dysfunction (Creager, Luscher et al. 2003). It plays a key role in the 
pathogenesis of various cardiovascular complications associated with diabetes, whether 
affecting microvasculature including retinopathy, nephropathy, and neuropathy or 
macrovasculature including ischemic heart disease, peripheral vascular disease, and 
cerebrovascular disease (Ebrahimian, Heymes et al. 2006). 
There is a large body of scientific evidence showing that hyperglycaemia, an important 
manifestation of diabetes, is implicated in the development of this endothelial dysfunction. 
Other molecular mechanisms involved in the vascular endothelial perturbations that ensue in 
such  metabolic disorder include disruption of a huge array of metabolic pathways within the 
endothelial cell leading to endoplasmic reticulum (ER) stress, oxidative stress, inflammation 
and apoptosis (Cosentino and Luscher 1998). 
Hemeoxygenase (HO) is one of the cytoprotective proteins that could confer a beneficial 
effect on vascular endothelial cells. HO functions as a rate-limiting enzyme in heme 
degradation, yielding carbon monoxide [CO], iron, and biliverdin as the end products 
(Kikuchi, Yoshida et al. 2005) [Figure 1]. HO-1, HO-2, and HO-3 are the main isoforms of 
HO in mammals (Maines 1997; Stocker, Yamamoto et al. 1987). In particular, the role of 
HO-1 as a protective enzyme is well-known. Its antioxidant, anti-apoptotic, and anti-
inflammatory effects have been extensively studied (Poss and Tonegawa 1997; Yachie, Niida 
et al. 1999). 
The cytoprotective effects of HO-1 may have several distinct underlying mechanisms, 
including the degradation of heme to the antioxidant bilirubin, the co-ordinate induction of 
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ferritin, which chelates free iron, and release of CO, which exerts significant anti-
inflammatory and anti-apoptotic effects (Durante 2003; Hyvelin, Maurel et al. 2010). 
 
 
 
 
Figure 1. Heme oxygenase catalyzes the breakdown of heme molecules utilizing NADPH as a 
cofactor.  In this process, HO action releases iron, CO and bilirubin which are proven to have numerous 
cellular cytoprotective functions. 
 
HO-1 can be induced by numerous oxidizing agents and stimuli, including ultraviolet 
radiation, heavy metals, cytokines and heme/hemoglobin (Li, Tian et al. 2011). The 
cytoprotective effects of HO-1 are extensively studied both in vitro as well as in vivo. For 
example, HO-1-deficient mice were shown to develop severe iron deposition in the kidneys 
and liver and exhibit tissue injury, chronic inflammation and oxidative damage (Poss and 
Tonegawa 1997). At the molecular level, there is convincing evidence indicating that HO-1 
can protect the vasculature against remodeling and endothelial dysfunction (Zhang, Zhang et 
al. 2016; Durante 2011). There are several strategies that can be used to target HO-1 in the 
vasculature with the use of pharmacological inducers being one of the most promising 
approaches (Hyvelin, Maurel et al. 2010), such as heme and its synthetic analogues have been 
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shown to protect against the development of vascular disease in numerous studies both in in 
vitro and in vivo (Li, Tian et al. 2011). 
A study conducted by Yang et al., (2015) where the serum of rats exposed to cigarette smoke 
was used as an oxidative stress inducer in HUVECs, has shown a significant reduction in 
endogenous production of ROS in response to HO-1 induction by hemin. 
These cytoprotective effects of HO-1 also include anti-inflammatory actions, as Chang et al., 
(2014) have shown that the treatment of HUVECs with iodine contrast medium to cause anti-
proliferative and inflammatory reaction, induced an increase in the expression of intercellular 
adhesion molecule-1 [ICAM-1] and adhesion molecules receptor, while cells incubated with 
the HO-1 inducer were completely protected. 
Despite the numerous cytoprotective effects of HO-1 that have been well-documented in the 
literature, the role it plays in modulating the activation of ER stress response, which was 
reported to contribute to the development of endothelial dysfunction in diabetes and insulin 
resistant states, is not fully elucidated. 
The aim of this study was to examine in vitro whether HO-1 induction would alleviate ER 
stress-induced endothelial dysfunction and impaired angiogenic capacity in the context of 
high glucose conditions. As such, I hypothesized that HO-1 would prevent high glucose-
induced ER stress response and ER stress-mediated endothelial dysfunction, and improve 
endothelial angiogenic capacity. In terms of molecular mechanisms involved, in my PhD 
work I have focused on the roles of ER stress-mediated cell death and inflammation and its 
impact on the regulation of NO pathway and ROS generation. 
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1.1 Physiological role of endothelium 
Forming a vast interface between the blood and surrounding tissues, the endothelium forms a 
monolayer comprising the innermost lining of blood vessels. Advances over recent decades 
have revealed the complexity of this semi-permeable membrane and its key role in 
maintaining vascular homeostasis (Michiels 2003). While facilitating the passage of 
substances such as nutrients and leukocytes across the vessel wall, the endothelium secretes 
numerous mediators necessary for normal vascular functioning including those that regulate 
vascular tone, coagulation, modulate immune responses and control vascular cell growth 
(Pearson 2000). 
Arguably, the most significant endothelium-derived mediator is NO, which plays multiple 
roles in maintaining normal vascular homeostasis and in preventing atheroma formation 
(Davignon and Ganz 2004). Produced by the action of endothelial nitric oxide synthase 
[eNOS], NO diffuses into neighboring vascular smooth muscle cells activating guanylyl 
cyclase and producing cyclic guanosine monophosphate [cGMP] which acts by activating 
kinases responsible for vascular relaxation (Pearson 2000). Additionally, NO inhibits platelet 
aggregation, smooth muscle cell [SMC] proliferation and nuclear transcription of leukocyte-
adhesion molecules including vascular cell adhesion molecule [VCAM] and ICAM (Tronc, 
Wassef et al. 1996). Arterial wall shear stress and coupling of agonists such as acetylcholine 
and bradykinin to endothelial-bound receptors are potent stimuli for NO synthesis. Although 
these stimuli act via different intracellular mechanisms, each increases NO production via 
enhanced expression of eNOS. Other important vasodilatory factors are endothelium-derived 
hyperpolarizing factor [EDHF] and prostacyclin (PGI2), the latter also playing a role in 
platelet inhibition (Pearson 2000). 
Conversely, the endothelium is able to secrete the potent vasoconstrictor endothelin-1 [ET-1], 
which through its pro-inflammatory and mitogenic effects augments the pathogenesis of 
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cardiovascular disease. ET-1 also has been shown to instigate antagonistic effects on NO at 
different levels including direct inhibition of eNOS and reduction of NO bioavailability, 
increased ROS production via activation of NOX with the consequent scavenging of NO to 
form peroxynitrite [ONOO-], and uncoupling of eNOS due to tetrahydrobiopterin [BH4] 
blockade resulting in production of superoxide [O2-] instead of NO (Bohm and Pernow 
2007). Other endothelial-derived vasoconstrictors include prostaglandin H2 [PGH2], 
thromboxane A2 [TXA2] and ROS. Moreover, endothelial cell-bound angiotensin-converting 
enzyme [ACE] catalyzes production of the vasoconstrictive angiotensin II (Varin, Mulder et 
al. 2000). 
Furthermore, through NO production the endothelium plays a crucial role in preventing 
leukocyte adhesion; however, when ‘activated’, expression of adhesion molecules aids the 
passage of leukocytes across the vascular wall promoting a pro-inflammatory environment. 
Under these conditions, endothelial cells produce pro-inflammatory cytokines, including 
tumor necrosis factor-α [TNF-α] and IL-6 which further enhance inflammation (Sumpio, 
Riley et al. 2002). 
In addition, the endothelium plays a key role in angiogenesis initiated by tissue growth 
factors, particularly VEGF. The VEGF receptor is coupled to activation of mitogen-activated 
protein kinase [MAPK] signalling, promoting angiogenesis by increasing nuclear 
transcription of relevant genes. This mechanism is counteracted by the anti-angiogenic 
factors angiostatin and thrombospondin, which suppress angiogenesis unless required 
(Pearson 2000). 
1.2 Endothelial dysfunction and hyperglycaemia 
In normal physiological conditions, endothelial cells are exposed to circulating blood glucose 
levels in the range of 3.8–6.1 mmol/L, which are tightly regulated as part of metabolic 
homeostasis. Exposure of vascular endothelial cells to glucose levels over 11.1 mmol/L or 
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more [in vitro or in vivo, as in diabetes mellitus] is regarded as a diabetic condition in vivo 
[NICE guidelines, 2015]. However, unlike in vivo conditions, when growing cells under 
diabetic conditions, cells and cellular products undergo glycation and glyoxidation at much 
higher glucose levels than in vivo, eventually causing post-translational secondary 
modifications of therapeutic proteins that are produced in cell cultures (Clyne, Zhu et al. 
2008). Additionally, the  definition of high glucose for in vitro cultures varies considerably 
according to the cell model used. Two examples which demonstrate such variability are the 
endothelial cell line EA.hy926, and the primary endothelial cells HUVECs, where the former 
is selected in culture media containing 25 mM glucose, whereas the latter is only grown in 
culture media containing 5.5 mM glucose. Therefore, although 25 mM glucose would be 
considered a high concentration for HUVECs, it is the standard glucose concentration used 
for EA.hy926 culture medium. EA.hy926 endothelial cell line is a hybrid of immortalized 
HUVECs resulting in phenotypic changes rendering these cells more resistant to extracellular 
stresses, thus explaining why they can maintain normal proliferative capacity in higher 
glucose levels (Cade et al. 2010). The abnormally high glucose concentration perturbs cells’ 
homeostasis and biochemistry, triggering modifications both in large vessels 
[macrovasculature] and in small blood vessels, such as arterioles, venules, and capillaries 
[microvasculature]. As a consequence of high glucose concentration, their normal function is 
impaired, and ‘‘endothelial cell dysfunction” results. Endothelial cell dysfunction is 
characterized by one or more of the following features: (I) deficiency in bioavailable NO, (II) 
reduced endothelium-mediated vascular wall relaxation, (III) impaired fibrinolytic ability, 
(IV) enhanced turnover, overproduction of growth factors, increased expression of adhesion 
molecules and inflammatory genes, excessive generation of ROS, increased oxidant stress, 
and aberrant angiogenesis (Cade 2008). 
Macrovascular and microvascular complications have been shown to be mainly or partly 
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dependent on hyperglycaemia (Zoungas, Chalmers et al. 2012), that can induce vascular 
endothelial damage through different pathways: (I) enhanced polyol activity, causing sorbitol 
and fructose accumulation; (II) increased formation of advanced glycation end products 
[AGEs]; (III) activation of protein kinase C [PKC]; (IV) increased hexosamine flux pathway 
and (V) a decrease of antioxidant defenses (Brownlee 2001). 
There is considerable evidence that these biochemical pathways can be induced by excessive 
generation of ROS, ultimately leading to increased oxidative stress in a positive feedback 
loop (Son 2012). Oxidative stress occurs when the concentrations of ROS exceed those of 
antioxidant neutralizing species, such as NADPH, glutathione [GSH] and HO. ROS are a 
heterogeneous population of molecules including free radicals, such as hydroxyl  [OH− ], O2-, 
peroxyl [RO2], and hydroperoxyl [HRO2-], and non-radical species, such as hydrogen 
peroxide [H2O2] and hydrochloric acid [HCl] (Pieper, Langenstroer et al. 1997). Under 
intracellular hyperglycemic conditions, excessive production of ROS develops through 
several mechanisms the most important of which is excessive activation of mitochondrial 
electron transport chain, other sources of ROS include glucose induced activation of NOX 
and xanthine oxidase (Nishikawa, Edelstein et al. 2000). This excessive ROS production 
inflicts DNA damage resulting in Poly (ADP-ribose) polymerase [PARP] activation, which in 
turn inhibits the glycolytic enzyme glyceraldehyde 3 phosphate dehydrogenase [G3PDH] 
resulting in the accumulation of upstream glycolytic intermediates, with the resulting influx 
into polyol pathway, hexosamine pathway, diacylglycerol [DAG] and PKC pathway, and 
AGEs (Du, Matsumura et al. 2003) [Figure 2]. 
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Figure 2. Intracellular hyperglycaemia resulting in increased production of mitochondrial ROS. 
ROS cause DNA damage releasing PARP which inhibits G3PDH, this results in the accumulation of 
upstream glycolytic intermediates. Other pathways are activated as a result of the accumulation of 
glycolytic intermediates upstream of G3P which have detrimental effects on the cell, these pathways are; 
[1] Polyol pathway which depletes the cell of its antioxidant GSH system due to scavenging of NADPH, 
thereby augmenting ROS production, [2] Methylglyoxal which is a precursor to AGEs/RAGEs which 
activate pro-inflammatory and pro-oxidant molecules, [3] DAG/PKC which impairs insulin signalling and 
eNOS activity, activates pro-inflammatory and pro-oxidant molecules, [4] Hexosamine pathway with the 
resultant activation of pro-inflammatory molecules, inhibition of eNOS at the Akt activation site and 
activation of TGF-β with increase in ROS. All pathways lead to increase in ROS in a positive feedback 
loop. 
 
Glucose through the polyol pathway is converted to polyalcohol sorbitol by aldose reductase 
utilizing NADPH as cofactor, which in turn reduces intracellular concentrations of the 
NADPH resulting in the inhibition of glutathione/peroxidase antioxidant system which is 
dependent on NADPH as a cofactor, and consequently inducing overproduction of H2O2 and 
ROS. Moreover, ROS accumulation inhibits glucose-6 phosphate dehydrogenase, which is 
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the rate limiting enzyme for the pentose shunt pathway that is fundamental to reduce 
equivalents for the antioxidant system glutathione/peroxidase system, amplifying the 
oxidative stress [Figure 3]. 
 
Figure 3. Pentose phosphate pathway (PPP) is inhibited by hyperglycaemia and ROS. 
Hyperglycaemia-induced ROS cause the inhibition of G6PDH which is the rate limiting enzyme for this 
pathway. This will result in reduced NADPH production, a cofactor fundamental in the GSH/peroxidase 
antioxidant system, with the consequent build up of more ROS causing a vicious circle of oxidative stress 
induction. 
 
Furthermore, sorbitol is oxidized to fructose by sorbitol dehydrogenase using NAD as a 
cofactor, increasing the intracellular ratio of NADH/NAD+, exacerbating the inhibition of 
G3PDH which is dependent on NAD as a cofactor; thus amplifying the accumulation of 
glyceraldehyde 3 phosphate [G3P] with the consequent flux into triose phosphate pathway 
via triose phosphate isomerase [TPI] yielding dihydroxyacetone phosphate [DHAP]. Higher 
levels of triose phosphate promote the formation methylglyoxal and DAG. Methylglyoxal is a 
precursor of AGEs, which are formed by binding of methylglyoxal to the free amino groups 
of intracellular and extracellular proteins (Brownlee 2001) [Figure 4]. 
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Figure 4. Polyol and Triose phosphate pathways activation caused by hyperglycaemia-induced ROS. 
Hyperglycaemia results in excess of ROS production which inhibits G3PDH with the consequent 
accumulation of glycolytic intermediates upstream to G3P leading to increase flux into other pathways, 
namely polyol and triose phosphate. In polyol pathway, NAD reducing equivalent is consumed by sorbitol 
dehydrogenase reaction leading to reductions in NAD levels inside the cell which further confounds the 
inhibition of G3PDH. 
 
DAG activates PKC isoforms by binding to their cell surface receptors. Consequently, PKC 
activation contributes to hyperglycaemia-induced vascular endothelial damage by inhibiting 
insulin stimulated eNOS expression and NO production in endothelial cells, increasing 
nuclear factor-kappa B [NF-κB] activity and promoting the activity of the pro-oxidant 
enzyme NOX (Liu, Lei et al. 2012). 
In hyperglycaemia, AGEs bind to plasma membrane receptors of advanced glycation end-
products [RAGEs] resulting in ROS overproduction (Brownlee 2001), with the subsequent 
activation of the redox sensitive transcription factor NF-κB, which modulates the expression 
of a variety of genes associated with inflammation and atherosclerosis, including IL-6, TNF-
α, ICAM-I, VCAM-I and monocyte chemotactic protein-I [MCP-I] (Bierhaus, Schiekofer et 
al. 2001). In addition to binding to RAGEs, AGEs can bind to eNOS decreasing availability 
of NO, and reducing endothelium dependent vasodilatation resulting in endothelial 
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dysfunction (Xu, Ji et al. 2005). 
Finally, the activation of the hexosamine pathway contributes to the vascular damage induced 
by hyperglycaemia because of its capacity to interfere with various cellular functions, 
including signal transduction, transcriptional activity, cell proliferation, apoptosis, and 
proteasomal degradation (Love and Hanover 2005). In this pathway, fructose-6-phosphate is 
converted to glucosamine-6-phosphate by L-glutamine: D- fructose-6-phosphate 
amidotransferase [GFAT]. Glucosamine-6-phosphate is further metabolized to uridine 
diphosphate N-acetylglucosamine [UDP-GlcNAc] which then undergoes O-lined enzymatic 
glycosylation and post-translational modifications of several proteins such as transcription 
factors, which in turn regulate the expression of pro-inflammatory and pro-coagulant genes, 
such a plasminogen activator inhibitor-1 [PAI-I], ICAM-I, VCAM-1, implicated in the 
pathogenesis of vascular complications. The hexosamine pathway activation can also inhibit 
eNOS activity by impairing insulin-stimulated insulin receptor substrate 
[IRS]/phosphatidylinositol 3-kinase [PI3-K]/Protein Kinase B [Akt] pathway and promote 
oxidative stress increasing ROS production [Figure 5] (Rajapakse, Ming et al. 2009). 
	
	
27	
	
 
Figure 5. Hexosamine pathway activated in hyperglycaemia due to increased ROS. Hyperglycaemia 
leads to increased mitochondrial ROS which inhibits G3PDH, resulting in the accumulation of G3P. This 
will lead to the generation of glucosamine-6-P with O-linked glycosylation which enhances the 
transcription of pro-inflammatory molecules, increases ROS production and decreases NO production. 
 
In addition to hyperglycaemia-induced oxidative stress, ER stress has also been closely 
linked to various aspects of endothelial cell dysfunction in diabetic patients with decreased 
NO bioavailability and aberrant angiogenesis being two prominent features (Sheikh-Ali, 
Sultan et al. 2010). Aberrant angiogenesis may be either an excessive angiogenic response 
[e.g. retinopathy, nephropathy] or a deficiency in angiogenesis [e.g. impaired wound healing, 
impaired collateral vessel formation, neuropathy, ischemia and peripheral vascular disease] 
(Kota, Meher et al. 2012). 
The ER is an important organelle found in eukaryotic cells. Under normal physiological 
conditions, it plays a central and key role in protein synthesis and co-translational protein 
modification through the folding of newly synthesized proteins by native disulphide bond 
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formation to attain the final stable conformational state prior to being directed to their final 
destination whether it is to be secretory or membrane bound proteins. The physiological state 
of the ER is challenged when the influx of the nascent unfolded polypeptides exceeds the 
processing capacity of the ER, which is commonly referred to as ER stress (Schroder and 
Kaufman 2005). 
ER stress response develops in diabetes mellitus whether it is type 1 or 2 due to the presence 
of hyperglycaemia which increases the demand for the synthesis of enzymatic machinery 
necessary to carry out complete glucose oxidation through glycolysis, tricarboxylic acid cycle 
[TCA] and oxidative phosphorylation by mitochondrial electron transport chain (Tu and 
Weissman 2004). This increase in protein load on the ER increases the chances of 
accumulation of unfolded or misfolded proteins within the ER by the formation of incorrect 
or non-native disulphide bonds due to mispairing of cysteine residues in the protein being 
synthesized (Lisa, Domingo et al. 2012). When this occurs, it triggers the unfolded protein 
response [UPR] which aims to resolve the problem by three different mechanisms working 
synergistically together: A] The increase of gene expression of molecular chaperones to aid 
in the proper protein folding; B] The activation of ER-associated degradation machinery 
[ERAD] to get rid of the misfolded proteins which is basically a retrograde transport of 
misfolded proteins from the ER into the cytosol for ubiquitination and subsequent 
degradation; and C] The attenuation of translation rate to slow down the entry of new 
proteins to the ER lumen. 
The molecular system involved in such response includes three membrane bound proteins 
that orchestrate the whole process, namely inositol requiring enzyme 1-α [IRE1-α],  protein 
kinase RNA-like endoplasmic reticulum kinase [PERK] and activation transcription factor-6 
[ATF-6] which under basal conditions are kept in an inactive state by binding to GRP78 [or 
BiP]; however, when there is an increase of misfolded proteins, GRP78 preferentially binds 
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to them hence relieving those ER effectors from their inhibition state followed by the 
dimerization and activation of both IRE1-α and PERK, and the translocation of ATF-6 to the 
Golgi body where is activated by proteolytic cleavage before finally translocating to the 
nucleus where it acts as a transcription factor. The UPR is a physiological pro-survival 
process which attempts to restore normal homeostatic state of the ER within the cell; 
however, if the stress condition remains unresolved, these three effectors involved in the UPR 
can also activate several inflammatory responses and eventually can lead to cell death 
through the activation of several pro-apoptotic sub-pathways (Gardner and Walter 2011) 
[Figure 6]. 
IRE1-α is a transmembrane protein with N-terminal luminal domain and a C-terminus 
cytosolic domain that features protein kinase and endo-ribonuclease activities. When GRP78 
dissociates freeing it up from its inhibition, it undergoes oligomerization resulting in auto 
phosphorylation and subsequent stimulation of its endo-riboneuclease activity which splices 
an intron in the mRNA sequence of the X-box Binding Protein -1 [XBP-1], which then allows 
the translation of the an active splice variant of XBP-1 protein. XBP-1 binds to the promoter 
regions of several genes involved in the synthesis of chemical chaperones and ERAD 
proteins to restore normal protein homeostasis as part of the UPR response (Hassler, Cao et 
al. 2012). When the UPR fails to resolve the situation of stress, this same enzyme IRE1-α 
triggers an apoptotic signalling cascade by recruiting TNF-α receptor associated factor-2 
[TRAF-2] and apoptosis signalling kinase-1 [ASK-1] leading to the phosphorylation and thus 
activation of inflammatory pathways p38-Mitogen Activated Protein Kinase [p38 MAPK] 
and c-Jun N-terminal Kinase [JNK] (Ron and Hubbard 2008). Activated JNK translocates 
then to the mitochondrial membrane and catalyzes the phosphorylation of the anti-apoptotic 
protein Bcl-2 and the pro-apoptotic protein Bim with subsequent inhibition and activation, 
respectively, resulting in the activation of apoptosis (Lei and Davis 2003). While p38 MAPK 
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phosphorylates and activates CHOP which alters gene expression to favor apoptosis by the 
induction of Bim and suppression of Bcl-2 which will eventually lead to the activation of 
caspases and apoptosis (Puthalakath, O'Reilly et al. 2007). 
PERK is the second protein in the UPR. It phosphorylates eIF-2α, which is essential factor 
for the initiation step of protein synthesis, consequently causing the inhibition of protein 
synthesis therefore preventing more protein influx into the ER lumen. PERK also 
phosphorylates nuclear erythroid related factor-2 [NrF-2] leading to its dissociation from 
NrF-2-Keap-1 [Kelch-like ECH-associated protein-1] complex where Keap-1 protein acts as 
an inhibitor of NrF-2,  the free NrF-2 will then enhance the expression of genes with 
antioxidant response elements [ARE] promotor regions such as HO-1 enzyme as a 
mechanism to counteract oxidative stress which is concomitantly enhanced with ER stress. If 
the UPR fails to resolve ongoing stress, PERK will also play a significant role in inducing 
apoptosis through the phosphorylation of eIF-2α which leads to preferential and selective 
increase in translation of other UPR-dependent genes most significant of which is ATF-4, 
which causes the induction of pro-apoptotic CHOP protein expression (Cullinan and Diehl 
2004). 
Finally, the last key effector in the UPR response is the ATF-6 which dissociates from 
GRP78 due to the increase in misfolded proteins, then translocates to the Golgi body for 
further processing and cleavage by Site 1 protease [S1P], a serine protease, and site 2 
protease [S2P], a metalloprotease that cleaves the N-terminal cytosolic domain. Cleaved 
ATF-6 translocates then to the nucleus where it induces the expression of many ER stress 
response genes especially molecular chaperones such as GRP78 and GRP94 to further assist 
in the proper protein folding. If the cell finally decides to go into a suicidal mode due to 
failure of UPR to resolve the stess condition, ATF-6 also plays a significant role as it also 
induces CHOP protein expression (Bailey and O'Hare 2007). It is noteworthy that the exact 
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time point at which the cell switches from pro-survival mode to pro-apoptotic mode remains 
elusive. 
 
 
Figure 6. UPR response activation. ER membrane-bound proteins, PERK, ATF-6 and IRE1-α, are 
activated when unfolded proteins accumulate within the ER lumen and GRP78/BiP dissociates form them. 
Downstream effects of PERK involve the phosphorylation of eIF-2α resulting in the attenuation of 
translation of proteins with the preferential increase in ATF-4 expression. ATF-6 translocates to the Golgi 
body where it undergoes cleavage. Active cleaved ATF-6 translocates then to the nucleus and stimulate the 
expression of molecular chaperones to aid in the folding process. Finally, active IRE1-α through its 
endoribonuclease activity undergoes intron splicing of XBP-1 mRNA to synthesize the active XBP-1 
which binds to the promoter regions of several genes involved in the synthesis of chemical chaperones and 
ERAD proteins to restore normal protein homeostasis as part of the UPR rescue response. 
 
Previous studies have demonstrated the role of ER stress response in the endothelial cell 
inflammatory response and apoptosis in diabetic vascular diseases. Recent work by Chenet 
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al., (2012) demonstrated that activation of signal transducer and activator of transcription 3 
[STAT3], which is mediated by ER stress molecule ATF-4, is responsible for inflammation, 
vascular endothelial damage and loss of angiogenic capacity in the streptozotocin [STZ]-
induced model of type I diabetes in mice. Conversely, ATF-4 knockout ameliorated these 
effects. Interestingly, complementary in vitro studies also showed that the inhibition of 
STAT3 attenuated ER stress activation in response to high glucose, suggesting a reciprocal 
regulation of the ER stress and inflammatory pathways. Moreover, another study on diabetic 
cardiovascular complications in STZ-induced mouse model of diabetes, demonstrated that the 
activation of the epidermal growth factor receptor tyrosine kinase [EGFR] contributed to ER 
stress induction and microvascular dysfunction, impaired angiogenesis as well as cardiac 
fibrosis, in this model. Specifically, elevated EGFR phosphorylation was responsible for the 
activation of the PERK/eIF-2α/ATF-4 axis of ER stress response. Blockade of EGFR’s 
kinase activity with a pharmacological inhibitor improved endothelium-dependent relaxation 
and increased NO production (Galan, Kassan et al. 2012). 
The role of ER stress in ischemia-induced neovascularization in type 2 diabetic dyslipidemic 
db/db mice demonstrated that the ER stress inhibitor tauroursodeoxycholic acid [TUDCA], as 
well as 4-phenylbutyrate [PBA] had similar beneficial effects on hind-limb ischemia after 
femoral artery ligation. Both inhibitors reduced ATF-4 and CHOP expression levels, 
improved blood flow recovery, and upregulated the expression of pro-angiogenic factors 
(Amin, Choi et al. 2012). 
Interestingly, there is also growing evidence that the ER stress and UPR pathways might play 
an important role in promoting angiogenesis, and therefore may act as novel mediators of the 
angiogenic process. This evidence implicates these pathways in the upregulation of 
angiogenic factors such as VEGF-A, FGF, IL-8, and ET-1 (Paridaens, Laukens et al. 2014). 
Notably, it was shown that ER stress-mediated upregulation of VEGF-A was dependent on 
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the IRE1-α/XBP-1, PERK/ATF-4, as well as ATF-6 arms of ER stress response.  The up-
regulation of VEGF-A expression by the UPR mediators was also observed during diabetic 
nephropathies and retinopathies, suggesting the involvement of the UPR and ER stress 
responses in the enhancement of angiogenesis beyond the physiological conditions (Ghosh, 
Lipson et al. 2010). However, the exact molecular mechanisms involved in the switch 
between pro- and anti-angiogenic stimulation by ER stress response are not fully elucidated. 
ER stress also plays an important role in the development of atherosclerosis in diabetes, 
another major feature of endothelial dysfunction. Several independent risk factors for 
cardiovascular diseases, including hyperglycaemia (Werstuck, Khan et al. 2006), hyper-
homocysteinemia (Werstuck, Lentz et al. 2001), obesity (Ozcan, Cao et al. 2004), and 
dyslipidemia have been associated with ER stress response, suggesting that this pathway may 
represent a common or unifying mechanism of accelerated atherogenesis (Cunha, Hekerman 
et al. 2008). The activation of the UPR response has been noted at all stages of 
atherosclerotic development, from a fatty streak to an advanced occlusive plaque (Zhou, 
Lhotak et al. 2005). ER stress-inducing agents promote lipid accumulation by activating the 
sterol regulatory element binding proteins, which are transcription factors that control lipid 
biosynthesis and uptake in endothelial cells (Colgan, Tang et al. 2007). ER-stress-inducing 
agents also activate NF-κB, the transcription factor responsible for promoting inflammatory 
and pro-coagulant gene expression exacerbating thus the atherogenic process (Jiang, Wek et 
al. 2003). Moreover, ER stress effector IRE1-α causes the activation of JNK which impairs 
insulin signalling reducing thus insulin-stimulated eNOS activity with subsequent reduction 
of NO production (Andreozzi, Laratta et al. 2007). ER stress has also been shown in vivo and 
in vitro to activate caspases and promote apoptosis of human aortic endothelial cells and 
other vascular endothelial cell types (Xu, Bailly-Maitre et al. 2005). Furthermore, there is 
evidence suggesting a crosstalk between ER stress and oxidative stress. The maintenance of 
	
	
34	
	
ER homeostasis is intimately intertwined with the cellular redox potential. In contrast to the 
cytosol, the ER lumen is an oxidizing environment with a high ratio of oxidized to reduced 
glutathione [GSSG/GSH] that allows proper native disulfide bond formation (van der Vlies, 
Makkinje et al. 2003). During the process of disulfide bond-dependent protein folding, the 
proteins are oxidized to form disulfide bonds by protein disulfide isomerase which allows 
proper polypeptide rearrangement to reach their final native conformational state. Any 
mispairing of cysteine residues would result in the formation of non-native disulfide bonds 
which prevents proteins from attaining their native conformation and leads to misfolding, a 
condition which results when there is an abnormally high demand for protein synthesis as in 
the case of hyperglycaemia. In addition, hyperglycaemia-induced AGEs accumulation as well 
as hexosamine and polyol pathways activation can impair the correct protein folding, leading 
to the activation of UPR and ER stress responses  (Chakravarthi and Bulleid 2004). 
In normal conditions, during protein folding, electrons are transferred from targeted cysteine 
residues in the protein chain being synthesized forming native disulfide bonds to bring the 
protein structure to it final conformational state. This reaction is catalyzed by two crucial 
enzymes namely protein disulfide isomerase (PDI)  and ER oxidoreductase 1(ERO-1) aiding 
in this electron transfer chain from the target cysteine residues to molecular oxygen 
generating H2O2; however, in the presence of heavy protein load, as observed in 
hyperglycaemia, there is an increase in non-native disulfide bonds formation which results in 
GSH consumption as a protective mechanism. This results in GSH depletion contributing 
thus to excessive ROS generation and consequent development of oxidative stress (van der 
Vlies, Makkinje et al. 2003) [Figure 7]. 
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Figure 7.  Schematic representation showing ER protein folding as a source of ROS. During ER stress 
response; there is accumulation of misfolded proteins within the ER where non-native disulphide bonds 
form resulting in the depletion of GSH that is trying to correct the aberrant bonds. 
 
Moreover, hyperglycaemia-induced oxidative stress is suggested to contribute to the 
inactivation of disulfide isomerases resulting in the accumulation of unfolded proteins in 
addition to the misfolded ones (Tu and Weissman 2004). Since protein-folding is a highly 
energy-dependent process, protein misfolding-induced ATP depletion leads to more glucose 
consumption to promote mitochondrial oxidative phosphorylation to increase ATP synthesis 
and consequently increasing ROS production to pathological levels (Gutiérrez and Simmen 
2017). As a result of unfolded/misfolded protein accumulation, Ca2+ leak ensues from the ER 
lumen into the cytosol, and increased cytosolic Ca2+ levels further stimulates mitochondrial 
ROS production. In fact, Ca2+ increases the permeability of inner mitochondrial membrane 
and blocks the respiratory chain at complex III level, thereby causing electron leak to 
molecular O2, thus exacerbating the ongoing ROS production (Gorlach, Klappa et al. 2006) 
[Figure 8]. 
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Figure 8. Hyperglycaemia-induced ROS, can promote the accumulation of unfolded proteins within 
the ER, thus contributing to ER stress response through different mechanisms. ER dysfunction 
causes GSH depletion, Ca2+ leak from the ER lumen into the cytosol and into the mitochondria, and ATP 
depletion that can impair its structural and functional integrity and stimulate mitochondrial ROS 
production. ROS, in turn, can alter protein folding, thereby inducing unfolded protein accumulation within 
the ER. 
 
Taken together, there is substantial evidence that both ER stress and oxidative stress are 
concomitantly induced in hyperglycemic milieu and they play an important role in the 
perturbations that ensue in the vascular endothelium leading to the development of 
endothelial dysfunction in diabetes. 
1.3 Molecular Mechanisms involved in endothelial dysfunction 
1.3.1 ER stress-induced apoptosis 
 
If the various UPR-induced mechanisms fail to alleviate ER stress response, both the intrinsic 
and extrinsic pathways for apoptosis will be activated. Several key cellular mechanisms 
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involved in cell death response can be triggered by ER stress: (I) PERK/eIF-2α-dependent 
induction of the pro-apoptotic transcriptional factor CHOP; (II) IRE1-α-mediated activation 
of TRAF2, which stimulates the ASK1/ JNK cascade, and (III) Bax/Bcl2-regulated Ca2+ 
release from the ER. CHOP plays a convergent role in the UPR and it has been identified as 
an important mediator of ER stress-induced apoptosis (Oyadomari, Koizumi et al. 2002). 
Apoptosis-relevant targets of the CHOP transcription factor include (a) Growth arrest death 
domain 34[ GADD34]; (b) DR5 [TRAIL Receptor-2], a caspase-activating cell-surface death 
receptor of the tumor necrosis factor receptor family; and (c) Ero1, which hyperoxidizes the 
ER, thus exacerbating the stress condition to an unresolvable state promoting cell death. 
Ero1α can also activate the inositol triphosphate receptor [IP3R] stimulating excessive Ca2+ 
transport from the ER to the mitochondria, and thereby triggering cell death (Li, Mongillo et 
al. 2009). CHOP-mediated activation of GADD34 promotes protein de-phosphorylation of 
elF-2α reversing translational inhibition (Novoa, Zeng et al. 2001).  Release of the 
translational inhibition contributes to accumulation of unfolded proteins in the ER 
compartment and, at the same time, permits translation of mRNAs encoding pro-apoptotic 
proteins. Another possible mechanism by which CHOP induces apoptosis is via direct 
inhibition of Bcl-2 transcription (anti-apoptotic) (McCullough, Martindale et al. 2001) and 
induction of Bim expression (pro-apoptotic) (Puthalakath, O'Reilly et al. 2007), thus allowing 
for mitochondrial release of cytochrome c into the cytoplasm triggering intrinsic apoptotic 
reaction cascade. Additional ER stress-induced mechanisms contributing to cell death may 
include the activation of the kinase function of IRE1-α involving the activation of ASK, p38 
MAPK, and JNK where p38 MAPK is able to activate CHOP via the phosphorylation of its 
transactivation domain (Wang and Ron 1996). Additionally, both p38 MAPK and JNK are 
reported to promote the phosphorylation and thus activation of pro-apoptotic protein Bim and 
the inhibition of the anti-apoptotic Bcl-2 [Figure 9] (Kim, Ryu et al. 2006). 
	
	
38	
	
 
Figure 9. ER stress induced apoptotic signalling pathway. IRE1-α can recruit TRAF2 and ASK1, 
leading to downstream activation of JNK and p38 MAPK. Activated JNK translocates to the mitochondrial 
membrane and promotes [a] activation of Bim and [b] inhibition of Bcl-2, whereas p38 MAPK 
phosphorylates and activates CHOP. CHOP can induce transcriptional activation of genes that contribute 
to cell death, including Ero1α [hyperoxidizes the ER and activates IP3R]. Bax and Bak can also [a] bind to 
and activate IRE1-α and [b] induce the release of Ca2+ from the ER. PERK phosphorylates elF-2α and 
attenuates protein translation. However, translation of selected mRNAs is favored under these conditions, 
including ATF-4, which then induces the expression of CHOP and GADD34. 
 
1.3.2 ER stress induced inflammation 
 
ER stress-induced inflammation plays an important role in the stress response triggered by 
the metabolic perturbations induced in diabetes, and whether this inflammation aids in the 
attenuation of the ER stress response and or aid in its progression depends solely on the ER 
stress severity and the resistance of the UPR to be resolved. According to several studies, ER 
stress-induced UPR signalling is associated with the production of many pro-inflammatory 
molecules (Li, Schwabe et al. 2005). All three main branches of the UPR response [i.e., those 
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based on the activities of the proteins PERK, IRE1-α, and ATF-6] have been shown to 
mediate pro-inflammatory transcriptional programs with IRE1-α being the most prominent of 
the three, and are mainly mediated by transcription factors such as NF-κB  and activator 
protein-1 [AP-1] (Verfaillie, Garg et al. 2013) [Figure 10]. NF-κB, being one of the central 
mediators of pro-inflammatory pathways, it is activated by all three UPR branches via 
different mechanisms. Genes transcribed by NF-κB  include those encoding crucial pro-
inflammatory cytokines and enzymes involved in immunomodulation, such as 
cyclooxygenase-2, IL-6, IL-23 and TNF-α (Pahl 1999). Generally, NF-κB is kept in an 
inactive form within the cytoplasm by the inhibitor of NF- κB [IκB] protein, which prevents 
its activation and nuclear translocation. The classical inducers of NF-κB pathway activate 
IKK protein complex, which causes proteasome-based degradation of the IκB proteins. 
Degradation of IκB proteins releases NF-κB, allowing its nuclear translocation (Bonizzi and 
Karin 2004). The IRE1-α branch of the UPR activates NF-κB by causing IκB degradation 
(Hu, Han et al. 2006). The PERK branch of the UPR activates NF-κB by translational 
suppression of IκB through phosphorylation of eIF-2α, which frees NF-κB for nuclear 
translocation. 
AP-1 is another transcription factor that can activate an inflammatory gene program. The 
IRE1-α branch of the UPR is responsible for AP-1 activation through the TRAF2-JNK axis. 
Genes regulated by AP-1 include those encoding TNF-α, keratinocyte growth factor, 
granulocyte macrophage colony-stimulating factor, IL-8, and certain cytokine receptors 
(Angel, Szabowski et al. 2001). 
Furthermore, UPR signalling pathways can contribute to the initiation of the highly complex 
inflammatory process called acute-phase response [APR], which depends on intricate cell-to-
cell paracrine/autocrine signalling and hence is not entirely ‘cell autonomous’  (Verfaillie, 
Garg et al. 2013). In most cells including endothelial cells, the ATF-6 branch of the UPR can 
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activate events leading to APR activation (Zhang and Kaufman 2008). 
 
Figure 10. PERK activates NF-κB via translational attenuation. The activated PERK/eIF-2α arm 
causes translational arrest, which leads to decreased levels of IκB protein and a consequent increase in the 
ratio of NF-κB to IκB resulting in NF-κB activation. This is associated with a preferential increase in ATF-
4 translation and synthesis, ATF-4 induces CHOP, which in turn, causes the induction of the pro-
inflammatory cytokine IL-23. CHOP activation can also negatively regulate the inflammatory responses 
by modulating NF-κB as well as JNK leading to modulation of downstream AP-1 activity. ER stress 
effector IRE1-α, activates TRAF2. This activation complex can then activate IKK. Activated IKK then 
causes IκB degradation, thereby freeing NF-κB to transcribe the pro-inflammatory gene program. IRE1-α–
TRAF2 complex has also been shown to activate JNK protein, which consequently phosphorylates and 
activates the pro-inflammatory transcription factor AP-1. Finally, ATF-6 can induce ER stress mediated 
inflammation, where it can leave the ER and reach the Golgi complex, undergoes cleavage and activation, 
then the activated ATF-6 fragments transcribe acute APR-associated genes, such as those encoding for the 
acute-phase proteins [APPs]. 
 
1.3.3 Mitochondrial dysfunction 
 
There is a large body of evidence that suggests mitochondrial dysfunction is a major source 
for hyperglycaemia-induced oxidative stress. Overproduction of ROS by mitochondrial 
electron-transport chain is thought to be the hyperglycaemia-induced process which activates 
oxidative damage pathways as discussed above, namely the polyol, triose phosphate, 
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hexosamine and AGEs pathways (Nishikawa, Edelstein et al. 2000). 
Normally, NADH and FADH2 produced from the TCA cycle transfer from the mitochondrial 
matrix to inner mitochondrial membrane, where they serve as electron donors to the 
mitochondrial membrane-associated redox enzyme complexes. The electrons [e-] are shuttled 
through oxidoreductase complexes I, II, III and IV [cytochrome c], until they are donated to 
molecular oxygen, eventually forming water. The electrons transfer into complexes I, III and 
IV produces a proton gradient in the intermembrane space between the inner and outer 
mitochondrial membrane, generating a proton potential gradient across the inner 
mitochondrial membrane, that drives ATP synthesis. As electrons are transferred from 
complex III to complex IV ROS are produced as by-products in low levels during normal 
oxidative phosphorylation, then they are quenched by cellular antioxidants such as GSH and 
superoxide dismutase [SOD]. Under hyperglycaemic condition, higher levels of glucose-
derived pyruvate and acetyl-CoA enter the TCA cycle increasing the generation of NADH 
and FADH2 that, in turn, transfers electrons into the electron transport chain, and 
consequently massively increases the voltage gradient across the mitochondrial membrane. 
This abnormally high proton gradient blocks complex III, causing the electrons to back up to 
coenzyme Q10, which donates the electrons to molecular oxygen in what is known as 
electron leak, thereby generating O2- (Rolo and Palmeira 2006).  As abovementioned, in 
normal physiological conditions there is still some mitochondrial ROS being generated 
during the electron migration at complex IV, however it is within the capacity of the 
Glutathione/peroxidase system and SOD to scavenge it and prevents building up of oxidative 
stress [Figure 11]. 
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Figure 11. Mitochondrial electron transport chain in hyperglycaemia. Under hyperglycaemic 
condition, higher levels of glucose-derived pyruvate increase the flux of NADH and FADH2 into the 
electron transport chain and consequently the voltage gradient across the mitochondrial membrane. The 
electron transfer inside complex III is blocked, causing the electrons to back up to coenzyme Q10, which 
donates the electrons to molecular oxygen, thereby generating O2-. Abbreviations: CoQ10: coenzyme Q10, 
e: electrons, O2-: superoxide, Pi: phosphate, SOD: O2- dismutase, GSH: glutathione, GSSG: oxidized 
glutathione, H2O2: hydrogen peroxide. 
 
Moreover, hyperglycaemia does not induce ROS formation in so called rho zero endothelial 
cells, where the mitochondrial electron transport chain has been inhibited. This mitochondrial 
overproduction of O2- causes the inhibition of GAPDH activity, which in turn, leads to 
increased levels of all the glycolytic intermediates upstream of GAPDH and, consequently, 
promotes the flux into the 4 pathways described above (Du, Matsumura et al. 2003). 
 
1.3.4 NOX 
In addition to the mitochondrial dysfunction being a major source of hyperglycaemia-induced 
ROS overproduction, studies have shown there are other principal sources include: NOX and 
uncoupled eNOS (Inoguchi, Li et al. 2000). NOXs are a family of enzymes that have been 
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identified first in phagocytic cells, neutrophils and macrophages. They are the only family of 
enzymes whose primary function is the generation of ROS [H2O2, O2-] as a primary product 
by catalysing the electron transfer from cytosolic NADPH to molecular O2 across plasma and 
lysosomal membranes (Thannickal and Fanburg 2000). There is a total of 7 isoforms 
identified so far which are abundantly expressed in phagocytic cells. These are NOX1, 
NOX2, NOX3, NOX4, NOX5, DUOX1 and DUOX2. Four of these are expressed by 
endothelial cells, NOX1, NOX2, NOX4, and NOX5 (De Deken, Wang et al. 2000).  In these 
cells, NOXs are thought to be responsible for producing, in a controlled manner, the 
moderate, non-cytotoxic levels of ROS needed for redox signaling during normal cellular 
metabolism. However, in pathophysiological settings such as hypertension, diabetes, and 
hyperlipidemia, NOX activity in the vascular wall is markedly increased, leading to an 
overproduction of ROS. All four endothelial NOX isoforms are comprised of a catalytic 
‘NOX’ subunit, which may reside in the nucleus, ER, or plasma membranes, which catalyzes 
the electron transfer from cytosolic NADPH to molecular O2. For NOX1, 2, and 4, additional 
regulatory subunits in different combinations are required for full enzyme activity namely, 
p22phox, p47phox, p67phox, and p40phox. By contrast, NOX5 is a single protein subunit whose 
activity is regulated by Ca2+ binding. The topology of the NOXs is such that NADPH binds 
to the cytoplasmic domains of the proteins with ROS generation always occurring on the 
opposite side of the membrane [i.e., within the nucleus, ER, or the extracellular 
compartment]. It is also noteworthy that whereas NOX1, 2, and 5 generate O2-, NOX4 
appears to generate H2O2 (Drummond and Sobey 2014). 
The subunit p47phox is pivotal for NOX activation and is frequently named the ‘organizer 
subunit’ which is crucial for the formation of the active NAPH oxidase complex. It is 
residing within the cytosol in resting state, upon phosphorylation at several serine residues it 
undergoes conformational changes to expose its intramolecular SH-3 domain which interacts 
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with the cytosolic activator p67phox subunit, and chaperones it to the membrane bound 
subunits gp91phox (NOX) and p22phox to finally form the active NOX complex. 
Hyperglycaemia, free fatty acid, and oxidized low-density lipoprotein [LDL] have also been 
shown to promote endothelial NOX activity (Shen 2010). Vessels isolated from diabetic 
subjects exhibit increased O2- production and higher expression levels of several NOX 
subunits [p22phox, p47phox, and p67phox], suggesting that NOX are more active in diabetes 
(Pitocco, Zaccardi et al. 2010). The excess of O2- can react with NO and promote the 
synthesis of ONOO- which in turn oxidizes BH4, thus reducing its availability to eNOS. In 
the presence of reduced concentrations of BH4, eNOS becomes uncoupled and transfers 
electrons to molecular oxygen instead of L-arginine, producing O2- rather than NO. Clinical 
studies have demonstrated that BH4 supplementation improves endothelium-dependent 
vasodilation in diabetic patients, indicating that uncoupled eNOS plays an important role in 
diabetic endothelial dysfunction (Son 2012). Collectively, NOX activation and mitochondrial 
dysfunction are unequivocally considered to be the major direct sources of ROS 
overproduction and therefore oxidative stress in pathophysiological conditions such as 
diabetes and endothelial dysfunction which are mainly triggered by the associated 
hyperglycaemia. 
 
1.4 Endothelial dysfunction and NO 
Endothelial dysfunction occurs in diabetes and its cardiovascular complications (Hirata, 
Nagata et al. 2010), characterized by reduced eNOS activity and/or expression and decreased 
NO bioavailability resulting in part from enhanced oxidative stress as briefly discussed above 
(Reiter, Teng et al. 2000). The expression of eNOS is regulated by multiple mechanisms that 
include transcriptional and post-transcriptional regulation of mRNA (Searles 2006), and post-
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translational regulation of the protein function where Akt activity enhances phosphorylation 
of eNOS at Ser1177 causing its activation (Shen, Zhang et al. 2006). In early stages of 
hyperglycaemia-induced cellular stress, high glucose-induced ROS generation disrupt Ca2+ 
homeostasis leading to leakage of Ca2+ from the ER lumen into the cytosol (Ding and Triggle 
2010). As a result, intra-ER Ca2+ levels fall below a critical level interfering with the activity 
of many ER chaperones which depend on Ca2+ availability inside the ER lumen and thus 
interfering with proper protein folding leading to development of UPR and eventually 
apoptosis (Morgan, Kim et al. 2008). Furthermore, the resulting increase in cytosolic Ca2+ 
induces stimulation of eNOS which can yield large amounts of NO that can react with the O2- 
anion to form ONOO−, thereby oxidizing BH4 and promoting eNOS uncoupling with 
reduction in the bioavailability of NO (Ding and Triggle 2010). In advanced stages, when the 
ER stress reaches a point where it cannot be resolved, the cell must finally decide to undergo 
apoptosis. In endothelial cells exposed to high glucose, disrupted Ca2+ homeostasis, due to 
ROS generation, can thus evoke an ER stress apoptotic response which are primarily 
mediated through IRE1-α (Bishara and Ding 2010).  IRE1-α activation leads to the activation 
JNK and p38 MAPK pathways triggering downstream pro-apoptotic mediators ASK-1 and 
caspase-12 via CHOP activation (Xu, Bailly-Maitre et al. 2005).  ASK-1 causes NO 
deficiency [a hallmark of endothelial cell dysfunction in diabetes by inhibiting eNOS through 
reduced phosphorylation at Ser1177 (Yamashita, Yamamoto et al. 2007). 
Moreover, in vitro studies conducted on human aortic endothelial cells [HAECs] 
demonstrated a decrease in eNOS mRNA and protein expression levels following chronic 
high glucose exposure. They reported mitochondrial ROS to cause the activation of oxidative 
stress transcription factor AP-1 with subsequent DNA binding at the eNOS promotor region 
causing its suppression. This effect was found to be reversed by the mutation of AP-1 sites in 
the human eNOS promotor region. In addition, they showed that compared with C57BL/6J 
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control mice, eNOS mRNA levels in diabetic dyslipidemia db/db mouse aortic endothelial 
cells were reduced by 60%. This decrease was reversed by the overexpression of manganese 
SOD using an adenoviral construct. They also reported reduced phosphorylation of eNOS 
and hence its activity at Ser1177 in response to mitochondrial ROS (Srinivasan, Hatley et al. 
2004). However, Salt et al., (2003) reported that high glucose exposure reduced eNOS 
production in HAECs without changes in phosphorylation at Ser1177.  
Another study conducted by Galán et al., (2014) demonstrated in coronary artery endothelial 
cells that were subjected to high glucose or ER stress inducer tunicamycin, the role of NOX 
in the suppression of eNOS promotor region and decreased phosphorylation that was restored 
by ER stress inhibitor PBA. They also reproduced these results in vivo by showing 
significantly impaired vascular endothelium-dependent and independent relaxation in 
C57BL/6J mice compared with p47phox−/− mice indicating the involvement of p47phox subunit 
of NOX as an intermediate for ER stress induced reduction in NO production and the 
consequent vascular endothelial dysfunction. Nevertheless, regardless of the exact 
mechanisms involved in the inhibition of eNOS, it is generally accepted that high glucose 
induces a reduction in NO production and bioavailability and hence development of 
endothelial dysfunction. 
As above mentioned, aberrant angiogenesis is one of the hallmarks of hyperglycaemia-
induced endothelial dysfunction. NO synthase pathway plays a critical role in promoting 
angiogenesis in part due to the pro-survival nature of NO and inhibition of apoptosis, and in 
part due to enhancing endothelial cell proliferation, migration, endothelial progenitor cell 
[EPCs] recruitment, and EPCs release by the bone marrow perhaps in part by increasing the 
expression of VEGF and in part by the activation of VEGF tyrosine kinase receptor flk-1. 
There is a large body of evidence indicating that flk-1 activation is defective in models of 
diabetes both in vitro and in vivo. A study conducted by Sasso et al., (2005) demonstrated 
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that in hearts of diabetic patients with chronic coronary heart disease, there was 
downregulation of VEGF-dependent intracellular signalling and eNOS phosphorylation.  
They reported reduced VEGF receptor flk-1 phosphorylation concomitant with decreased Akt 
phosphorylation and decreased eNOS protein phosphorylation and expression. This 
highlights a complex molecular interplay in the pathophysiology of diabetes/hyperglycaemia-
induced endothelial dysfunction. 
 
1.5 Endothelial dysfunction and angiogenesis 
Micro-and macro-vascular beds are altered in diabetes by various changes in angiogenic 
mechanisms (Simons 2005).  However, from a vascular standpoint, diabetes is a paradoxical 
disease (Costa and Soares 2013). Excessive angiogenesis plays a pivotal role in diabetic 
retinopathy (Wilkinson-Berka 2004) and nephropathy (Osterby and Nyberg 1987).  
Insufficient angiogenesis contributes to impaired wound healing and skin ulcers, impaired 
coronary collateral vessel development, embryonic vasculopathy in pregnancies complicated 
by maternal diabetes, and transplant rejection in diabetic recipients (Galiano, Tepper et al. 
2004). Furthermore, diabetic neuropathy is a complication linked with reduced nutritive 
blood flow secondary to diabetes. Defective arteriogenesis, a process of formation or 
remodeling of arterioles and arteries, has also been reported in diabetic patients (Abaci, 
Oguzhan et al. 1999). Impaired release of EPCs from the bone marrow and defective function 
of these cells are the other features of diabetes that further contribute to abnormal 
neovascularization and increased cardiovascular risk (Tepper, Galiano et al. 2002). 
Angiogenesis is the process of formation of new capillary network [microvascular] in 
response to hypoxia or other pro-angiogenic molecular stimuli. The process of angiogenesis 
involves the local secretion of angiogenic factors from both hypoxic endothelium and 
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supporting pericytes that induce endothelial proliferation and sprouting of neo-vessels. This 
is different from arteriogenesis, a process of growth and expansion of existing arteriole 
networks in response to acute arterial occlusion [e.g. arterial occlusion] or physical forces e.g. 
exercise-induced shear stress (Folkman and Shing 1992). 
Cardiovascular complications associated with diabetes mellitus, can be attributed in part to 
this aberrant angiogenesis (Ebrahimian, Heymes et al. 2006). Indeed, there are a number of 
equally tenable hypotheses regarding the mechanisms underlying alterations in blood vessel 
growth in diabetes, including a reduction in VEGF-A signalling, changes in inflammation-
related pathways, development of ER stress, accumulation of AGEs initiating oxidative stress 
and over-production of ROS (Tamarat, Silvestre et al. 2003). Much evidence suggests that 
the effects of ROS on vascular function depend critically on the amount of ROS present. 
However, precise amounts and the species of ROS involved are not fully understood. Low 
levels of ROS [principally H2O2] under physiological conditions can act as intracellular 
secondary messengers modulating pro-angiogenic pathways such as VEGF-A signalling and 
postnatal vasculogenesis; conversely, higher levels of ROS can impair neovascularization 
(Griendling and FitzGerald 2003). 
VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 
148, 165, 183, 189, or 206 amino acids. The primary VEGF-A transcript is derived from a 
single VEGF-A gene, encoding for eight exons (Neufeld, Cohen et al. 1999). The amino 
acids encoded by exons 1 to 5 and 8 are conserved in all isoforms except VEGF-A148, 
whereas variable alternative splicing occurs in exons 6 and 7, resulting in encoding different 
VEGF-A isoforms (Ortega, Hutchings et al. 1999).  
These ROS include O2-, H2O2, OH− radicals, lipid peroxides, and ONOO-, which are 
recognized to play major roles in vascular biology controlling the angiogenic process (Tojo, 
Ushio-Fukai et al. 2005). 
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Ebrahimian et al., (2006) demonstrated that diabetes-induced over-production of ROS 
impairs post-ischemic neovascularization. This study also reported that the blockade of 
oxidative stress in the setting of diabetes restores key pathways involved in angiogenesis, 
such as VEGF-A signalling pathway. Moreover, the exact source of ROS has been under 
extensive investigation where Nishikawa et al., (2000) suggest that glucose-induced 
mitochondrial production of ROS stimulates several biochemical mechanisms involved in 
diabetic vascular complications related to aberrant angiogenesis. Other studies indicate that 
O2- production by NOX has a primary role in VEGF expression and neovascularization in a 
mouse model for diabetic ischemic vascular disease. In addition, increased expression of 
NADPH subunit NOX2 [gp91phox] has been found to correlate with increases in ROS and 
decrease in VEGF-A in ischemic diabetic retinopathy (Al-Shabrawey, Rojas et al. 2008). 
Furthermore, O2- over-production by NOX likely reduces NO bioactivity by scavenging or 
through uncoupling of eNOS and may also lead to the formation of other signalling species 
such as ONOO- (Guzik, Mussa et al. 2002). These alterations in NO signalling might 
contribute to modulation of post-ischemic neovascularization because NO is a well-known 
mediator of bone marrow mononuclear cells [BM-MNC] mobilization and differentiation, as 
well as basal neovascularization reaction (Aicher, Heeschen et al. 2003). Evidence shows that 
blockade of NOX activity or the scavenging of ROS restores post-ischemic 
neovascularization in diabetes. Hyperglycaemia-induced overproduction of ROS also impairs 
EPCs function leading to impairment of angiogenesis in diabetes (Fadini, Agostini et al. 
2007). However, EPCs implications on ROS and angiogenesis under diabetes is still not clear 
and a subject of extensive study. 
It has been reported by Tepper et al., (2002) that diabetes-induced increase in ROS caused 
inhibition of BM-MNCs differentiation into EPCs which was mediated by p38 MAPK 
phosphorylation, thus impairing their pro-angiogenic potential in vitro and in vivo. Similarly, 
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diabetes has been shown to activate p38 MAPK in vascular cells via PKC-dependent and 
independent pathways (Igarashi, Wakasaki et al. 1999). Moreover, p38 MAPK activation is 
known to downregulate EPC proliferation and differentiation that may contribute to impaired 
angiogenesis in diabetes. Not only development of oxidative stress with increase production 
of ROS has been reported in in vitro and in vivo diabetic models of impaired angiogenesis, 
but also the antioxidant defense capacity is reduced which can also contribute to diabetes-
induced oxidative stress (Wohaieb and Godin 1987). There are previous reports that show 
chronic exposure of HUVECs to high glucose causes suppression of Keap1-NrF-2 pathway 
which is the major regulator of cytoprotective responses to endogenous and exogenous 
stresses caused by ROS including the HO system. They also reported a correlation between 
the suppression of Keap1-NrF-2 and impaired migration and tube formation capacity of these 
endothelial cells (Chen, Lu et al. 2015) [Figure 12]. 
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Figure 12.  Mechanisms of aberrant angiogenesis induced in hyperglycaemia. Increased ROS 
production in hyperglycemic milieu both in vitro and in vivo is believed to cause insult on the angiogenic 
process. Theories proposed include suppression of VEGF-A signalling, suppression of EPC mobilization, 
proliferation and differentiation, reduction in NO bioavailability and suppression of Keap1-NrF-2 pathway 
with resultant suppression in HO-1 expression. 
 
1.6 Heme-oxygenase [HO] 
HOs are a group of antioxidant enzymes that play a central role in regulating the levels of 
intracellular heme by catalyzing the oxidative degradation of heme to liberate Fe2+, CO, and 
biliverdin in mammalian cells (Abraham and Kappas 2008). Biliverdin which is a water 
soluble molecule,  is then metabolized to bilirubin by biliverdin reductase. Excess free heme 
catalyzes the formation of ROS, which leads to endothelial dysfunction as seen in numerous 
pathologic vascular conditions including systemic hypertension and diabetes, as well as in 
ischemia/reperfusion injury. The HO system, through its products, may cause different 
cytoprotective effects on the vascular system: (I) Prevention of endothelial cell apoptosis; (II) 
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Attenuation of the inflammatory response and oxidative stress in the vessel wall; (III) 
Regulation of the vascular tone; and (IV) participation in angiogenesis and vasculogenesis. 
Among all products of HO-1, bilirubin and biliverdin are the most potent endogenous 
scavengers of ROS, and CO exerts anti-apoptotic and anti-inflammatory effects through the 
induction of soluble guanylyl cyclase (Stocker, Yamamoto et al. 1987).  It suppresses the 
production of TNF-α, IL-1β and macrophage inflammatory protein-1β and induces the 
synthesis of anti-inflammatory IL-10 (Otterbein, Bach et al. 2000). Finally, free iron, despite 
participation in Fenton reaction that leads to formation of highly reactive OH−  radicals, 
activates Fe-ATPase, which is a transporter that removes intracellular iron as well as induces 
expression of ferritin heavy chains which sequester free iron and exert specific cytoprotective 
roles (Crichton, Wilmet et al. 2002). 
Three isoforms of HO have been described: an inducible isoform, HO-1, and two 
constitutively expressed isoforms, HO-2 and HO-3. HO-1 is a 32 kDa microsomal protein 
with generally very low expression levels in normal tissues, apart from liver and spleen, 
where it participates in the processing of senescent or damaged erythrocytes and in protection 
against oxidative damage caused by free porphyrins. Although HO-1 is an integral protein of 
the smooth ER, it can localize to other compartments including caveolae, mitochondria, and 
the nucleus, where it can mediate a variety of signalling functions (Gottlieb, Truman et al. 
2012). 
In all tissues, low basal expression of HO-1 can be upregulated by a wide variety of stimuli 
that cause oxidative stress, including its substrate heme, heavy metals, cytokines, ultraviolet 
rays, lipopolysaccharide [LPS], hyperglycaemia, hydrogen peroxide, growth factors, NO, and 
also CO (Ryter, Alam et al. 2006).  On the other hand, HO-2, a 36 KD protein is 
constitutively expressed, and localized primarily in the brain, testis, and vascular endothelium 
(Chen, Yet et al. 2003). Recently, its novel role has been postulated in the regulation of the 
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inflammatory and reparative response to injury, which is a cytoprotective mechanism 
typically associated with HO-1 induction. HO-2 may constitute an essential protective circuit 
responsible of a basal tone of anti-inflammatory signals critical to the execution of self-
resolving inflammatory-reparative processes (Seta, Bellner et al. 2006). HO-3, is a 33-kDa 
protein encoded by a pseudogene derived from HO-2 transcript that has been found only in 
rats (McCoubrey, Huang et al. 1997). 
The modulation of HO-1 expression involves a complex molecular interplay between 
different regulatory mechanisms. It has been reported that MAPKs, phosphatidyl inositol 3-
kinase/Akt, protein kinases (PKA, PKC, and PKG) (Stocker and Perrella 2006), NrF-2, AP-1, 
NF-ΚB , cyclic adenosine monophosphate-responsive element-binding protein [CREB], and 
activation transcription factor 2 [ATF2] play a role in HO-1 gene regulation (Kim, Pae et al. 
2011). The transcription factor NrF-2 plays a central role in the transcriptional activation of 
HO-1 in response to oxidative stress. Activation of NrF-2 is regulated by the cytosolic protein 
Keap1 that negatively modulates the nuclear translocation of NrF-2 and facilitates 
degradation of NrF-2 via the proteasome. Upon activation, NrF-2 enters the nucleus where it 
binds to the AREs in the HO-1 promoter to trigger gene expression. NrF-2 has been 
previously reported to regulate the induction of HO-1 in response to various forms of cellular 
stress, including hemodynamic, oxidative, and ER stress.  Moreover, previous reports have 
shown that fibroblasts and lung tissue from NrF-2-deficient animals express reduced levels of 
HO-1 further implicating NrF-2 in the induction of HO-1(Liu, Peyton et al. 2007). 
Other transcription factors have been identified, such as the transcription factor YY1 that is a 
downstream effector of CO produced by HO-1, and hypoxia-inducible factor 1 [HIF-1]. It has 
been found that the increase in the transcription factor YY1 is involved in the inhibition of 
neo-intimal hyperplasia in vivo by HO-1 (Beck, Wu et al. 2010). Moreover, the results of 
Dawn and Bolli., (2005) show that HIF-1-mediated upregulation of HO-1 was beneficial to 
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the ischemic myocardium. 
Several heavy metal protoporphyrins induce the expression of HO-1; however, CoPP is 
regarded as probably the most potent. CoPP indirectly modulates the production of two 
factors involved in regulating the expression of HO-1, NrF-2 and Bach1. Bach1 is a basic 
leucine zipper transcription factor which forms heterodimers with small proteins of the Maf 
family and together, these heterodimers can repress transcription of the HO-1 gene by 
binding to the AREs in the 5’UTR of the HO-1 promoter. CoPP induces an increase in the 
degradation of Bach1 protein. NrF-2 is also a member of the family of basic leucine zipper 
transcription factors, which is involved in protection against oxidative stress though its AREs 
directed induction of HO-1. CoPP induces an increase in NrF-2 levels by decreasing its 
degradation, and being a basic leucine zipper transcription factor, the NrF-2 dimerizes with 
the Maf family transcription factors and together these heterodimers bind to AREs of the HO-
1 promotor region resulting to enhancement in expression (Shan, Lambrecht et al. 2006).  
More recently, Liu et.al., (2013) reported that CoPP enhances the expression of FOXO1 and 
facilitates FOXO1 binding to HO-1 promoter resulting in increase in its transcriptional 
activity enhancing HO-1 expression. 
In addition to the transcriptional regulation, it has been reported that a post-transcriptional 
mechanism may exist to attenuate HO-1 expression rendering it a transient nature of 
expression. It has been demonstrated that two miRNAs, miR-217 and miR-377, combine to 
attenuate HO-1 protein expression, resulting in a significant reduction in HO-1 enzyme 
activity. The knockdown of both miR-217 and miR-377 resulted in the abrogation of this 
attenuation (Beckman, Chen et al. 2011).  Moreover, reports by Lin et al., (2008) showed that 
HO-1 is subjected to posttranslational regulation by the ubiquitin-proteasome system through 
an ER-associated degradation pathway. These findings were supported by increased HO-1 
expression in response to MG-132, which is a proteasome inhibitor and has been shown to 
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protect from heme-mediated oxidative injury (Chen and Regan 2005). 
 
1.6.1 Role of HO-1 in Vascular Inflammation 
 
HO-1 represses inflammation by removing the pro-inflammatory molecule heme and by 
generating CO and bilirubin. These HO-1 reaction products are capable of blocking innate 
and adaptive immune responses by modifying the activation, differentiation and maturation 
of numerous cell types, including endothelial cells, monocytes/macrophages, dendritic cells, 
T lymphocytes, mast cells, and platelets. These cellular actions by CO and bilirubin result in 
diminished leukocyte recruitment and infiltration, and pro-inflammatory mediator 
production. (Durante 2011). 
The role of HO-1 in inflammation is demonstrated in HO-1 knockout mice, in which HO-1 
deficiency leads to increased production of pro-inflammatory cytokines (Kapturczak, 
Wasserfall et al. 2004). In patients subjected to bypass surgery, a higher activity of HO-1 
resulted in a lower concentration of IL-6 (Taha, Skrzypek et al. 2010). HO-1 has been 
reported to reduce inflammatory cell rolling, adhesion, and migration from the vascular 
compartment, by downregulating the function and expression of adhesion molecules on the 
vessel wall.  In contrast, inhibition of HO-1 increases adhesion molecule expression (Belcher, 
Mahaseth et al. 2006). 
Preclinical and clinical studies have been performed in many inflammatory vascular diseases 
to understand whether HO-1 overexpression can be protective in the pathogenesis and 
progression of the inflammatory process. In atherosclerosis, experimental evidence 
demonstrates that the induction of HO-1 in vascular cells suppresses oxidized LDL-induced 
monocyte transmigration and inhibits atherosclerotic lesion formation in LDL receptor 
knockout mice (Ishikawa, Sugawara et al. 2001). Interestingly, the levels of bilirubin in the 
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normal human population correlate inversely with the incidence of atherosclerotic events 
(Mayer 2000), and it has been shown that bilirubin attenuates vascular endothelial activation 
and dysfunction in vitro (Kawamura, Ishikawa et al. 2005). 
Recent interest has also focused on peroxisome proliferator-activated receptor δ [PPARδ] 
ligands and induction of HO-1 expression. Ali et al., (2010) showed in vivo that PPARδ 
ligands induce vascular endothelial HO-1 expression, thus supporting the hypothesis that 
PPARδ represents an important potential target for the treatment of endothelial dysfunction 
and atherogenesis. Finally, it has been shown that, in human monocytes, HO-1 activity is 
involved in attenuation of TNF-α production (Drechsler, Dolganiuc et al. 2006). 
 
1.6.2 Role of HO-1 in Angiogenesis 
 
Angiogenesis involves the formation of new blood vessels and is critical for fundamental 
events such as development, and repair after injury. Recently, it has been shown that HO-1 
and its gaseous product CO have potent pro-angiogenic properties in addition to well-
recognized anti-inflammatory, anti-oxidant, and anti-apoptotic effects. Angiogenic factors, 
such as VEGF and stromal cell-derived factor-1 [SDF-1], mediate their pro-angiogenic 
effects through induction of HO-1, hence being an attractive target for therapeutic 
intervention. It has been reported that the role of HO-1 in angiogenesis regulation could be 
“good” or “bad.” The role of HO-1 in favoring angiogenesis responses is crucial for proper 
placental vascularization, wound healing, and neovascularization of ischemic heart. However, 
it may have detrimental outcomes in diseases where new blood vessel formation is 
undesirable, such as in tumor neovascularization (Dulak, Deshane et al. 2008). 
In investigating the role of HO-1 in promoting angiogenesis, Zhao and collaborators, (2011) 
showed that a partial deficiency of maternal HO-1 resulted in the malformation of feto-
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maternal interface, alteration of the placental vasculature, insufficiency of spiral artery 
remodeling, and alteration of uterine natural killer cell differentiation and maturation. These 
changes were independent of the fetal genotype, but relied on the maternal HO-1 level, which 
determined the balance of expression levels of pro- and anti-angiogenic factors in the 
decidual region (Zhao, Azuma et al. 2011). According to these results a reduction in HO-1 
placental expression was associated with recurrent miscarriages, spontaneous abortions, and 
preeclampsia (Lyall and Myatt 2002). 
Moreover, the replacement of damaged capillaries and reestablishment of the normal oxygen 
amounts to a wound are accomplished by neovascularization. Wound-healing process 
includes a coagulation phase [characterized by endothelial dysfunction and platelet 
activation], an early extracellular matrix deposition, the release of factors by platelets, an 
inflammatory phase, and the resulting granulation, which are all events that rely on 
angiogenesis (Bauer, Bauer et al. 2005). Growth factors including VEGF, chemokines like 
SDF-1, and HIFs also coordinate the multifaceted events involved in wound healing (Tepper, 
Capla et al. 2005). Interestingly, compared with wild-type littermate mice, HO-1-deficient 
mice exhibit impaired wound healing due, in part, to reduced recruitment of EPCs and 
capillary formation at the site of injury (Deshane, Chen et al. 2007). In addition, the induction 
of HO-1 in wounded skin was relatively weak and delayed in diabetic mice, in which also 
angiogenesis and wound closure were impaired. In such animals, local delivery of HO-1 
transgene, using adenoviral vectors, accelerated the wound healing and increased the 
vascularization (Grochot-Przeczek, Lach et al. 2009). 
Furthermore, it has been recognized that HO-1 has a protective effect in ischemic 
myocardium by increasing the expression of angiogenic growth factors in the infarcted tissue 
(Zeng, Lin et al. 2010). VEGF is a strong therapeutic reagent by inducing angiogenesis in 
ischemic myocardium, and it can mediate the ischemia-induced mobilization of EPCs from 
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bone marrow (Jeon, Song et al. 2007). Lin et al., (2008) showed that HO-1 gene transfer after 
myocardial infarction provides protection at least in part by promoting angiogenesis through 
inducing angiogenic growth factors VEGF-A. In addition, preclinical and clinical studies 
have demonstrated that mesenchymal stem cells [MSCs] transplantation can attenuate 
ventricular remodeling and augment cardiac function when implanted into the infarcted 
myocardium. In HO-1-transfected MSCs-treated hearts, the myocardial apoptosis was 
marked with significantly reduced fibrotic area and the cardiac function and remodeling were 
also significantly improved (Jeon, Song et al. 2007). 
It is important to point out that in addition to the numerous lines of evidence supporting the 
positive role of HO-1 in angiogenesis regulation, several authors reported some negative 
effects of this enzyme in tumor angiogenesis. In particular, it has been shown that several 
human tumors, including renal cell and prostate cancer, express high levels of HO-1 
(Goodman, Choudhury et al. 1997). HO-1 may promote tumor cell survival, hindering the 
effectiveness of anticancer therapies (Nowis, Legat et al. 2006). In contrast, inhibition of HO-
1 has been shown to enhance tumor regression in animal models suggesting that the HO-1 
pathway may be a therapeutic target in carcinogenesis (Dulak, Deshane et al. 2008). 
However, there are reports that show HO-1 has an anti-angiogenic role. In prostatic cancer 
cells [PC3], Ferrando et al., (2011) identified a set of inflammatory and pro-angiogenic genes 
downregulated in response to HO-1 overexpression, in particular NF-κB, VEGF-A, VEGF-C, 
and HIF1-α. An in vivo angiogenic assay showed that intradermal inoculation of PC3 cells 
stably transfected with HO-1 [PC3HO-1] generated tumors less vascularized than controls, 
with decreased microvessel density and reduced CD34 and MMP9 positive staining. 
Interestingly, longer-term grown PC3HO-1 xenografts displayed reduced neovascularization 
with the subsequent downregulation of vascular endothelial growth factor receptor 2 [VEGF-
R2] expression. Additionally, HO-1 repressed NF-κB-mediated transcription, which strongly 
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suggests that HO-1 may regulate angiogenesis through this pathway. Taken together, these 
data support a key role of HO-1 as a modulator of the angiogenic process in different 
pathophysiological conditions where it could be a potential therapeutic target for the 
inhibition of angiogenesis in carcinogenic conditions, as opposed to being a therapeutic target 
for induction of angiogenesis in diabetic cardiovascular complications. 
 
1.6.3 Role of HO-1 in oxidative stress 
 
HO-1 was first recognized for its anti-oxidant ability by the studies that demonstrated HO-1 
induction by oxidative stress and had illustrated that HO-1 protected against oxidative insult 
(Hayashi, Takamiya et al. 1999). In a previous study conducted by Ishikawa et al., (2012) it 
was elucidated that HO-1 knockout mice had lower anti-oxidant protection and higher lipid 
peroxide level. 
HO-1 owes its anti-oxidant capacity to biliverdin and CO which are generated from HO-1 
enzymatic activity resulting in heme degradation. Various mechanisms have been put 
forward for explaining the antioxidant actions of biliverdin/bilirubin and CO. Bilirubin 
efficiently scavenges singlet oxygen, O2-, ONOO- and RO2 radicals. Moreover, in contrast to 
GSH, bilirubin, being lipophilic, is closely associated with lipid plasma cell membranes, thus 
protects the membrane against lipid peroxidation. In a recent study, bilirubin was 
demonstrated to be a better O2- scavenger and ONOO--mediated protein tyrosine nitration 
inhibitor than biliverdin (Jansen, Hortmann et al. 2010). In addition to ROS scavenging 
ability, there are also few studies which suggest that the protective effects of bilirubin are in 
part derived from inhibition of iNOS which results in lesser production of highly reactive and 
damaging ONOO- radical (Wang, Smith et al. 2004). CO to some extent mediates some of 
the antioxidant effects of HO-1(Srisook, Han et al. 2006). The ONOO--induced 
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nitrosative/oxidative stress in vascular endothelial cells is also abrogated by CO which 
elevated the intracellular GSH level through the induction of glutamate-cysteine ligase (Li, 
Jang et al. 2007). 
Since there is ample evidence that oxidative stress is involved in the initiation as well as the 
progression of diabetic vascular complications, HO-1 can be exploited as a viable therapeutic 
target. Protective effects of HO-1 have been observed in models of diabetic complications, 
particularly in diabetic cardiomyopathy and vasculopathy (Li, Liu et al. 2012).  Moreover, in 
vitro studies have demonstrated the highly potent anti-oxidant effect of bilirubin with 
increased protection of vascular endothelial cells, where even nanomolar concentrations of 
bilirubin protect against oxidative stress both directly through ROS scavenging ability, and 
indirectly through the inhibition of NOX (Abraham and Kappas 2008). 
 
1.6.4 Role of HO-1 in apoptosis 
 
As previously discussed, apoptosis of endothelial cells has been suggested to be a probable 
mechanism for endothelial dysfunction in diabetes. In animal models of diabetes induced 
vascular disease, a significantly high percentage of endothelial cells undergoing apoptosis as 
demonstrable by terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL], in 
comparison with normal control counterparts (Negi, Kumar et al. 2011). Clinical data also 
suggest the involvement of apoptosis in diabetic vascular diseases where the expression of 
pro-apoptotic markers was elevated whereas expression of anti-apoptotic markers was 
reduced (Arya, Pokharia et al. 2011). 
HO-1 exerts its anti-apoptotic effects via various mechanisms including the inhibition of 
oxidative stress, ER stress and inflammation. Inflammatory transcription factor NF-κB has 
been shown to play a crucial role in regulating cellular apoptosis. However, HO-1 induction 
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by CoPP was found to reduce the expression of NF-κB  regulated gene [IL-6], and CHOP in 
response to ischemia reperfusion injury associated with the consequent inhibiton of apoptosis 
that was elicited by this ischemia reperfusion injury (Ben-Ari, Issan et al. 2013). Other 
mechanisms suggested for the anti-apoptotic  effects of HO-1 include suppressing TNF-
α/TNF receptor-1 mediated apoptotic signalling (Jaeschke and Woolbright 2013). These anti-
apoptotic effects of HO-1 might be derived in a crucial manner from CO generation which 
contributes greatly to its overall protective effect. Various cell types of different origins like 
endothelial cells, fibroblasts, hepatocytes and pancreatic β-cells have been shown to be 
protected from apoptosis upon CO treatment. Brouard et al., (2000) were able to show that 
HO-1 inhibits apoptosis, namely by generating CO. When HO-1 enzymatic activity is 
blocked by tin protoporphyrin [SnPPIX] or when the action of CO is inhibited by hemoglobin 
[Hb], HO-1 no longer prevents endothelial cell apoptosis. To confirm the direct effect of CO 
on apoptosis, exposure of endothelial cells to exogenous CO while inhibiting HO-1 activity 
by SnPPIX, resulted in preventing apoptosis suggesting that the anti-apoptotic effect of HO-1 
is mainly attributed to its by-prodcut CO.  Moreover, they have also explored some of the 
signalling pathways behind the action of HO-1/CO, and showed that is partially mediated by 
the activation of p38 MAPK signalling transduction pathway. This was supported by the 
observation that specific inhibition of p38 MAPK by the pyridinyl imidazole or through the 
over-expression of a p38 MAPK dominant negative mutant resulted in abolishing the anti-
apoptotic effect of HO-1. In additon, as previously discussed in diabetic vascular disease, 
oxidative stress occurs in endothelial cells which subsequently leads to apoptosis. Hence, 
HO-1 by merely exerting its anti-oxidant effects is reported to protect these cells from 
apoptosis (Schmeichel, Schmelzer et al. 2003).  Other studies focused on the role of bilirubin 
in this pro-survival behavior of HO-1.  It has been recently shown that bilirubin generated by 
HO-1 activity was found to be exerting this anti-apoptotic effect by increasing expression of 
	
	
62	
	
ERK and PI3K-Akt/eNOS pathways (Hung, Liou et al. 2010). Though the evidence is scarce, 
studies point towards the possibility that the activation of HO-1 may represent a new 
stratagem to prevent apoptosis in endothelial cells through its by-products bilirubin and CO, 
which may delay the development of various diabetic cardiovascular complications. 
Taken together all the cytoprotective effects of HO-1 against endothelial dysfunction in 
diabetic cardiovascular complications are carried out by exerting anti-oxidant, anti-
inflammatory, anti-apoptotic and pro-angiogenic effects mediated mainly by its by-products 
CO and bilirubin, however, its role against ER stress has not been fully elucidated and 
remains to be elusive. 
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2 Hypothesis 
HO-1 induction in endothelial cells by the pharmacological inducer CoPP protects against 
high glucose-mediated endothelial dysfunction through inhibition of ER stress which would 
underscore the existence of complex molecular interplay between ER stress and oxidative 
stress. 
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3 Project’s aims 
1) To determine the protective role of HO-1 induction against high glucose-mediated ER 
stress response. 
2) To assess the protective role of HO-1 induction against high glucose induced oxidative 
stress, apoptosis and inflammation. 
3) To assess the protective role of HO-1 induction on impaired endothelial dysfunction 
mediated by high glucose, through investigating  NO bioavailability, eNOS activation and 
tube formation capacity. 
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4 Methodology, materials and methods 
To address the aims of this project, EA.hy926 endothelial cells and HUVECs were used as 
cell models. Analysis of angiogenesis, VEGF-A expression, NO production, and regulation 
of Akt/eNOS/NO pathway were used as readouts for the assessment of endothelial function. 
Cells were treated with either ER/oxidative stress inducers or 33 mM glucose (high glucose 
model) in the presence or absence of HO-1 inducer (CoPP) or chemical chaperones to 
alleviate ER stress response. Furthermore, the effects of HO-1 in modulating ER stress, 
oxidative stress, apoptotic and inflammatory pathways were evaluated in the process.  All 
manipulations unless otherwise stated were carried out in class 2 microbiological cabinet 
using good aseptic techniques. The diagram below summarizes the methodology followed to 
achieve the objectives of this project [Figure 13]. 
 
Figure 13. A flowchart showcasing the methodology used in this project. 
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4.1 Cell cultures 
Human EA.hy926 endothelial cells were obtained from the American Type Culture 
Collection [ATCC]  and  routinely cultivated in high glucose [25mM] Dulbecco's Modified 
Eagle's Medium [DMEM] [Sigma-Aldrich, Gillingham, UK] supplemented with 10% fetal 
bovine serum [FBS] [Invitrogen, Paisley, UK], 2 mmol/L L-glutamine, 1% non essential 
amino acids [NEAA] and 1% penicillin/streptomycin [Sigma-Aldrich, Gillingham, UK], and 
was maintained at 37 °C in a humidified atmosphere with 5% carbon dioxide [CO2]. 
For maintenance, cells were passaged at 80-90 % of confluency using trypsin-EDTA 0.05 % 
[Sigma-Aldrich, Gillingham, UK] and plated in 75 cm2 ventilated flasks. For all treatments, 
cells were seeded into 6-well plates at the density of 200,000 cells/well or 25 cm2 ventilated 
flasks at the density of 300,000 cells/T25 flask 24 hrs before the treatments. Cells were 
counted using haemocytometer and tally counter. Trypan blue in phosphate buffer saline 
[0.4%] was used to satin dead cells which were counted with the live non stained cells to 
detect cell viability which was ≈ 90%.  Cells were then used for experiments up to passage 35 
post-recovery and culture medium was changed every 48 hrs until desired confluency was 
reached. 
HUVECs were obtained from Life Technologies [Fisher Scientific, UK] and were routinely 
cultivated in M200 medium [Gibco, Paisley, UK] supplemented with low serum growth 
supplement [LSGS] which contains the following;FBS, 2% v/v; hydrocortisone, 1 ug/ml; 
human epidermal growth factor, 10 ng/ml; basic fibroblast growth factor [FGF-β], 3 ng/ml; 
and heparin, 10 ug/ml [Gibco, Paisley, UK] and was maintained at 37 °C in a humidified 
atmosphere with 5% CO2. For maintenance of HUVECs, they were passaged at 80 % of 
confluency using trypsin-EDTA 0.05 % [Sigma-Aldrich, Gillingham, UK] and plated in 75 
cm2 ventilated flasks. For all treatments, cells were seeded into 6-well plates at the density of 
200,000 cells/well or 25 cm2 ventilated flasks at the density of 300,000 cells/flask before the 
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treatments. HUVECs were then used for experiments up to passage 10 post-recovery. Culture 
medium was changed every 48 hrs until desired confluency was reached. 
 
4.2 Cell viability assay [MTT assay] 
This assay is based on the conversion of the yellow tetrazolium salt 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide [MTT] to purple formazan crystals by metabolically 
active cells and provides a quantitative estimate of viable cells. EA.hy926 cells were seeded 
into 96-well plates [50,000 cells/well], grown for 24 hrs, and then treated with thapsigargin 
[TG] at the concentration of 300 nM for 6, 8, 12, 18 and 24 hrs. The same experiment was 
repeated in HUVECs. As for CoPP and SnPP treatments, HUVECs were treated with CoPP 
for 12 and 24 hrs at concentrations 10 µM, 25 µM, 50 µM , 75 µM  and 100 µM, while SnPP 
was added for 6, 12 and 24 hrs at the concentration of 20 µM . 
After incubation, MTT [Sigma-Aldrich, Gillingham, UK] at the final concentration of 0.5 
mg/mL was added to each well and incubated for 4 hrs at 37°C, 95% humidified incubator 
with 5% CO2. Then, 100% [v/v] of a solubilisation solution [10% S-Dodecyl Sulphate (SDS) 
in 0.01 M hydrochloric acid] was added to each well to solubilize the formazan crystals for 
spectrophotometric reading. 
A slightly different approach was followed with high glucose treatments of HUVECs, where 
cells were first grown in T25 cm2 culture flasks in high glucose media [10 mM, 20 mM, 25 
mM, 33 mM and 50 mM] for 1, 2, 3, 4, and 5 days, then cells were seeded into 96-well plates 
after which the same procedural steps were followed as above for MTT assay analysis. 
Spectrophotometric absorbance was measured at 540 nm using a multi-plate reader. For more 
exact results, reference wavelength 620 [OD 540-OD 620] and blanks with all solutions 
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without cells [samples blanks] were used. Samples were loaded in 5 replicates, and the 
relative cell viability [%] was expressed as a percentage relative to the untreated control cells. 
 
4.3 Cell treatments 
4.3.1 TG treatment 
A stock solution of 300 µM of TG [Fisher Scientific, UK] was prepared by adding 1 mg of 
TG into 5 mL of dimethyl sulfoxide [DMSO] and filtered through a 0.2 µm filter. Cells were 
seeded into 6-well plates at the density of 200,000 /well, and 24 hrs later, culture media were 
replaced with fresh complete media, DMEM + 10% FBS + 2 mM L-glutamine+ 1% NEAA+ 
1% penicillin/ streptomycin for EA.hy926 cells and M200+LSGS for HUVECs, then cells 
were incubated with TG [300 nM] at different time points for the MTT assay [6, 8, 12, 18 and 
24 hrs], then for 12 hrs for the rest of the experiments. After the incubation period is over, 
total proteins for western blot analysis or total RNA for real time qPCR were harvested from 
cells as described below. 
 
4.3.2 TUDCA 
A stock solution of 200 mg/mL of chemical chaperone, TUDCA [Calbiochem, UK] was 
prepared by adding 5 g of TUDCA into 25 mL of phosphate buffered saline [PBS] and 
filtered through a 0.2 µm filter. Cells were seeded into 6-well plates at the density of 200,000 
cells/well and TUDCA was added [500 ug/mL] 12 hrs prior to incubation with 33 mM 
glucose or TG. 
 
4.3.3 PBA 
A stock solution of 3 M of chemical chaperone, PBA [Sigma Aldrich, UK] was prepared by 
dissolving 25 g of PBA in 50 mL of autoclaved diH2O under water bath sonication, then 
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filtered through a 0.2 µm filter and aliquoted in 2 mL tubes. HUVECs were seeded into T 25 
cm2 ventilated flasks at the density of 300,000cells/flask, PBA was added at 10 mM working 
concentration 1 hour before being further treated with TG or 33 mM glucose for 12 hrs 
before the harvest. 
 
4.3.4 HO-1 induction and CoPP treatment 
A stock solution of 7.6 mM of CoPP [Santa Cruz Biotechnology, Texas, USA] was prepared 
by dissolving 25 mg of CoPP to 5 mL of DMSO and filtered through a 0.2 µm filter. Then 
dose-response and time-course studies were performed using MTT cell viability assay.  
HUVECs were seeded into 6-well plates at the density of 200,000 cells/well, and after 
overnight incubation culture medium was replaced with fresh complete M200 medium, then 
cells were treated with different concentrations of CoPP [10, 25, 50, 75, 100 µM] at two time 
points [12 or 24 hrs]. 
 
4.3.5 SnPP treatment 
A stock solution of 5 mM of SnPP [Santa Cruz Biotechnology, Texas, USA] was prepared by 
dissolving 25 mg of SnPP in 6.5 mL of DMSO and filtered through a 0.2 µm filter. To 
perform MTT assay, HUVECs were seeded into 6-well plates at the density of 200,000 
cells/well, and after overnight incubation culture medium was replaced with fresh complete 
M200 medium, then cells were treated with SnPP [20 µM] (Zakhary, Gaine et al. 1996), at 
different time points [6, 12 and 24 hrs]. When the optimum time point for SnPP was chosen, 
SnPP added 1 hour prior to CoPP which is further added for 12 hrs before the harvest. 
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4.3.6 High glucose treatments 
 
D-glucose from Sigma Aldrich [Gillingham, UK] was used in all high glucose treatment 
experiments. The desired concentrations were prepared by dissolving glucose either in 
DMEM + 10% FBS + 1% NEAA + 1% penicillin/ streptomycin for EA.hy926 cells or 
M200+LSGS for HUVECs, then filtered by 0.2 µm filter and stored at 4°C until subsequent 
use. DMEM already contained 25 mM of D-glucose in its composition, while M200 
contained 5.5 mM, so this was taken into account during calculation of the desired glucose 
concentration. The amount of glucose in cell culture formulations ranges from 1 g/L (5.5 
mM) to as high as 10 g/L (55 mM), thus MTT cell viability assay was performed on 
HUVECs treated with different glucose concentrations [10 mM, 20 mM, 25 mM, 33 mM and 
50 mM] for different durations [1, 2, 3, 4 and 5 days]. Concentrations of glucose approaching 
10 mM are pre-diabetic levels, whereas concentrations above 10 mM are analogous to a 
diabetic condition within the cell culture system. This is important because the same 
processes that can affect cells and molecules in vivo can occur in vitro, however, the 
consequence to growing cells under conditions that are essentially diabetic is that cells and 
cell products are modified by the processes of glycation and glyoxidation at much higher 
glucose levels than in vivo, eventually causing post-translational secondary modifications of 
therapeutic proteins that are produced in cell cultures (Clyne, Zhu et al. 2008). 
Two methods of high glucose treatment in culture were attempted to induce metabolic stress; 
1) 33 mM for 48 hrs continuous applied in both cell models; 2) 33 mM for 5 days with 8 hrs 
intermittent recovery periods applied only in HUVECs model [Figure 14]. 
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Figure 14.  Timeline for treatment of HUVECs with high glucose for 5 days with intermittent 8 hrs 
recovery periods. Cells are seeded in normal complete M200 [M200 + LSGS] which is then replaced as 
shown above with complete M200 supplemented with 33 mM filtered D-glucose. 
 
4.3.7 Mannitol Treatments 
 
To factor out the osmotic stress effect which high glucose treatments might have on all the 
observed effects in cells, mannitol [Sigma Aldrich, Gillingham, UK] was used as an osmotic 
stress control where a control group of HUVECs was treated in parallel to glucose in exactly 
the same fashion, with mannitol [33 mM] for 5 days with 8 hrs overnight recovery periods. 
Any mannitol treated samples that showed ER stress, oxidative stress, inflammation or 
apoptosis would cast doubt on the whole experiment and therefore would be discarded. 
 
4.4 Western Blot analysis 
4.4.1 Protein extraction 
 
After treatments, plates were removed from the incubator and put on ice to keep the 
temperature close to 4°C to inhibit any enzymatic activity that may cause protein degradation 
(proteases) or de-phosphorylation (phosphatases). Then culture medium was removed and 
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cells were carefully washed twice with 1 mL of cold PBS. Then, whole-cell lysates were 
prepared by extraction in 200 µL/well in a 6-well plates or 350 µl/T25 flask of radio-
immuno-precipitation assay [RIPA] lysis buffer [10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 
0.1% SDS; 1% Triton-X100; 1% Sodium deoxycholate; 1 mM NaF; 5 mM EDTA; 1 mM 
sodium orthovanadate; protease inhibitor mini tablets 1tab/10ml] on ice. The cells were then 
scraped using a cell scraper to collect all the lysates and then transferred to a pre-labelled 1.5 
mL micro-tube. The cell lysates were then centrifuged at 4°C for 15 minutes at 14,000 g. The 
pellet was discarded and the supernatant was carefully transferred into a second pre-labelled 
1.5 mL micro-tube. Cell lysates [samples] were assayed for protein quantification using 
bicinchoninic acid assay [BCA] then stored at -20° C until further analysis. 
 
4.4.2 Protein assay 
 
Protein concentrations were determined using the colorimetric [BCA] assay [Thermo 
Scientific, Loughborough, UK]: 
A) Bovine serum albumin [BSA] standard curve samples [0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2 
mg/mL] were prepared in RIPA according to the manufacturer’s instructions. 
B) 10 µL of samples and standards were added in duplicates into a 96-well plate. The blank 
used was RIPA buffer only. 
C) 200 µL of mixture of ThermoScientic kit reagents A [sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide] and B 
[cupric sulphate] at the ratio 50:1 were added to each well containing standards, samples 
or blanks. 
D) The plate with samples was then gently mixed for few seconds on a plate shaker. After 
incubation for 30 minutes at 37°C, a purple colour had developed in the wells. 
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E) Protein quantification was performed by measuring OD at 540 nm using microplate 
spectrophotometry within one hour of incubation, extrapolated on BSA standard curve 
where protein concentrations were calculated from the standard curve. 
F) This standard curve was constructed using Microsoft Excel by plotting BSA standard 
protein concentrations on the X-axis against OD on Y-axis, and the desired coefficient of 
determination [R2] was always ≥ 0.99 [Figure 15]. 
 
 
Figure 15. Representative standard curve for BCA assay; constructed by plotting BSA standards 
concentrations [0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2 mg/mL] against OD values [540 nm] obtained from 
spectrophotometer reading. Total protein concentration in each sample was extrapolated by applying the 
OD of samples to the curve. 
 
 
4.4.3 Sample preparation and protein denaturation for electrophoresis 
 
Protein samples were prepared for gel electrophoresis by mixing them with loading buffer 
containing 250 mM Tris-HCl pH 6.8, 10 % [SDS], 50 % glycerol and 0.025 % bromophenol 
blue [all reagents from Sigma-Aldrich, Gillingham, UK]. SDS is an anionic detergent which 
denatures secondary and non–disulphide–linked tertiary structures, and applies a negative 
charge to each protein in proportion to its mass. Glycerol is added to make the proteins 
heavy, and 50% bromophenol blue is a tracking dye to monitor protein migration. Then 
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samples were heated to 95°C [6 minutes] in a dry heating block to further promote protein 
denaturation, helping SDS to bind. Samples were then processed for western blotting or 
stored at -20°C until further analysis. 
 
4.4.4 Electrophoresis 
 
Proteins of equal amounts [10-20 µg] and molecular weight markers were loaded into 8 x 10 
cm2 Tris-Glycine precast 8-12% gels [Thermo Scientific, Loughborough, UK] and were 
resolved on SDS-PAGE. The 10X electrophoresis running buffer [0.25 M Tris base + 1.9 M 
glycine + 0.03 M SDS in 1000 mL of diH2O + pH 8.3, [all reagents obtained from Sigma 
Aldrich, Gillingham, UK] had to be diluted 1:10 with diH2O water to run the gel at 130 volts 
at constant voltage for 1 hour and 20 minutes or until the dye front reached the bottom. 
 
4.4.5 Proteins transfer [wet transfer method] 
 
After the electrophoresis run was finished, the gel was put in 50 mL of transfer buffer for 15 
minutes to equilibrate [25 mM Tris base+192 mM glycine+20 % methanol, pH 8.3, Sigma 
Aldrich, Gillingham, UK]. The transfer sandwich was performed in a tray full of 1L transfer 
buffer, the gel cassette [ThermoScientific, Loughborough, UK] was dismantled and put in the 
tray submerged in the buffer with black side facing down, and the layers were stacked from 
top to bottom as follows; sponge, 2.5 mm thick filter paper, 0.45 µm nitrocellulose membrane 
from GE health care life science, gel, 2.5 mm thick filter paper,  and sponge. A roller was 
used between each layer to make sure there are no air bubbles then the sandwich was closed 
and put in the gel tank [Bio-Rad, Hemel Hempstead, UK] with the membrane facing the 
anode relative to the gel, the transfer buffer is poured into the tank with ice pack inclusion 
[Figure 16]. 
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Figure 16. Transfer sandwich using wet transfer method. This figure shows the sandwich layers from 
top to bottom with the direction of current. 
 
The transfer process took place at 4°C degrees in the following conditions; Tank placed on 
ice connected to power supply from [Bio-Rad, Hemel Hempstead, UK] for 2 hrs and 30 
minutes at 30V. 
 
4.4.6 Blocking 
 
After the transfer has finished, the membranes were then blocked for 1 hour in blocking 
buffer [ previously defined Tris-buffered saline + 0.1% Tween 20 [TBS-T] + 3 % [v/v] non-
fat Marvel® dry milk] at room temperature on an orbital shaker. Then, the membrane was 
washed for 2 min with TBS-T prior to being incubated overnight with primary antibody in 
TBS-T+ 3% BSA at 4°C, in a 50 ml tube with constant rotation. 
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4.4.7 Primary antibody incubation 
 
All primary antibodies used were diluted in TBS-T containing 3 % [v/v] of BSA and 
incubated with the membranes overnight at 4°C with gentle shaking/rolling. Monoclonal 
mouse anti- β-Actin was used as loading control [Table 1]. 
Table 1. Primary antibodies used for western Blotting experiments 
Primary antibody Host Manufacturer Dilution MW 
Polyclonal anti-
GRP78/BiP 
Rabbit Cell Signalling 1:350 75KD 
Polyclonal anti-HO-
1 
Rabbit Santa Cruz 
Biotechnology 
1:100 32KD 
Monoclonal anti- β-
Actin 
Mouse Santa Cruz 
Biotechnology 
1:1000 42kD 
Polyclonal anti-
ATF-4 
Rabbit Cell Signalling 1:1000 38KD 
Polyclonal anti-p-
eIF-α 
Rabbit Cell Signalling 1:600 38KD 
Polyclonal anti-C-
caspase 3 
Rabbit Cell Signalling 1:1000 17, 19KD 
Polyclonal anti-C-
caspase 7 
Rabbit Cell Signalling 1:1000 18KD 
Polyclonal anti-C-
PARP 
Rabbit Cell Signalling 1:750 89KD 
Polyclonal anti-p-
p47phox [Ser345] 
Rabbit Sigma Aldrich 1:800 47KD 
Polyclonal anti- 
p47phox 
Rabbit Cell Signalling 1:1000 47KD 
Polyclonal anti- Rabbit Cell Signalling 1:1000 87/85KD 
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PIKK α/β 
Polyclonal anti- 
IKK 
Rabbit Cell Signalling 1:1000 85KD 
Polyclonal anti- p-
C-JUN 
Rabbit Cell Signalling 1:750 48KD 
Polyclonal anti- 
VEGF-A 
Rabbit Sigma Aldrich 1:750 42KD 
Polyclonal anti p-
Akt [Ser473] 
Rabbit Cell Signalling 1:800 60KD 
Polyclonal anti-Akt Rabbit Cell Signalling 1:800 60KD 
Polyclonal anti-p-
eNOS [Ser1177] 
Rabbit Cell Signalling 1:1000 140KD 
Polyclonal anti-
eNOS 
Rabbit Cell Signalling 1:1000 140KD 
Polyclonal anti-HO-
1 
Rabbit Santa Cruz 
Biotechnology 
1:100 32KD 
Monoclonal anti- β-
Actin 
Mouse Santa Cruz 
Biotechnology 
1:1000 42kD 
Polyclonal anti-
ATF-4 
Rabbit Cell Signalling 1:1000 38KD 
Polyclonal anti-p-
eIF-α 
Rabbit Cell Signalling 1:600 38KD 
Polyclonal anti-C-
caspase 3 
Rabbit Cell Signalling 1:1000 17, 19KD 
Polyclonal anti-C-
caspase 7 
Rabbit Cell Signalling 1:1000 18KD 
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Polyclonal anti-C-
PARP 
Rabbit Cell Signalling 1:750 89KD 
Polyclonal anti-p-
p47phox [Ser345] 
Rabbit Sigma Aldrich 1:800 47KD 
Polyclonal anti- 
p47phox 
Rabbit Cell Signalling 1:1000 47KD 
Polyclonal anti- 
PIKK α/β 
Rabbit Cell Signalling 1:1000 87/85KD 
Polyclonal anti- 
IKK 
Rabbit Cell Signalling 1:1000 85KD 
Polyclonal anti- p-
C-JUN 
Rabbit Cell Signalling 1:750 48KD 
Polyclonal anti- 
VEGF-A 
Rabbit Sigma Aldrich 1:750 42KD 
Polyclonal anti p-
Akt [Ser473] 
Rabbit Cell Signalling 1:800 60KD 
Polyclonal anti-Akt Rabbit Cell Signalling 1:800 60KD 
Polyclonal anti-p-
eNOS [Ser1177] 
Rabbit Cell Signalling 1:1000 140KD 
Polyclonal anti-
eNOS 
Rabbit Cell Signalling 1:1000 140KD 
 
4.4.8 Secondary antibody incubation 
 
After incubation with primary antibody time has finished, the membranes were washed in 20 
ml TBST 4 X5 min, and then incubated with appropriate secondary antibodies. All antibodies 
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were diluted in filtered TBST containing 3 % non-fat milk + 0.1% SDS and incubated with 
the membranes at RT for 1 hour with gentle shaking. 
 
Table 2.  Secondary antibodies used in western blotting experiments. 
Secondary antibody Host Manufacturer Dilution 
HRP-conjugated anti-mouse Goat LI-COR Biosciences 1:3,000 
HRP-conjugated anti-rabbit Goat LI-COR Biosciences 1:20,000 
Fluorescence-conjugated 
anti-mouse 
Goat LI-COR Biosciences 1:10,000 
Fluorescence-conjugated 
anti-rabbit 
Goat LI-COR Biosciences 1:10,000 
 
4.4.9 Detection 
 
After secondary antibody incubation has finished, the membranes were washed in TBS-T 4X 
5 min, and then washed in diH2O 2X5 min, and then detected as follows: 
A) HRP-conjugated secondary antibodies 
Detected using C-DiGit® scanner using Western sure ultra enhanced chemiluminescence 
[ECL] from LI-COR Biosciences according to the manufacturer’s protocol. Using the built in 
image studio version 5.x software, total signal strength of the target and the loading control 
[b-actin] were quantified, then the target was normalized against the loading control using 
Microsoft excel. 
B) Fluorescence-conjugated secondary antibodies 
Detected using Odyssey® CLx imaging system from LI-COR Biosciences according to 
manufacturer’s guidelines. This is a direct fluorescence detection and no ECL was required. 
Using the built in image studio version 5.x software, total signal strength of the target and the 
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loading control [b-actin] were quantified, then the target was normalized against the loading 
control using Microsoft excel. 
 
4.5 RNA extraction and qPCR analysis 
4.5.1 RNA extraction 
 
RNA extraction from EA.hy926 cells and HUVECs was performed using the Qiagen RNeasy 
mini kit following the manufacturer’s protocol. After treatments, 6-well plates/T25 flasks 
were removed from the incubator. Then culture medium was aspirated off and cells were 
carefully washed twice with 1 mL cold PBS. Then, whole-cell lysates were prepared by 
extraction in 300 µL/well or 600 µl/T25 flask of RLT (+guanidine thiocyanate) lysis buffer. 
The lysate was collected using a cell scraper, then transferred into a labelled 2 mL microtube. 
The cell lysates were then homogenized using small volume sonicator (XL-2000, Fisher 
Scientific, UK) for 30 seconds. To avoid cross contamination between samples, the sonicator 
probe was washed with 70% ethanol [v/v] then RNAse free water in between. Equal volumes 
of 70 % ethanol [v/v] were added and mixed well by pipetting up and down. The sample 
lysate was then transferred to the spin column in 2 mL collection tube [provided with the kit] 
which was then centrifuged at 14,000 g for 15 seconds at 20°C-25°C with discarding the flow 
through. This was followed by three washes, one with RW1(+guanidine thiocyanate)  buffer 
and the last two were with RPE buffer (+100% ethanol) and spun as outlined above with 
discarding the flow through each time. 30-50 µL of RNase free water was then added and the 
elute containing the RNA was collected by centrifugation at 14,000 g for 1 minute. 
 
4.5.2 RNA quantification 
 
Total RNA quantification was performed using UV spectrophotometry [Thermo-Scientific  
NanoDrop 2000/2000c] measured at 260 nm [1OD=40ug/ml], purity was checked by ratios 
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of the readings 260/280 nm and 260/230 nm [≥1.8].  This was followed by DNA digestion 
and cDNA synthesis using RNase free DNase 1 and RevertAid first strand cDNA synthesis 
kits respectively [Fisher Thermo-Scientific, UK]. 
 
4.5.3 DNA digestion 
 
Before cDNA synthesis, 300 ng of total RNA was loaded from each sample in 96-well plate, 
followed by adding 1 µL of 10X reaction buffer {[100 mM Tris-HCl/pH 7.5], 25 mM MgCl2, 
1 mM CaCl2}, then 1 µL [1U] of DNase I and finally topped up to 10 µL with RNase-free 
water. The plate was then incubated at 37°C for 30 minutes using a thermal cycler (Applied 
Biosystems 2720, Foster City, CA,  USA). Then, 1 µL of EDTA was added and incubated 
again at 65°C for 10 minutes to stop the reaction. 
 
4.5.4 cDNA synthesis 
 
First strand cDNA was synthesized from 300 ng of total RNA using Applied Biosystems 
2720 thermal cycler and an oligo [dT] primer as reverse primer. One µL of oligo [dT] was 
added to total RNA in 96-well plate and then incubated at 65°C for 5 min. After incubation 
the plate was put back immediately on ice and 8 µL of reverse transcriptase master mix {4 µL 
of  5X reaction buffer [250 mM Tris-HCl with pH 8.3, 250 mM KCl, 20 mM MgCl2, 50 mM 
DTT ] + 0.5 µL [10U] of  Riboblock RNase inhibitor + 2 µL  [1mM] of  dNTPs + 1 µL l 
[200U] of reverse transcriptase + 0.5 µL of RNase free water; Thermoscientific, 
Loughborough, UK} was loaded in each well then centrifuged briefly to mix. The plate was 
then incubated at 42°C for 60 minutes and then at 70°C for further 5 minutes to stop the 
reaction. Finally, cDNA was diluted 1:10 in Tris-EDTA [TE] buffer {1M tris-HCL [pH=8] + 
0.1M EDTA} and used directly for qPCR or stored at -80°C until further analysis. 
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4.5.5 Real time qPCR 
 
Target genes were amplified by real-time qPCR using GoTaq Master Mix [Promega, 
Southampton, UK], which uses the same filters and settings of SYBR® Green with the 
advantage of brighter fluorescence and less PCR inhibition than SYBR® Green enabling a 
more efficient amplification and and earlier quantification cycle or cycle threshold. Relative 
gene expression was calculated using the relative standard curve method. 
4.5.5.1 Standard curve preparation 
 
Five standard dilution points were prepared by serial 1:3 dilution of the cDNA sample with 
expected highest expression of the gene of interest [1:1, 1:3, 1:9, 1:27 and 1:81]. 
4.5.5.2 Master mix preparation 
 
To prepare the master mix: 3 µL of RNase-free water + 6 µL of 2X Gotaq master mix + 1 µL 
of each primer [forward and reverse] were added together to 10 µM concentration. 
4.5.5.3 cDNA loading 
 
After loading the wells with the master mix, 2 µL of cDNA of standards and unknowns 
[loaded in triplicate] were added to bring total volume to 12 µL/well, and then the plate was 
centrifuged briefly to mix reagents and finally real time qPCR was run using Fast Real Time 
PCR Applied Biosystems 7500/7500 set on standard mode with the following reaction 
profile; Holding: 95°C/10min; 40 cycles of denaturation [95°C/15sec] and annealing [60 
°C/1min] followed by generation of melting curve to ensure a single specific PCR product is 
generated with no primer dimers [Figure 17]. 
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Figure 17. Melting curves in RT qPCR. The presence of a single peak indicates the generation of a pure 
and single specific amplicon or qPCR product. This is a representative melting curve included in all qPCR 
analysis used in this project. Melting curves that showed more than one peak were excluded. 
 
4.5.5.4 Quantification [Relative quantification standard curve method] 
 
Using Microsoft Excel, the standard calibration curve was constructed by plotting Log cDNA 
of the standards on the X-axis against their CT [cycle threshold= number of cycles for a 
fluorescence signal to cross the background levels] values on the Y-axis [Figure 18].  Using 
this standard curve, the CT values of the target gene in each experimental sample was 
extrapolated and the relative expression of the gene was determined using the following 
formula [10[CT-Y intercept/slope]]. A separate standard calibration curve was constructed for 
the housekeeping gene [GAPDH/β-actin] of the same sample which was run in the same 
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plate with the target gene. Finally, the relative expression of the target gene is normalized 
against that of the housekeeping gene [target/housekeeping], and then the normalized 
numbers were compared between samples to get a fold change in expression. 
 
Figure 18. Representative standard calibration curve; constructed by plotting CT values [Y-axis] 
against Log cDNA [X-axis]. Each gene whether target or housekeeping had its own standard curve 
constructed. The correlation coefficient [R2] for the line was always ≥0.98. 
 
4.5.5.5 Housekeeping gene 
 
GAPDH and β-actin were used for house keeping since they have shown stable relative 
expression across different experimental conditions, treated and non treated. 
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Figure 19.  GAPDH and β-actin mRNA expression in HUVECs and EA.hy926 [A], [B] Real time 
qPCR analysis assessed mRNA levels of GAPDH and β-actin  markers in HUVECs in different treatment 
conditions. [C] Real time qPCR for assessment of mRNA levels of GAPDH in EA.hy926  in different 
conditions.  RT-PCR analysis were carried out using 7500/7500 Fast Real-Time PCR System and SYBR 
Green detection. Quantifications were realized according to the relative standard curve method and data 
represent relative expression of target normalized to loading control.  Data are represented as mean± SEM 
and were analysed by one-way ANOVA, normalized by a Tukey's multiple comparison test [n=6]; Ctl: 
non-treated control; TG: thapsigargin; TD: TUDCA; HG: 33 mM glucose/5 days with 8 hrs intermittent 
recovery in HUVECs and 33 mM for 48 hrs in EA.hy926; PBA: Phenyl Butyric Acid; CoPP: Cobalt 
Protoporphyrin IX; Man: mannitol in same duration and dose as glucose. 
 
 
4.5.5.6 Primers 
 
4.5.5.6.1 Primer concentration 
 
Forward [F] and reverse [R] primers [Sigma-Aldrich, UK], were reconstituted separately to 
100 µM stock concentration using RNase free water. Another stock of F+R mix was prepared 
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by 10X dilution to a concentration of 10 µM and this was used in the master mix preparation 
mentioned above. 
4.5.5.6.2 Primer efficiency 
 
The efficiency [E] of each primer used was determined by running a standard curve [Ct vs 
log cDNA] using cDNA from a control sample, diluted in 1:3 serial dilutions. E = 10^[-
1/slope]. The slope and the efficiency of each primer are listed with base sequence in table 3. 
Table 3. List of human forward and reverse primers used in qPCR experiments. 
Target Gene 5′ → 3′ Forward primer 5′ → 3′ Reverse primer Slope Primer 
efficiency 
[2=100%] 
GAPDH CCAGCCGAGCCACATCGCTC ATGAGCCCCAGCCTTCTCCAT -3.945 
 
1.869 
 
B-actin CATCACGCCGTCCTATGTCG CGTCAAAGACCGTGTTCTCG -3.682 
 
1.793 
 
 
ATF-4 GAACGGCTCAAGCAGGAAATC TTCACCATTCGGTCAATCAGAG -3.512 1.926 
 
BiP GCTGACGATGAAGTTGATGTGG CATCCGTCCTTGATCCTTCTCTA -3.376 1.978 
 
CHOP CCCTTCACCTTCTTACAACCTC TGCCCAGCTCTAAACTAAAGGA -3.481 1.938 
 
GRP94 AAGACTGCGTTCCTGCTCAAC AAAGCCCTACAGCAACTGTCG -3.601 1.895 
 
IL-6 TGATGGCGAAGCGAGTGAAG ACTCATCCATACACAGGACCC -3.472 1.941 
 
VEGF-A GGTGGGCCAAAGGATGAAGAG CCACAAGCCAAACGACTTCC -3.291 2.013 
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4.6 Measurement of ROS by flow cytometry 
ROS such as H2O2, ONOO-, OH− OH-, HOO-, O- are produced in the cells and the 
accumulation of intracellular ROS contributes to endothelial dysfunction. 
Dihydroethidium [DHE] dye is specifically oxidized by O-2, the main ROS in the vasculature, 
and the oxidized dye intercalates within nuclear DNA to fluoresce a red color. The intensity 
and number of red dots in the nucleus is proportional to the amount of O2- present in the cell. 
HUVECs were seeded in T25 flasks in normal M200 medium at density 300,000 cells/flask. 
The following day, medium was replaced with 33 mM glucose-containing medium for 5 days 
with 8 hrs intermittent recovery periods as described above. On the 5th day, PBA [10 mM] or 
CoPP [10 µM] was added 1 hour before the last  application of 33 mM glucose treatment and 
maintained for an additional 12 hrs before harvest.  Osmotic stress was controlled by 
preparing an additional flask of cells grown in medium supplemented by mannitol [33 mM]. 
All flasks were kept at 37°C, 95% humidity and 5% CO2. As a positive control, H2O2 at the 
concentration of 100 µM was added to some cells for 30 minutes to induce ROS release. 
After the incubation period is over, cells were detached with trypsin-EDTA for 2-3 minutes at 
37°C, 95% humidity and 5% CO2 and trypsin deactivated with 2 mL of complete medium. 
Cell suspensions were then transferred into 15 mL tubes followed by centrifugation at 187 g 
for 10 minutes. The pellet was then washed twice with PBS. Following this, cells were re-
suspended in 1 mL of PBS and mixed with DHE at a final concentration of 10 µM. Cells 
were incubated for 30 minutes in the incubator at 37°C, 95% humidity and 5% CO2.  Cells 
for ROS were then analyzed by flow cytometry using FACS CANTO II [BD Bioscience, 
UK]. Unstained untreated cells were used to set the photomultiplier tube amplification 
voltage gain. Stained negative control cells [untreated] were used to set the gates. Using the 
stained positive control [H2O2/30 min], negative and positive cells were plotted and DHE 
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negative cells [P3] were separated from the positive cells [P2]. All cells in the P2 channel 
were considered positive for DHE [Figure 20]. 
 
Figure 20. Representative flow cytometer histogram showing DHE-positive and DHE-negative cells. 
HUVECs treated with 100 µM of H2O2 to discriminate DHE-positive cells from the DHE negative cells. 
DHE-negative cells were captured in the P3 channel and the DHE positive cells were collected in the P2 
channel. 
 
 
4.7 Assessment of apoptosis using flow cytometry 
Apoptosis was measured using Annexin V Apoptosis Detection Kit APC [eBioscience, UK] 
which employs an R-phycoerythrin-labelled Annexin V [Annexin V-PE] in concert with 
Propidium Iodide [PI] to evaluate sub-populations of cells undergoing apoptosis. During the 
early stages of apoptosis, cells begin to display the inner negatively charged phospholipid 
membrane component called phosphatidylserine [PS] on the outer leaflet of the cell 
membrane. PS becomes readily detectable by staining the cells with Annexin V-PE which 
binds to the negatively charged PS. PI on the other hand, is excluded from cells as it cannot 
cross the phospholipid bilayer. As the plasma membrane becomes increasingly permeable as 
during the later stages of apoptosis, PI can readily move across the cell membrane and bind to 
cellular DNA, providing means for identifying those cells that have lost membrane integrity 
through mechanisms including necrosis. 
HUVECs were seeded in T25 flasks in normal M200 medium at density 300,000cells/flask. 
The following day, medium was replaced with medium containing 33 mM glucose and this 
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was considered day one. The cells left to grow in high glucose medium for 5 days with 8 hrs 
overnight recovery periods. On the 5th day, CoPP [10 µM] was added 1 hour before the last 
high glucose treatment and SnPP [20 µM] added 1 hour before CoPP, and cells were then 
cultured for additional 12 hrs before harvest. Cells grown in normal complete M200 were 
used as controls.  All flasks were maintained at 37°C, 95% humidity and 5% CO2.  After 
incubation period is over, medium was discarded and cells were detached with trypsin-EDTA 
for 2-3 minutes at 37°C, 95% humidity and 5% CO2 and trypsin deactivated with 2 mL of 
complete medium. Cells were collected by centrifugation at 187 g for 10 minutes. The pellet 
was washed twice with PBS. Cells were then re-suspended in 15 ml tubes in cold 1X binding 
buffer at the concentration of 1-5x106 cells/mL counted by haemocytometer and tally 
counter. Then, 100 µL of cell suspension was added to flow cytometry tube for each sample. 
Cells and controls were incubated with 10 µL of Annexin V-PE dye for 15 minutes on ice, 
protected from light, followed by the addition of 380 µL of 1X binding buffer and 10 µL of 
PI dye. Samples were then immediately processed by FACS Canto II and data captured and 
analyzed using Diva 8.0 software. 
Compensation set up was performed before each experiment to ensure the accuracy and the 
quality of the results and to discriminate spillover of PI fluorescence on the background of 
the Annexin V fluorescence. Four tubes were set up as follows: 
§ Tube 1: No stain 
§ Tube 2: PI dye 
§ Tube 3: Annexin V dye 
§ Tube 4: Both PI and Annexin-V dyes. 
Compensation was performed and targeted at less than 40 % of the ‘spillover’ of each dye 
into the other dye [PE-%PerCy5-5= 20% and PerCy5-5-%PE= 39%]. 
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For gating to generate entire population of cells without debris, cellular fragments or auto 
florescence, untreated cells double stained with Annexin V-PE and PI showed four different 
cell populations [Figure 21]: unstained cells, cells stained with Annexin-V or PI only, and 
cells that are stained with both Annexin V and PI dyes. 
 
 
Figure 21. Representative analysis of gated double negative non debris region using the double 
staining Annexin V and PI. PE-A represents the detector for the Annexin V and PerCPcy5-5 represent 
the detector for PI dye. Q1 is for necrosis, Q3 is the negative live cells and Q2 and Q4 are late and early 
apoptotic cells, respectively. This figure represents a gated non debris region derived from a gated double 
negative region. 
 
4.8 Caspases 3/7 activity 
Caspases 3/7 activity was measured using Caspase-Glo® 3/7 Assay [Promega, Madison, 
USA]. Caspase-Glo® 3/7 reagent contains a luminogenic substrate [Aminoluciferin] attached 
to tetra-peptide sequence Z-DEVD, which is specific for protease cleavage by caspase-3 and 
caspases-7. Caspase-3/7 cleaves Z-DEVD releasing Aminoluciferin which is a luminescent 
substrate for the luciferase reaction. The light output from the luciferase reaction is directly 
proportional to the activity of the caspases enzyme. 
HUVECs were seeded in T25 flasks in normal M200 medium at density 300,000 cells/flask. 
The following day, medium was replaced with 33 mM glucose-containing medium and this 
was considered day one. The cells left to grow in high glucose medium for 5 days with 8 hrs 
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overnight recovery periods. On the 4th day, cells were seeded overnight in a 96-well white-
walled plate, at the density of 20,000 cells per well in 100 µL of normal complete M200 
medium with LSGS. Cells were then incubated at 37°C in 5% CO2 and 95% humidity. After 
overnight incubation, CoPP was added in the following morning at a concentration 10 µM for 
1 hour and kept in the same incubation conditions as above, then medium discarded and 
replaced with 33 mM glucose containing medium supplemented with CoPP at 10 µM and 
cultured for additional 12 hrs. Three hrs before the start of the experiment, Staurosporin [1 
mM] was added to normal cells cultured in normal M200 to create a positive control for 
apoptosis. Untreated cells cultured in normal medium were used as negative controls. 
Complete medium without cells was used as blanks [no cell control]. After incubation period 
is over, culture Plates were left to equilibrate at room temperature for 15 minutes and 100 µL 
of Caspase-Glo® 3/7 Reagent [Promega Corporations, Madison, USA] was added to each 
well. The plate was then mixed by using a plate shaker at 400 rpm for 30 seconds and left in 
the dark at room temperature for 2 hrs. The activity of caspase 3/7 was then measured using 
luminometer [LUMIstar Omega from BMG LABTECH] [Figure 22]. 
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Figure 22.  Schematic representation for the Protocol used for Caspase 3/7 luminscent assay. 
 
Luminescence in relative light units [RLU] was subtracted from the blank, and caspase 
activity of the samples was calculated as RLU percentage of the positive control using 
Microsoft Excel.  Values were exported to GraphPad prism version 7 where one way-
ANOVA was used to plot the graph. 
 
4.9 IL-6 analysis by ELISA 
To assess the pro-inflammatory effect of 33 mM glucose on HUVECs after treatment for 5 
days with 8 hrs overnight recovery periods as well as assess the potential protective role HO-
1 induction, ELISA was performed to detect IL-6 in culture medium of treated cells using 
human IL-6 ELISA kit [Thermoscientific, UK] following manufacturer recommendations. 
HUVECs were cultured in T25 flasks and treated with 33 mM glucose, CoPP [10 µM] and/or 
SnPP [20 µM] exactly as stipulated above. A positive control was created using LPS [Sigma 
Aldrich, UK] treatment 1 µg/ml for 30 minutes.  After incubation period, culture medium 
was collected and transferred into 15 mL tubes followed by centrifugation at 10,000 g for 10 
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minutes to remove dead cells and any cell debris. Pellets were discarded and supernatants 
were collected and used for ELISA immediately or stored at -80°C until subsequent use. On 
the day of the experiment, IL-6 standards were reconstituted in ultrapure water to a stock 
concentration of 1000 pg/ml, then was serially diluted 1:2.5 in M200 media + LSGS to a 
range of 400 to 0 pg/mL [tube 1 to 6 in Figure 23]. Each tube was prefilled with 240 µL 
ultrapure water before the serial dilution. 
 
Figure 23.  Schematic representation of the serial dilution for IL-6 standard preparation. The 
standard vial was reconstituted in 1 ml of ultrapure water to prepare a stock standard IL-6 of 1000pg/ml. 
The 6 standard tubes were filled with 240 µL ultrapure water. 160 µL of the stock was added in tube 1 and 
mixed with pipetting, then 160 µL from tube 1 to tube 2. This repeated three more time using 160 µL to 
complete the standard curve points. 
 
Samples were allowed to thaw at room temperature and mixed gently by tube inversion. 
Biotinylated antibody reagent was added to each well [50 µL/well], then standards and 
samples were added in duplicates to each well and mixed well by gently tapping the plate 
several times.  The plate was then carefully covered by an adhesive plate cover and incubated 
for two hrs at room temperature. Thereafter, the plate was washed 3 times with wash buffer 
overfilling the wells, then 100 µL of Streptavidin-HRP solution was added to each well then 
covered and incubated at room temperature for 30 minutes. After washing the plate again 3 
times with wash buffer overfilling the wells, 100 µL of tetra methyl benzidine [TMB] 
substrate was added in each well and developed in the dark for 30 minutes at room 
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temperature. Finally, 100 µL of stop solution was added to each well and the plate taken to 
microplate spectrophotometer for reading OD at 450 nm. 
Standard curve was plotted as shown below and all sample OD values were extrapolated on 
the the curve to calculate unknown samples concentration [Figure 24]. 
 
 
Figure 24.  Standard curve for IL-6 constructed by plotting standard IL-6 concentrations [400 pg/mL, 160 
pg/mL, 64 pg/mL, 24.5 pg/mL, 10.2 pg/mL, 0] against OD [450 nm] obtained from spectrophotometer 
readings. OD of the samples were extrapolated on that curve to calculate IL-6 concentration. 
 
 
4.10 Measurement of NO production [Greiss assay] 
NO is rapidly oxidized to nitrite and/or nitrate by oxygen therefore NO produced can be 
estimated by determining the concentration of nitrite end-products in biological systems. The 
Greiss assay was used to measure the concentration of nitrite as an indirect way of estimating 
the levels of NO. In this method, the Greiss reagent kit [Life Technologies, UK] was used 
according the manufacturer’s protocol. 
HUVECs were cultured in T25 flasks and treated with 33 mM glucose for 5 days with 8 hrs 
intermittent recovery periods in 5.5mM glucose in the presence and absence of CoPP, then 
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collected and transferred into 15 mL tubes followed by centrifugation at 10,000 g for 10 
minutes remove dead cells and any debris. Pellets were discarded and supernatants were 
collected and used for Greiss assay immediately or stored in -80°C until subsequent use. On 
the day of the experiment, equal volumes of sulphanilamide [SA] and N-naphthyl-
ethylenediamine [NED] were mixed to form Greiss reagent, standards were prepared from a 
manufacturer’s stock 1mM of nitrite and diluted to 100 µM in complete M200 culture media. 
A 1:2 serial dilutions were carried out in a 96 well plate where the highest point of the 
standard curve is 100µM and the lowest point is 1.56 µM of standard nitrite concentration. 
Complete M200 media was used as the diluent to match the sample matrix [Figure 25]. 
 
Figure 25.  Schematic representation of the serial dilution for nitrite standard preparation.  A new 
diluted stock [100 µM] was prepared from the manufacturer standard stock [1mM] in M200 medium. The 
first well was loaded with 300 µL of the new stock, where as the rest of the wells were loaded with 150 µL 
of M200 medium except the 0 well was loaded with 280 µL of M200 medium. Then 1:2 serial dilution 
was carried out using 150 µL from each well with mixing well as shown above. 
 
After standard preparation in the 96 well plate [total volume =150 µL/well], samples were 
loaded into their respective wells [150 µL/well], then 20 µL of Griess reagent was added to 
all samples and standards then adjusted to total reaction volume of 300 µL/ well by adding 
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130 µL of deionized water, which is the optimum reaction volume for microplate assays 
according to manufacturer recommendations, then incubated for 30 minutes at room 
temperature. Samples and standards were assayed in duplicate. SA is dissolved in 5% 
phosphoric acid and it reacts with nitrite and/or nitrate to form a transient diazonium salt 
which reacts with NED to form a stable azo compound. Spectrophotometric absorbance was 
measured at 540 nm using a micro-plate spectrophotometer [Figure 26]. The intensity of the 
azo dye is directly proportional to the amount of nitrite/nitrate in the sample which is also 
proportional to the amount of NO produced. 
 
Figure 26.  Standard curve for Nitrite constructed by plotting standard nitrite concentrations [100µM, 50 
µM, 25 µM, 12.5µM, 6.25µM, 3.13 µM, 1.56 µM, 0] against OD [450 nm] obtained from 
spectrophotometer readings. OD of the samples were extrapolated on that curve to calculate sample nitrite 
concentration. 
 
4.11 Tube formation assay 
Tube-formation assay is one of the simplest, but yet well-established in vitro angiogenesis 
assays based on the ability of endothelial cells to form three-dimensional capillary-like 
tubular structures when cultured on a gel of growth factor-reduced basement membrane 
matrix. During the assay, endothelial cells differentiate, directionally migrate to align, 
branch, and form the tubular polygonal networks of blood vessels. Matrigel matrix [Corning, 
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UK] was used in this project to mimic the  in vivo tube formation capacity of endothelial cells 
under different physiological and pathological conditions. 
Sufficient Matrigel was aliquoted to cover 250 µL/well in a 24-well plate wells and kept 
submerged in ice in 4°C overnight before the day of the experiment. On the day of the 
experiment, it was loaded in a 24 well plate while it was being kept on ice, then put in the 
incubator at 37°C and 5% CO2 for 1 hour to allow it to solidify. During that time HUVECs 
which have been grown in T25 flasks and treated with 33 mM glucose, PBA or CoPP in 
exactly the same manner mentioned above, then harvested, counted using haemocytometer 
and tally counter, re-suspended in the designated culture medium and seeded on top of the gel 
at a density of 50,000 cells/well. Cells cultured in M200 medium without LSGS were used as 
the negative control, while those cultured in M200 medium supplemented with the LSGS that 
has 2% FBS +3 ng/mL β-FGF were used as positive control. After seeding the cells in the 
appropriate medium onto the Matrigel, the plate was placed in the incubator at 37°C and 5% 
CO2 and checked under the light microscope after 6, 12 and 24 hrs and final images were 
taken after 24 hrs.  Using NIH image J, the length of the tubes formed was counted in 5 
different blind fields, averaged then compared across different samples. 
 
4.12 Assessment of HO-1 activity [Bilirubin assay] 
Bilirubin colorimetric assay Kit [Cell Biolabs, Inc. CA, USA] was used to measure indirect 
bilirubin in HUVECs lysates following the manufacturer’s protocol. The principle of the 
assay is based on the reaction between diazotized sulfanilic acid [Sodium Nitrite+ Salfanilic 
acid] and bilirubin in the Van Den Bergh reaction, producing red-violet pigment [azo-
bilirubin] which can be detected at OD of 540nm. HUVECs were cultured in T25 flasks and 
glucose [33 mM] for 5 days, CoPP [10 µM], and SnPP [20µM] as previously described. After 
incubation period is over, cells were washed twice in ice cold PBS, then lysed by adding 
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RIPA lysis buffer [10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% SDS; 1% Triton-X100; 
1% Sodium deoxycholate; 1 mM NaF; 5 mM EDTA] 350 µL/T25 flask and centrifuged at 
10,000 x g for 10 minutes at 4°C, then the supernatant aliquoted for storage at -80°C until the 
day of the experiment. On the day of the experiment, bilirubin standards were prepared in 1:2 
serial dilutions in di H2O with range [0 to 32 mg/dL as shown in Figure 27]. 
 
 
Figure 27. Schematic representation of the serial dilution for indirect bilirubin standard 
preparation. The stock concentration in the vial is 800mg/dl. Tubes 1 to 8 were prefilled with di H2O [288 
µL in 1 and 150 µL in tubes 2 to 8] 2:1 serial dilution was carried out as shown by the arrows in the figure 
to get the desired concentration of all the standard curve points. 
 
Samples were thawed, then 50 µL of both samples and standards were loaded in duplicate in 
a 96-well microtiter plate and each sample well has a parallel negative control well where 
only RIPA was added. Accelerant [EtOH % undisclosed by manufacturer] was added and 
mixed the well contents thoroughly [125 µL/well]. Diazo reagent [Sodium Nitrite + Salfanilic 
acid] was loaded to samples and standards [25 µL/well] while negative control reagent 
[Salfanilic acid] was added to negative control wells. Reagent A [Sodium Hydroxide] was 
then added to all wells [75 µL/well] and the plate left for incubation for 1 hour at room 
temperature protected from light. After incubation is over, assay reagent B was added to each 
well [5 µL/well] and the absorbance at wavelength of 540 nm was measured using a 96-well 
plate spectrophotometer. The net OD for each sample was calculated by subtracting OD from 
negative control wells from each sample well, which was then plotted against standard curve 
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that has been constructed in Microsoft Excel sheet from bilirubin standards using their 
concentrations and OD [Figure 28]. 
  
Figure 28. Standard curve for indirect bilirubin standards.  Constructed by plotting standard bilirubin 
concentrations [32 mg/dL, 16 mg/dL, 8 mg/dL, 4 mg/dL, 2 mg/dL, 1 mg/dL, 0.5 mg/dL, 0] against OD 
[450 nm] obtained from spectrophotometer readings. OD of the samples were extrapolated on that curve to 
calculate bilirubin concentration. 
 
4.13 Statistical Analyses 
Statistical analysis was performed using GraphPad Prism® version 7 software. Results are 
expressed as means ± S.E.M, and n represents the number of independent experiments or 
biological replicates. Statistical analyses were performed using ANOVA [Two-way or One-
way, as appropriate], followed by Tukey’s or Bonferroni is multiple comparison post-hoc 
tests. P < 0.05 was considered statistically significant. 
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5 Results 
To address the aims of this project, two endothelial cell models were used as the platform in 
the experiments through out this project, EA.hy926 human endothelial cell line and HUVECs 
primary endothelial cells. EA.hy926 is a permanent human cell line that is derived by fusing 
HUVECs with thioguanine resistant clone of the permanent human adenocarcinoma cell line 
A549, therefore creating hybrid of immortalized cells capable of dividing indefinitely. This is 
a robust cell model that provides the optimal platform for reproducible and consistent results 
over the long term, however, because these cells undergo significant mutations to become 
immortal, their cell biology is altered, rendering them a less representative model to the in 
vivo situation which should be taken into consideration during analysis. The second model is 
HUVECs, which is human primary endothelial cell derived from the veins in human 
umbilical cord by pooling from different donors. They were cryopreserved at the end of the 
primary culture stage in culture medium containing 10% DMSO, consequently, these cells 
were utilized in the current project starting from passage 2 up to passage 10. This is a 
superior model of the in vivo situation, however these cells have few disadvantages as well, 
they have a limited life span, slow proliferative capacity, and their cellular characteristics and 
phenotypic features are not stable across the different passage numbers with a relatively high 
likelihood of phenotypic change and the loss of integral cellular characteristics with higher 
passage numbers. 
To assess the toxicity of drugs and treatments used in the experiments and their effect on cell 
viability, MTT assay was used to test in a time and dose dependant manner the effects of high 
glucose treatment, TG, CoPP and SnPP on the viability of both cell models, and any cell 
viability below 80% was excluded [Figures 29 to 32]. This test specifically measures the 
metabolic activity of cells by determining their ability to convert MTT into a purple coloured 
formazan, a reaction only viable cells can perform, thus providing a robust indication of the 
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viability status of the cell. However, being a nonspecific and quantitative test, it doesn’t 
determine the underlying cause for the decrease in cell viability or metabolic activity, so it 
cannot distinguish between necrosis and apoptosis as the cause of cell death. 
After optimal concentration of stressors and duration of treatment were determined, ER stress 
induction by TG was assessed in EA.hy926 cells using western blot analysis to target a key 
ER stress marker, BiP [Figure 33]. Real time qPCR was also used to assess this effect on 
both EA.hy926 cells and HUVECs targeting the expression of genes of different ER stress 
markers [BiP, ATF-4, GRP94 and CHOP] [Figure 34]. The effect of high glucose treatment 
on ER stress induction in EA.hy926 cells and HUVECs was concurrently assessed in this 
experiment at the concentration of 33 mM for a duration of 48 hrs. 
As glucose treatment of EA.hy926 cells failed to induce ER stress at 33 mM for 48 hrs, I  
increased glucose concentration to 100 mM on EA.hy926 cells,  and mRNA and protein 
expression levels of BiP were assessed using real time qPCR and western blot respectively. 
Interestingly, this method has also failed to induce stress in this endothelial cell model which 
underscores the disadvantage of using EA.hy926 as a diabetic model [Figure 35]. 
Due to failure of the abovementioned methods of using > 5mM glucose to induce ER stress 
in both cell models, a different treatment method was implemented. As it has been reported 
by Zhong et al., (2012) that fluctuating high to normal glucose treatments induce ER stress 
and inflammation in  human retinal pericytes cell model  although the exact mechanisms 
behind such action still remain to be elusive, I implemented a similar treatment model in this 
project, where  HUVECs were treated for 5 days with 33 mM glucose with 8 hrs overnight 
recovery period  where the high glucose medium was replaced with normal M200 medium 
[5mM glucose]. This fluctuating high glucose treatment at this duration and concentration did 
not significantly affect cell viability as shown in [Figure 30]. Furthermore, Intermittent high 
glucose treatment successfully induced mRNA expression [BiP, CHOP, and ATF-4] and 
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protein expression [BiP, PeIF2α, and ATF-4], which are key markers of ER stress in 
HUVECs [Figures 39 and 40]. 
To determine the optimal conditions for the induction of HO-1 in HUVECs by CoPP, several 
concentrations and time incubations were tested. The treatment of cells with CoPP at the 
concentration of 10 µM for 12 hrs, caused a significant increase in HO-1 protein expression 
levels with adequate 80% cell viability in MTT assay. Subsequently, these conditions for the 
induction of HO-1 were followed throughout the rest of my experiments [Figures 36 and 
37]. 
In order to evaluate the enzymatic activity of HO-1, I attempted to assess bilirubin levels in 
cell lysates which is one of the byproducts of HO-1 catabolism of heme and heme analogues 
[in this project being CoPP]. Moreover, to confirm that the observed change in bilirubin 
levels with CoPP treatments is stemming from HO-1 activity, SnPP which is a specific HO-1 
competitive inhibitor, was concurrently used in select experiments to assess the reversal of 
such observed response (Abraham and Kappas 2008) [Figure 38]. 
Flow cytometry was used to assess oxidative stress induction and O2- production in HUVECs 
treated with 33 mM glucose for 5 days with intermittent recovery periods [Figure 41]. In this 
process, the protective role of HO-1 induction and the involvement of ER stress were 
assessed. 
To address whether NOX plays a role as a potential source of ROS and O2- production in 
HUVECs that were exposed to high glucose environment, western blot analysis was 
conducted to assess the protein expression levels of phosphorylated p47phox subunit, which 
is  the organizer subunit that coordinates the interaction of the different NOX subunits 
[p67phox, p22phox  , p40phox   and gp91phox ], translocating them to the plasma membrane thereby 
allowing the formation of an active complex (El-Benna, Dang et al. 2009) [Figure 42]. 
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Because there are several previous reports showing that the induction of ER stress response is 
associated with cellular dysfunction and apoptosis, flow cytometry was used to assess the 
apoptotic effects of intermittent treatment with 33 mM glucose in HUVECs in the presence 
and absence of of HO-1 induction [Figure 43]. These results were further supported by 
performing a caspase3/7 luminescent activity assay. In order to investigate the relationship 
between high glucose-induced apoptosis, oxidative stress and ER stress induction, western 
blot analysis analysis was performed to look for the activation [cleavage status] of several 
enzymes involved in the apoptotic cascade [Figure 44]. 
ER stress response is intimately linked to cellular inflammation and was reported to activate 
key inflammatory pathways that contribute to cellular dysfunction and cell death (Ozcan, Cao 
et al. 2004). In an attempt to examine the inflammatory response in HUVECs after their 
exposure to high glucose treatment in the presence or absence of HO-1 induction, key pro-
inflammatory pathways were analyzed. Of particular interest, I have analyzed the activation 
of NF-κB [p-IKK] and JNK [p-c-Jun] pathways because of their strong link to ER stress 
response [Figure 46]. Furthermore, mRNA levels of the key pro-inflammatory cytokine IL-6 
was detected by Real time qPCR, whilst the proteins levels were detected in cell culture 
supernatant using ELISA. In all these experiments the potential anti-inflammatory role of 
HO-1 induction was concurrently tested [Figure 47]. 
Angiogenesis is a complex multi stage process that involves; 1] Endothelial cell activation in 
response to angiogenic stimuli, 2] Degradation of the capillary wall in response to the action 
extracellular proteinases, 3] Formation of branching points for the new vessel [sprouting], 4] 
Migration of endothelial cells towards the extracellular matrix under the control of 
angiogenic factors, 5] Differentiation of endothelial cells to form new tubular structures, and 
finally 6] Interconnection of the new tubules to form a network [anastomosis] (Sun, Bai et al. 
2009). 
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In this study, the 5th stage which is the differentiation capacity of HUVECs in response to 
high glucose treatments was examined using a Matrigel assay. This is the preliminary stage 
for the formation of tubules with central lumen. Different glucose treatments conditions were 
tested, constant 33 mM glucose for 48 hrs [Figure 48] and fluctuating 5 and 33 mM glucose 
for 5 days [Figure 49]. The capacity of HO-1 induction to modulate the ability of endothelial 
cells to form tube-like structures under high glucose condition was examined. Western blot 
analysis analysis and real-time qPCR were performed to assess protein  and mRNA 
expression levels of the pivotal pro-angiogenic marker VEGF-A to evaluate its potential role 
in the tube formation capacity of HUVECs in high glucose conditions [Figure 50]. 
In order to shed more light over the molecular mechanisms underlying the protective role of 
HO-1 induction in high glucose-mediated impaired angiogenesis, phosphorylation status of 
eNOS and Akt as well as NO production were investigated using western blot analysis and 
Greiss assay, respectively [Figures 52 and 53] 
Finally, since one of the primary aims of this project is to trigger a stress response in 
endothelial cell models in cell culture whether ER stress, oxidative stress, apoptosis or 
inflammation through a metabolically active process mimicking in vivo diabetic situation, it 
was crucial to eliminate the possible involvement of osmotic stress in cell culture. For this 
purpose and as a control for osmotic stress, HUVECs in select experiments were treated with 
mannitol in parallel to glucose in the exact same treatment conditions (Kumar, Kain et al. 
2012). 
In this chapter, all the above-mentioned data are going to be discussed in further details. 
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5.1 Assessment of effect of various treatments on cell viability using MTT 
assay 
5.1.1 Effects of TG treatment on the variability of endothelial cells 
 
TG is a specific inhibitor of the sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase. 
Treatment with TG results in a decrease in ER calcium ion levels. When calcium ion levels 
are lowered in the ER, the calcium-dependent ER chaperones, such as calnexin and BiP, lose 
their chaperone activity, leading to the accumulation of unfolded proteins and eventually ER 
stress ensues if this UPR is kept unchecked (Oslowski and Urano 2011). TG in the range of 
0.1-1 µM can be used to induce ER stress in a huge array of different cell models including 
endothelial cells (Oslowski and Urano 2011), with an ED50 of 80 nM (Thastrup, Cullen et al. 
1990).  In this project, I used TG at a concentration of 300 nM to induce ER stress response 
in both endothelial cell models EA.hy926 cells and HUVECs, and this is why cell viability 
assay was done on both cells types. Typically, only few hrs are required to induce ER stress 
and long exposures often induce ER stress-mediated cell death, so a cell viability assay was 
conducted in order to determine the optimum time point for our experiments, and any 
viability below 80 % was excluded (Oslowski and Urano 2011).
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Figure 29.  Cell viability [MTT assay] in EA.hy926 and HUVECs following treatment with TG  [TG, 300 nM]. [A] MTT assay on EA.hy926 cells showing a 
reduction in cell viability to 38% after 18 hrs and 26% after 24 hrs of treatment compared to untreated control for 24 hrs [Ctl]. [B] MTT assay on HUVECs showing 
a reduction in cell viability to 49% after 18 hrs and 40% after 24 hrs of treatment compared to Ctl. Data obtained by spectrophotometric quantification of OD at 
620nm subtracted from 540nm, and represent the % of viable cells in each treatment condition in relation to Ctl. Data are represented as mean± SEM and were 
analyzed by one-way ANOVA, followed by a Tukey's multiple comparison test. ***P < 0.001 vs. control group [n=5]
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As shown above, in both EA.hy926 and HUVECs, exposure times of 6, 8, and 12 hrs to TG 
[300 nM] resulted in cell viability of 80%. However, longer exposure resulted in significant 
reduction in viability down to 38% [EA.hy926, 18hrs], 26% [EA.hy926, 24hrs], 49% 
[HUVECs, 18 hrs], and 40% [HUVECs, 24 hrs] 
Because cells treated with TG for 12 hrs showed 80% cell viability and exhibited a 
significant ER stress response induction as shown in Figure 33 [discussed further below], 
this time point and concentration were therefore used in the rest of the experiments involving 
TG treatment. 
 
5.1.2 Effects of high glucose treatment on the viability of HUVECs 
The concentration of glucose in HUVECs culture medium [M200] is 5 mM, whereas 
physiological plasma glucose concentration ranges between 3.5–5.5 mM before meals and 8 
mM postprandial, and concentrations ³ 10 mM postprandial are considered diabetic levels 
according to the latest NICE guidelines 2015. Hence, concentrations of glucose > 10 mM are 
considered to mimic in vivo diabetic condition in the cell culture system. Similar cellular 
processes affect cells and molecules in vivo and in vitro following exposure of the system to 
high glucose conditions. The direct biochemical consequence of growing cells under high 
glucose conditions is that cells and cell by-products could be modified by glucotoxicity. This 
could cause alteration in their metabolic activity which could be detrimental to the cells 
resulting in their demise (Giardino, Edelstein et al. 1996). For this purpose, MTT assay was 
performed to assess the viability of HUVECs treated with different glucose concentration [10 
mM, 20 mM, 25 mM, 33 mM, and 50 mM] for different durations [1 day, 2 days, 3 days, 4 
days, and 5 days] [Figure 30]. 
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Figure 30. High glucose treatment at the concentration of 50 mM for 5 days shows marked reduction in MTT cell viability [48.5%], whereas 33 mM for 5 
days showed maintained cell viability at 80%.  MTT assay was performed on HUVECs to detect cell viability under high glucose conditions using different 
concentrations [10 mM, 20 mM, 25 mM, 33 mM, and 50 mM] at different time points [1 day, 2 days, 3 days, 4 days, and 5 days]. Data obtained by 
spectrophotometric quantification of OD at 620nm subtracted from 540nm, and represent the % of viable cells in each treatment condition in relation to untreated 
CTL. Data are represented as mean± SEM and were analyzed by one-way ANOVA, followed by a Tukey's multiple comparison test. ***P < 0.001 vs. control group 
[n=5].
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Although high glucose concentrations [>5 mM] for different durations [1 day, 2 days, 3 days, 
and 4 days] did cause a steady decline in cell viability, it was still maintained above 80% 
range. In addition, glucose treatment at 33 mM for 5 days also showed significant reduction 
in cell viability, however, was maintained at 80% [P < 0.05]. On the other hand, high glucose 
treatment at 50 mM for 5 days caused a more significant reduction in cell viability at 48.5% 
[P < 0.001]. Therefore, treatment of HUVECs with 33 mM glucose for 5 days was used in 
the rest of the experiments to assess high glucose induced metabolic stress, endothelial 
dysfunction, as well as assessing the protective role of HO-1 induction by CoPP. 
 
5.1.3 Effects of CoPP [HO-1 inducer] treatment on the viability of endothelial 
cells 
 
It is a common understanding that CoPP which is a well-known potent inducer of HO-1, has 
cytotoxic effects on cells when these are chronically exposed to it at high concentrations 
(Abraham and Kappas 2008). It is believed that cell exposure to high concentrations of CoPP 
for long duration can cause cytotoxicity by compromising the integrity of DNA and 
occurrence of apoptotic events including DNA fragmentation, caspase 3 and PARP protein 
cleavage, and chromatin condensation (Chow, Huang et al. 2008). 
Therefore, before using CoPP for the purpose of this project it was essential to conduct a cell 
viability assay to exclude those critical concentrations and time points that can compromise 
the viability of cells in our hands. 
HUVECs were treated with different concentrations of [10 µM, 25 µM, 50 µM, 75 µM, and 
100 µM] for 12 and 24 hrs, and MTT assay was then performed [Figure 31]. 
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Figure 31. The treatment of HUVECs with CoPP [25 µM to 100 µM] for 24 hrs caused a significant 
decrease in cell viability ranging between 50% to 70%%, whereas treatments for 12 hrs showed cell 
viability ranging between 70% [100 µM] and 94% [10 µM]. MTT assay was performed on HUVECs 
treated with CoPP at different concentrations [10 µM, 25 µM, 50 µM, 75 µM, and 100 µM] for 12hrs and 
24hrs. Data obtained by spectrophotometric quantification of OD at 620nm subtracted from 540nm, and 
represent the % of viable cells in each treatment condition in relation to untreated CTL. Data are 
represented as mean± SEM and were analyzed by one-way ANOVA, followed by a Tukey's multiple 
comparison test. ***P < 0.001 vs. control group [n=5]. 
 
As shown in Figure 31, CoPP has a concentration dependent effect on cell viability which 
was more pronounced at 100 µM for 24 hrs [51%]. In addition, concentrations between 10 
and 100 µM has significantly reduced cell viability to range between 60% and 70% when 
applied for 24 hrs. However, CoPP at the concentration of 10 µM did not significantly affect 
cell viability at both time points, although it was more preserved after 12 hrs compared to 24 
hrs time point [94% at 12 hrs, 79% at 24hrs]. 
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5.1.4 Effects of SnPP treatment on the viability of endothelial cells 
 
To confirm that the effects observed with CoPP are attributed to HO-1 induction, it was 
crucial to assess the reversal of such effect using a specific inhibitor of HO-1 [SnPP]. 
SnPP is a potent competitive inhibitor of HO-1 with subsequent reduction in the 
cytoprotective by-products of heme, bilirubin, CO and Fe (Frank, Lornejad-Schafer et al. 
2007). 
In order to assess the cytotoxic effects of this drug on HUVECs, MTT assay was performed 
on cells treated with SnPP [20 µM] at three different time points [6 hrs, 12 hrs and 24 hrs] 
[Figure 32]. 
 
 
Figure 32. The treatment HUVECs with SnPP [20 µM] did not significantly affect cell viability 
which was maintained above 80%.  MTT assay was performed on HUVECs treated with SnPP [20 µM] 
at three different time points [6 hrs, 12 hrs and 24 hrs]. Data obtained by spectrophotometric quantification 
of OD at 620nm subtracted from 540nm, and represent the % of viable cells in each treatment condition in 
relation to Ctl. Data are represented as mean± SEM and were analyzed by one-way ANOVA, followed by 
a Tukey's multiple comparison test. ***P < 0.001 vs. control group [n=5]. Data are represented as mean± 
SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison test [n=5]. 
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range even after 24 hrs of incubation. Accordingly, in future experiments SnPP was used at 
the concentration of 20 µM for 12 hrs. 
 
5.2 Assessment of ER stress induction in EA.hy926 cells in response to TG 
treatment. 
Western blot analysis of BiP, a key ER stress marker, was performed to assess induction of 
ER stress in EA.hy926 cells by TG at a concentration of 300 nM for 6-24 hrs. 
 
Figure 33.  Treatment of EA.hy 926 cells with TG [300 nM] caused a time-dependent increase in 
protein expression of BiP. Western blot analysis analysis of protein expression levels of BiP in control 
versus TG [300nM]-treated cells for 5 different durations, 6hrs, 8hrs, 12hrs, 18hrs, and 24 hrs. Controls 
[CTL] were kept for 24 hrs before the harvest with the rest of the time points. Data are represented as 
mean± SEM and were analysed by one-way ANOVA, followed with a Tukey's multiple comparison test. 
*P < 0.05, **P < 0.001 vs. control group [n=4]. 
 
As shown in the above figure, treatment of EA.hy926 cells with TG [300nM] caused a time-
dependent activation of ER stress response as evidenced by increased protein expression of 
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BiP. The highest BiP expression was observed at 24 hrs post cell stimulation. However, due 
to the significant reduction in cell viability with treatment duration longer than 12 hrs 
according to MTT assay, I continued using TG at the concentration of 300 nM for 12 hrs in 
the rest of the experiments, as a positive control for ER stress induction. 
 
5.3 Assessment of ER stress induction in EA.hy926 cells and HUVECs in 
response to constant glucose treatment [33 mM, 48 hrs] 
In an attempt to further characterize the activation of ER stress response following treatment 
of cells with high glucose, EA.hy926 cells and HUVECs were incubated in 33 mM glucose  
containing medium for 48 hrs, and compared to cells treated with TG [300 nM, 12 hrs] used 
as a positive control. To determine the activation of ER stress response, mRNA expression of 
key markers of ER stress, BiP, GRP94, ATF-4 and CHOP, were assessed using real time 
qPCR. To harness the effect of high glucose in mediating ER stress response, cells were pre-
treated with the chemical chaperone TUDCA at 500 ug/ml, that is known to prevent ER 
stress response activation and to improve ER homeostasis (Ozcan, Ergin et al. 2009). 
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Figure 34. TG treatment of endothelial cells caused an activation of ER stress response in both EA.hy926 cells and HUVECs; however, high glucose treatment 
failed to modify ER stress markers expression. [A], [B], [C], and [D], Real time qPCR analysis assessed mRNA levels of key ER stress markers in EA.hy926 cells 
[BiP, GRP94, ATF-4, and CHOP] in response to TG treatment [300 nM, 12 hrs and high glucose [33 mM, 48 hrs] in the presence and absence of chemical chaperone 
TUDCA. [E] and [F] Real time qPCR for assessment of mRNA levels of BiP and CHOP in HUVECs in response to TG treatment [300 nM, 12 hrs and high glucose 
[33 mM, 48 hrs] in the presence and absence of chemical chaperone TUDCA. RT-PCR analyses were carried out using 7500/7500 Fast Real-Time PCR System and 
SYBR Green detection. Quantifications were realized according to the relative standard curve method and data represent relative expression of target normalized to 
loading control. Data are represented as mean± SEM and were analyzed by one-way ANOVA, normalized by a Tukey's multiple comparison test. *P < 0.05, **P < 0.001, 
***P < 0.001 vs. control group or indicated group [n=6].
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As expected, exposure of EA.hy926 and HUVECs to 300 nM TG for 12 hrs resulted in 
significantly increased levels of BiP mRNA consistent with western blot analysis. Moreover, 
TG caused a significant increase in mRNA expression of GRP94, ATF-4, and CHOP in 
EA.hy926 cells and CHOP mRNA expression in HUVECs; however, TUDCA [5 µg/mL] 
pre-treatment failed to reverse these effects except with CHOP which showed a mildly 
significant reverse in effect. Furthermore, the treatment of cells with constant 33 mM glucose 
for 48 hrs did not significantly modify the expression of ER stress markers in both 
endothelial cell models used. 
Further attempts to assess ER stress induction in endothelial cells by high glucose treatment 
were made, EA.hy926 cells were subjected to higher glucose concentrations [100 mM, 48 
hrs], and ER stress target markers were assessed both at the mRNA and protein levels. 
 
5.4 Assessment of ER stress induction in EA.hy926 cells in response to  
constant  glucose treatment [100 mM,  48 hrs] 
Due to failure of the glucose treatment to cause ER stress induction at 33 mM for 48 hrs in 
both endothelial cell models, and since glucose treatment of HUVECs higher than 33 mM 
caused significant reduction in cell viability to as low as 63 %, EA.hy926 cell model was 
used for higher glucose treatment [100 mM] for 48 hrs to assess ER stress induction. Protein 
expression levels of BiP were evaluated using western blot analysis. 
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Figure 35. TG treatment of EA.hy926 cells caused an activation of ER stress response; however, 
higher concentration of glucose treatment [100 mM] still failed to modify ER stress markers 
expression. Western blot analysis assessed protein expression levels of BiP in EA.hy926 cells in response 
to TG treatment [300 nM, 12 hrs and high glucose [100 mM, 48 hrs] in the presence and absence of 
chemical chaperone TUDCA. Signal strength was quantified using Odyssey image scanner from Li-COR 
and targets were normalized against b-actin. All the data are represented as mean± SEM and were analyzed 
by one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.001, 
***P < 0.001 vs. control group or indicated group [n=3]. 
 
As expected, TG [300 nM] treatment for 12 hrs successfully caused a strong activation of ER 
stress response in EA.hy926 cells as in previous experiments. TG caused a significant 
increase in protein expression of BiP; however, Pre-treatment with TUDCA [5 µg/mL] failed 
to significantly reverse the increase in ER stress marker expression. Moreover, increasing 
glucose treatment concentration up to 100 mM still did not show any significant induction in 
ER stress [Figure 35]. 
Accordingly, since TUDCA treatments failed to significantly reverse the effects of TG on ER 
stress, I sought for the rest of the experiments to use a different chemical chaperone which is 
PBA, at the concentration of 10 mM for  a duration of 12 hrs (Kim, Jeong et al. 2013). 
Importantly, because the incubation of cells with high glucose for a duration of 48 hrs failed 
to induce ER stress response in endothelial cells, a different treatment method was 
implemented, where cells were incubated in 33 mM glucose containing medium for 5 days 
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with 8 hrs overnight recovery periods, then ER stress response and the role of HO-1 
induction by CoPP were assessed simultaneously [Figures 39 and 40]. 
 
5.5 Determining the optimal conditions for the induction of HO-1 by 
CoPP 
HO-1 is an inducible isoform of the HO system that can be induced by many 
pharmacological inducers with the heme analogue CoPP being a strong inducer as well as a 
substrate (Abraham and Kappas 2008), hence was used in this project to fulfil this purpose. 
First, EA.hy926 cells were used to determine the optimum time and dose for inducing HO-1 
by CoPP where cells were treated with five different concentrations [10µM, 25µM, 50µM, 
75µM, and 100µM] for 12 and 24 hrs, and protein expression of HO-1 was assessed by 
western blot analysis. 
 
 
Figure 36.  Treatment of EA.hy926 cells with CoPP [10 µM, 25µM, 50µM, 75µM, 100µM] for 12 hrs 
strongly induced protein expression of HO-1; however, the expression signal was reduced after 24 
hrs treatment. Western blot analysis analysis was used to assess HO-1 protein expression in EA.hy926 
cells in response to CoPP, a well-known inducer of this enzyme. The blot shows increased expression of 
HO-1 following CoPP application at different concentrations for different durations [12, 24 hrs]. Western 
bot analysis was carried out by Odyssey image scanner from Li-COR bioscience. 
 
CoPP application successfully achieved the required HO-1 induction in EA.hy926 cells at 
different concentrations [10µM, 25µM, 50µM, 75µM and 100µM]; however, the strength of 
this expression was stronger after 12 hrs than after 24 hrs. This experiment together with 
MTT assay described previously above [Figure 31] provided the method for how CoPP 
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would be applied in the rest of this project, where a 24 hour time point was excluded due to 
relatively reduced expression as revealed by western blot analysis and reduced cell viability 
as revealed by MTT assay [HUVECs], and 10µM concentration was used in further 
experiments since it was successful in achieving an induction of HO-1. 
Moreover, since MTT assay showed optimal cell viability of HUVECs treated with CoPP at 
10 µM for 12 hrs, this time and dose points were used to finally confirm the optimum time 
and duration for CoPP treatment in HUVECs model in the rest of the project by conducting 
western blot analysis to assess HO-1 protein expression levels. In addition, to assess whether 
high glucose treatment would impact HO-1 induction by CoPP, HUVECs were concurrently 
treated with 33 mM glucose for 5 days intermittently with 8 hrs recovery periods and CoPP 
was added in the last day of glucose treatment. 
 
 
Figure 37. The treatment of HUVECs with CoPP [10 µM, 12 hrs] strongly induced protein 
expression of HO-1. Western blot analysis was used to assess HO-1 protein expression in HUVECs in 
response to CoPP, a well-known inducer of this enzyme. The blot shows increased expression of HO-1 
following CoPP application. Treatment of cells with high glucose [HG, 33 mM for 5 days with intermittent 
recover periods] also caused increased expression of HO-1, however, it was weaker than COPP treatment. 
Western bot analysis was carried out by Odyssey image scanner from Li-COR bioscience. 
 
As expected, the treatment of HUVECs with CoPP [10 µM, 12 hrs] strongly induced the 
protein expression of HO-1. Furthermore, the incubation of cells with high glucose [HG, 33 
mM for 5 days with intermittent recover periods] caused a slight, but noticeable induction of 
HO-1 which was further potentiated in the presence of CoPP. High glucose is known to cause 
oxidative stress and as such, the small induction of HO-1 expression observed here is an 
	
	
119	
	
adaptive cellular response and considered as a marker of oxidative stress (Lee, Lee et al. 
2011). 
 
5.6 Assessment of HO-1 activity 
CoPP is arguably regarded as the most potent inducer of HO-1. It indirectly modulates the 
production of two factors involved in regulating the expression of HO-1, namely NrF-2 and 
Bach1. Bach1 is a basic leucine zipper transcription factor and is a heme binding protein 
which represses transcription of the HO-1 gene by binding to the AREs in the 5’UTR of the 
HO-1 promoter. CoPP induces an increase in the degradation of Bach1 protein with the 
resultant increased in expression of HO-1. Similarly, NrF-2 is also a member of the family of 
basic leucine zipper transcription factors, which is involved in protection against oxidative 
stress though its ARE directed induction of HO-1. CoPP induces an increase in NrF-2 levels 
by suppressing its degradation (Shan, Lambrecht et al. 2006). 
HO-1 utilizes CoPP, which is a heme analogue as a substrate to exert its protective actions 
through heme degradation products, CO, Fe++ and bilirubin (Maines and Kappas 1977). A 
method of detecting HO-1 activity is by assessing bilirubin levels in cell lysates; hence, a 
colorimetric bilirubin assay was used in this study to achieve this aim. 
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Figure 38. The treatment of HUVECs with CoPP [10 µM] for 12 hrs significantly increases indirect 
bilirubin levels which is reversed by SnPP co-treatment. Bilirubin assay, a colorimetric assay for 
detection of indirect bilirubin in cell lysates in HUVECs treated with HO-1 inducer CoPP [n=5]. Data are 
represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple 
comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control or indicated groups. 
 
HUVECs treated with 33 mM glucose for 5 days and CoPP [10 µM] for 12 hrs showed a 
significant increase in bilirubin levels compared to controls [P < 0.001], an effect which has 
been partially reversed by co-treatment with SnPP which is a specific HO-1 inhibitor 
[P < 0.05], indicating that the observed effects in bilirubin levels are originating from the 
heme catabolic action of HO-1. However, high glucose treatment alone also caused a 
moderate increase in bilirubin levels when compared to controls although not statistically 
significant. This latter result is in line with western blot analysis in [Figure 37] where there 
was a slight increase in HO-1 expression observed with high glucose incubation and is 
mainly an indicator of oxidative stress. 
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5.7 Exposure of HUVECs to high glucose [33 mM] for 5 days with 8 hrs 
intermittent recovery induces ER stress response 
To investigate the effects of fluctuating glucose levels on ER stress response in HUVECs 
model, cells were incubated with 33 mM glucose with intermittent recovery periods for 8 hrs 
over night for 5 consecutive days in the presence or absence of chemical chaperone PBA [10 
mM, 12 hrs]. TG [300 nM, 12 hrs] was used as a positive control for ER stress activation. 
Some control groups were incubated in medium containing mannitol instead of glucose at the 
same concentrations and for the same durations, to be used as a control for osmotic stress. To 
determine the activation of ER stress response, mRNA expression of key markers of ER 
stress, BiP, CHOP, and ATF-4 and, were assessed using real time qPCR [Figure 39].
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Figure 39. Treatment of HUVECs with high glucose [33 mM] for 5 days with 8 hrs recovery induced ER stress. Real time qPCR showing mRNA expression 
levels of ER stress target markers BiP [A], CHOP [B] and ATF-4 [C] [n=6]. RT-PCR analysis were carried out using 7500 Fast Real-Time PCR System and SYBR 
Green detection. Quantifications were realized according to the relative standard curve method and data represent relative expression of target normalized to loading 
control (β-actin). Data are represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.01, 
***P < 0.001 vs controls or indicated groups.
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As shown in the above figure, when HUVECs were treated with 33 mM glucose for 5 days 
with intermittent recovery periods for 8 hrs overnight, a significant increase in mRNA 
expression levels of ER stress markers BiP, ATF-4, and the pro-apoptotic CHOP was 
observed [P < 0.001]. Furthermore, when they were co-treated with the chemical chaperone 
PBA, these observed effects were significantly attenuated [P < 0.001], thus confirming an 
induction of ER stress. To exclude any osmotic effects high glucose may exert on cells, 
mannitol was added to normal untreated samples at the same concentration and duration as 
high glucose, which showed no significant effect on mRNA expression levels of the targets 
abovementioned, thereby eliminating the possibility of any osmotic stress in the observed 
effects with high glucose. 
 
5.8 HO-1 induction prevents high glucose-mediated ER stress activation 
in HUVECs 
To investigate whether HO-1 induction would have a protective role against high glucose 
induced ER stress, cells were incubated with 33 mM glucose  with intermittent recovery 
periods for 8 hrs over night for 5 consecutive days in the presence and absence of CoPP [10 
µM, 12 hrs]. TG [TG, 300 nM, 12 hrs] was used as a positive control for ER stress activation. 
Mannitol was used to control for osmotic stress. To determine the effect of HO-1 on ER stress, 
protein expression of ER stress markers, BiP, p-eIF2α, and ATF-4 were assessed using western 
blot analysis [Figure 40].
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Figure 40. HO-1 induction in HUVECs prevents high glucose induced ER stress response. Western blot analysis showing protein expression levels of 
ER stress target markers of BiP [A], peIF-2α [A] and ATF-4 [B] [n=3]. Signal strength was quantified using Odyssey image scanner from Li-COR and 
targets were normalized against β-actin.  Data are represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple 
comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 vs.  controls or indicated groups.
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As expected, HUVECs treated with 33 mM glucose for 5 days with 8 hrs recovery periods, 
showed significant increase in protein expression levels of ER stress markers BiP [P < 0.001] 
and ATF-4 [P < 0.01]. Furthermore, there was also significant increase in phosphorylation of 
eIF2-α [P < 0.001]. These effects were significantly reversed by co-treatment with chemical 
chaperone PBA, which is consistent with the real time qPCR analysis further suggesting that 
ER stress induction is likley involoved in this high glucose treatment model in HUVECs. 
Moreover, HO-1 induction by CoPP treatment similar to PBA, has prevented the effects of 
high glucose on BiP and ATF-4 protein expression [P < 0.001] and phosphorylation of eIF2-α 
[P < 0.01], indicating that HO-1 has an antagonistic effect against ER stress. Incubation of 
cells with mannitol, however, did not affect the expression in any of tested ER stress markers 
indicating that the effects of high glucose are related to its metabolic perturbations rather than 
osmotic effects. 
 
5.9 HO-1 induction and chemical chaperones prevent high glucose-
mediated oxidative stress 
Oxidative stress, which is a key factor in the development of endothelial dysfunction in 
diabetic vascular complications has been shown to be linked to hyperglycaemia 
(Tesfamariam and Cohen 1992). Thus, the effect of high glucose treatment on HUVECs was 
evaluated in that regards by determining O2- production using DHE fluorescence staining 
combined with flow cytometry analysis to determine the percentage of positive cells [Figure 
41]. DHE, also called hydroethedine is freely permeable through plasma membranes of living 
cells where it gives the cytoplasm a blue stain. If there is any ROS accumulation due to 
oxidative stress, this dye reacts with O2- and becomes dehydrogenated to ethidium which then  
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intercalates with DNA giving red stain. DHE is a highly specific and robust dye as it is very 
well retained inside the cells and can tolerates mild fixation.
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Figure 41. HO-1 induction by CoPP protects against high glucose [HG, 33 mM for 5 days with intermittent recovery]-induced O2- production in HUVECs. 
Figure shows representative flow cytometry analysis for cells stained with DHE: [A] Negative control [NC] is untreated; [B] Positive control [PC], H2O2 added at 100 
µM for 30 minutes; [C] High glucose [33 mM] for 5 days; [D] CoPP [10 µM] added 12 hrs before the last high glucose treatment; [E] PBA [10 mM] added 12 hrs 
before the last high glucose treatment; [F] Mannitol [33 mM] for 5 days as an osmotic stress control. Untreated unstained cells [not shown], stained NC, stained PC 
were used to set the gate for the p2 positive and p3 negative population of cells. Positive cells for ROS were then analyzed by flow cytometry using FACS CANTO II 
by BD bioscience using Diva 8.0 software. Data are represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison 
test. **P < 0.01, ***P < 0.001 vs.  control and indicated groups [N=4]. 
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The incubation of HUVECs with intermittent high glucose (33 mM) for 5 days caused a 
significant increase in ROS production compared to untreated cells [NC] [P < 0.001], which 
was significantly attenuated by CoPP treatment and reduced it below the control levels 
[P < 0.001]. Interestingly, the pre-incubation of cells with chemical chaperone PBA also 
significantly reduced ROS induced by high glucose to untreated levels [P < 0.01], 
highlighting the role of ER stress in this effect. To control for osmotic effect, mannitol was 
used at the same concentration and duration as high glucose group. Mannitol did not modify 
production of ROS indicating that the effects of high glucose are attributable to metabolic 
stress and not osmotic stress. 
NOX system is arguably regarded as one of the major sources of ROS production in 
endothelial cells in addition to mitochondrial electron transport chain, Xanthine oxidase, 
cytochrome p450, and dysfunctional or uncoupled eNOS. It is a complex system comprised 
of a membrane bound catalytic subunit gp91phox [Nox 2] and regulatory subunit p22phox, as 
well as cytosolic subunits, p40phox, p47phox, and p67phox, GTPase, and Rac. It is activated in 
endothelial cells by a variety of stimuli such as growth factors, cytokines, shear stress, 
hypoxia, and activation of some G-protein coupled receptors (El-Benna, Dang et al. 2009). 
Given its important role in the generation of ROS in endothelial cells, western blot analysis 
was used to assess the phosphorylation of one of the cytosolic key subunits of NOX complex, 
p47phox [Ser 345], in HUVECs exposed intermittently to 33 mM glucose for 5 days in the 
presence or absence of HO-1 induction [Figure 42]. 
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Figure 42. Exposure of HUVECs to high glucose (33 mM) for 5 days with intermittent recovery 
periods increased phosphorylation of NOX subunit p47phox [Ser345], and was reversed by addition of 
CoPP. Western blot analysis of phosphorylation of NOX subunit p47phox [Ser345] in HUVECs 
intermittently incubated with Mannitol, 33 mM glucose for 5 days or TG [TG, 300 nM] in the presence or 
absence of PBA [10 mM] or CoPP [10 µM]. Signal strength was quantified using Odyssey scanner from 
LI-COR bioscience. Data represents Phosphorylated form of p47phox is normalized to total p47phox. Data 
are represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple 
comparison test. **P < 0.01, ***P < 0.001 vs.  control or indicated groups [N=3]. 
 
To the best of my knowledge, I show here for the first time that HUVECs subjected to 
elevated glucose [33 mM for 5 days with intermittent recovery periods], exhibited a 
significant enhancement in the phosphorylation of p47phox regulatory subunit of NOX when 
compared to untreated control condition [glucose; 5 mM] [P < 0.001]; whereas, co-treatment 
of cells with CoPP has resulted in a significant reversal of such effect [P < 0.001]. 
Additionally, the induction of ER stress response by TG also enhanced the phosphorylation 
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of p47phox [P < 0.001], and this effect was prevented by pre-incubation of cells with PBA, 
again suggesting the involvement of ER stress in this oxidative process. 
 
5.10 HO-1 induction prevents high glucose-mediated apoptosis in HUVECs 
Considering the growing evidence that  inhibition of apoptosis is one of the major 
mechanisms underlying the cytoprotective functions of HO-1 and a critical player in the 
survival machinery of cells in many vascular diseases (Banerjee, Basu et al. 2012), and given 
the importance of cell oxidative stress and ER stress-mediated death in cellular dysfunction, I 
postulated that high glucose by leading to the activation of ER stress and oxidative stress will 
cause apoptosis that will in turn cause endothelial dysfunction. In this context, because I 
showed that HO-1 protects against both stresses induced by high glucose, I have further 
investigated the impact of their alleviation on cell death in HUVECs. 
Cells were incubated intermittently in 33 mM glucose for 5 days in the presence or absence 
of CoPP [HO-1 inducer] and/or SnPP [HO-1 inhibitor] and then apoptosis was detected by 
flow cytometry using a double labelling [Annexin V/PI] [Figure 43]. In addition, the 
enzymatic activity of caspases 3 and 7 has been measured using a luminescent assay [Figure 
44A], and the presence of cleavage in key apoptotic markers PARP, caspase 3 and caspase 7 
was analyzed by western blot analysis [Figure 44B]. 
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Figure 43. Induction of apoptosis in HUVECs treated with 33 mM high glucose for 5 days 
intermittently [HG], and was attenuated by HO-1 overexpression by addition of CoPP. HUVECs 
were double-stained with Annexin V and PI followed by flow cytometry analysis. Data are presented as a 
percentage of the cell population. [A] HUVECs in 5 mM [CTL] with no drug [NT] showed 5.73% double 
positive staining. [B] HUVECs in 33 mM for 5 days [HG] with NT showed 44.28 % double positive 
staining. [C] HUVECs in CTL with SnPP [20 µM for 12 hrs] showed 7.03 % double positive staining. [D] 
HUVECs in HG with SnPP showed 35.68 % double positive staining . [E] HUVECs in CTL with CoPP 
[10 µM for 12 hrs] showed 6.25 % double positive staining . [F] HUVECs in HG with CoPP showed 16.22 
% double positive staining . [G] HUVECs in CTL with CoPP+SnPP showed 6.41 % double positive 
5.73% 44.28% 
6.25% 16.22% 
6.41% 40.71% 
7.03% 35.68% 
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staining. [H] HUVECs in HG with CoPP+SnPP showed 40.71 % double positive staining. All values 
represent the means and SEM of three samples in an independent experiment, which was repeated three 
times with similar results that were analyzed by two-way ANOVA, followed with a Tukey's multiple 
comparison. ***P < 0.001 vs. controls or indicated group. 
 
Analysis of annexin V and PI staining by flow cytometry showed that in HUVECs cultured in 
33 mM glucose [HG], the percentage of double positive cells [apoptotic] significantly 
increased to 44.28% % compared to 5.3% % in HUVECs cultured in 5 mM glucose 
concentration [CTL]. Whereas the percentage of the double positive cells was significantly 
reduced to 16.22 % after adding CoPP. To ascertain that the effect observed with CoPP is due 
to HO-1 induction, SnPP, which is an HO-1 inhibitor, was added at the concentration of 20 
µM for 1 hour before exposing HUVECs cultured in high glucose to CoPP. The pre-
incubation of cells with SnPP caused a loss of the protective effect of CoPP against high 
glucose-mediated cell death with an increase in percentage of double positive cells to 
40.71%. 
To further investigate caspase 3 and 7 activity, a caspase 3/7 luminescent assay was used to 
assess caspase 3 and 7 activity in the apoptotic response that was observed in flow cytomerty. 
This test is based on the luminescence released upon oxidation of the aminoluciferin that is 
liberated from caspase 3 and 7 cleavage of the aminolucifrein-tetrapeptide conjugate 
substrate. [Figure 44A]. 
In addition, the presence of cleavage in caspase 3 and 7 in addition to downstream PARP was 
analyzed by western blot  [Figure 44B]. 
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Figure 44. High glucose [33 mM] of HUVECs for 5 days with intermittent recovery [HG] induce 
caspase 3 and 7 activation, and attenuated by HO-1 overexpression by CoPP. [A] Test on HG-induced 
caspase-3/7-activation [can not be distinguished by this assay] in HUVECs by quantification of substrate 
cleavage using luminescence-based assays provided by Promega [Caspase-Glo 3/7 Assay]. Cleavage of 
tetrapeptide DEVD [Asp-Glu-Val-Asp] by caspase 3 and 7 was monitored in HG treated cells in presence 
and absence of CoPP in relation to a non-treated sample [NC]. As positive control [PC], HUVECs were 
treated with staurosporine [1 mM for 3 hrs]. Data are presented as fold-increase in luminescence all 
samples treated and untreated compared to the PC [relative luminescence units; RLUs]. Data are 
represented as mean± SEM [n=4] and were analyzed by one-way ANOVA, followed with a Tukey's 
multiple comparison. ***P < 0.001 vs. controls or indicated groups. [B] Western blot analysis to detect the 
cleavage in caspase 3/7 and PARP. Cleavage is detected in HUVECs treated with HG, TG and H2O2 [100 
µM, 30 miuntes] and attenuated in presence of PBA and CoPP. 
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In line with cell death findings by Annexin V/PI labelling, the measurement of caspase 3/7 
activities with luminescent assay showed a significant increase in their activity in HUVECs 
cultured in 33 mM glucose for 5 days with 8 hrs intermittent recovery [HG] compared to 5 
mM glucose [NC] [P < 0.001]; whereas, cells pre-incubated with CoPP were significantly 
protected [P < 0.001] [Figure 44A]. 
Western blot assessment of proteolytic cleavage of caspase 3, caspase 7 and their 
downstream effector PARP, detected the cleaved active subunits of all three markers in 
HUVECs exposed to HG, further emphasizing the activation of caspase 3 and 7 and 
consistent with the above findings. Interestingly, this effect was also noticeable with TG 
treatment and was reversed by ER stress inhibitor PBA [Figure 44B]. Furthermore, the 
addition of PBA to HUVECs cultured in HG showed no cleavage of these markers similar to 
TG and PBA treatment, which suggests that ER stress induction is involoved in high glucose-
mediated cell death in HUVECs. In addition, HUVECs treated with H2O2 [100 µM] for 30 
minutes to cause oxidative stress, also enhanced cleavage of all three pro-apoptotic markers; 
while cells pre-treated with CoPP to induce HO-1 were protected indicating the important 
role of ROS in initiating cell death in endothelial cells. Equally important to note, HO-1 
induction by CoPP completely prevented the cleavage of all three pro-apoptotic effectors in 
HUVECs incubated with high glucose. 
To exclude the involvement of osmotic stress in this apoptotic response, cells were incubated 
with mannitol in the same fashion as glucose. Mannitol did not show any effect on the 
cleavage of the target proteins. 
Altogether, these data underscores the interplay between ER stress and ROS in the mediating 
high glucose-induced apoptosis in endothelial cells with highlighting protective role of HO-1 
induction against high glucose induced apoptosis of endothelial cells. 
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5.11 HO-1 induction protects against high glucose-induced cellular 
inflammation in HUVECs 
Inflammatory responses have been mechanistically linked to the production of ROS. Previous 
observations have indicated that hyperglycaemia triggers the generation of free radicals that 
in turn activate pro-inflammatory transcription factors such as NF-κB which is known to 
induce the up-regulation of several pro-inflammatory cytokines such as IL-6. There is 
accumulating evidence that links this pro-inflammatory action of ROS to high glucose-
induced ER stress in endothelial cells through an increase in production of AGEs (Wu, Wang 
et al. 2014) [Figure 45]. 
 
 
Figure 45.  Schematic representation of high glucose-induced inflammatory response in HUVECs 
mediated by AGEs, oxidative stress and ER stress. High glucose induces the formation of advanced 
glycation end-products [AGEs]. AGEs activates NOX with increase in ROS production, which in turn 
induces ER stress and inflammation by IRE-1 mediated activation of NF-κB and c-Jun transcription 
factors, which promoted the transcription of inflammatory genes. 
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Therefore, I have investigated the role of HO-1 induction against inflammation induced by 
ER stress triggered by high glucose. To this end, western blot analysis analysis was 
performed to detect the activation of two major pro-inflammatory pathways that are linked to 
ER stress and endothelial dysfunction , namely NF-κB and c-Jun N-terminal kinases [JNK] 
[Figure 46]. NF-κB activation was assessed by evaluating the phosphorylation of regulatory 
protein IKK-α/β, and JNK activation was assessed by evaluating the phosphorylation of c-
JUN.
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Figure 46.  HUVECs exposed to high glucose [33 mM] for 5 days with intermittent recovery periods [HG] shows increase in the phosphorylation of key 
inflammatory markers that are attenuated by HO-1 expression by addition of CoPP. [A], [B] Western blot analysis showing significantly increased 
phosphorylation of IKK-α/β and c-Jun with HG, TG, and H2O2 compared to untreated [CTL]. PBA and CoPP applications attenuated this phosphorylation. Protein 
expression of p-IKK-α/β was normalized against total IKK, whereas protein expression p-c-JUN normalized against β-actin. Signal strength was quantified using 
Odyssey scanner from LI-COR bioscience, and represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison 
test. **P < 0.01, ***P < 0.001 vs.  controls or indicated groups [n=4].  
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The treatment of HUVECs with 33 mM glucose for 5 days significantly 
increased the phosphorylation of inflammatory markers, IKK-α/β and c-JUN, compared to 
untreated cells [CTL] [P < 0.001]. Similar effect was observed with TG treatment . Effects of 
both high glucose and TG were completely ablated by chemical chaperone PBA [P < 
0.001], suggesting the involvement of ER stress response in these effects. Furthermore, CoPP 
treatment of HUVECs cultured in high glucose has significantly rendered the 
phosphorylation level of IKK-α/β [P < 0.01] and c-JUN [P < 0.001] to untreated levels, 
highlighting the protective role for HO-1 induction against cellular inflammation. To harness 
the relationship between oxidative stress and activation of inflammatory signals stress, 
HUVECs were treated with H2O2 [100 µM] for 30 minutes. Hydrogen peroxide caused a 
significant increase in the phosphorylation of IKK-α/β and c-JUN inflammatory markers [P < 
0.001]; whereas, cells pre-treated with CoPP significantly reduced this effect [P < 0.001]; 
thus suggesting that HO-1 induction by CoPP induces its anti-inflammatory effect through 
inhibition of oxidative stress. To exclude the involvement of osmotic stress in this 
inflammatory response caused by high glucose, cells were treated with mannitol in same 
fashion as glucose, which failed to modulate the phosphorylation levels of both IKK-
α/β and c-JUN indicating the effects of high glucose are independent of osmotic stress. 
To further explore the protective role of HO-1 in high glucose-induced cellular inflammation, 
HUVECs were intermittently incubated with high glucose for 5 days, or stimulated with TG 
[300 nM, 12 hrs] in the presence or absence of chemical chaperone PBA, CoPP or SnPP, then 
I assessed the expression of pro-inflammatory cytokine IL-6 that is promoted by the  
transcription factor NF-κB, both at the mRNA level by real time qPCR, and at the protein 
level by measuring secreted protein in conditioned culture media by ELISA [Figure 47]. 
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Figure 47. HUVECs treated with 33 mM glucose for 5 days with intermittent recovery periods [HG] 
demonstrated elevated IL-6 expression, this effect was abolished in the presence of CoPP. [A] IL-6 
mRNA expression normalized against β-actin in HUVECs incubated with high glucose [HG] or TG in the 
presence and absence of CoPP or PBA [n=6]. [B] IL-6 protein levels in conditioned culture medium 
[ELISA] from HUVECs incubated with high glucose [HG] in the presence and absence of CoPP or SnPP 
[n=3] (NC: untreated controls; PC: LPS 1ug/ml for 30 min). Data are represented as mean± SEM and were 
analyzed by one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.01, 
***P < 0.001 vs.  control or indicated groups. 
 
IL-6 mRNA expression has significantly increased in HUVECs when treated with 33 mM 
glucose treatment for 5 days intermittently, and TG [300 nM] for 12 hrs compared to 
untreated controls [P < 0.001]. Addition of PBA significantly attenuated this increase to 
control levels [P < 0.001], suggesting the involvement of ER stress in this process. Moreover, 
CoPP treatment also reversed this effect in cells treated with 33 mM glucose as well as TG, 
and significantly reduced expression levels of IL-6 to levels similar to untreated controls 
[P < 0.001]. The changes observed with ELISA are consistent with the qPCR result, as IL-6 
secretion levels in conditioned culture medium were significantly higher in HUVECs 
exposed to high glucose for 5 days compared to untreated controls [P < 0.001]. Additionally, 
addition of CoPP to cells exposed to 33 mM glucose resulted in IL-6 secretion levels similar 
to control levels; furthermore, when SnPP [10 µM], a heme analogue inhibitor of HO-1, was 
added 1 hour before CoPP treatment, this has significantly inhibited the protective effects of 
	
	
140	
	
CoPP. This latter observation indicates that the effects mediated by CoPP are ascribed to HO-
1 expression [P < 0.05]. 
 
5.12 Assessment of the effects of continuous high glucose treatment [33 
mM, 48 hrs] on the tube formation capacity of endothelial cells 
Perturbations in angiogenesis contribute to the pathogenesis of diverse clinical conditions 
involving endothelial dysfunction such as macro- and micro-vascular complications of 
diabetes mellitus (Kolluru, Bir et al. 2012).To mimic diabetes-related impaired angiogenic 
response in vitro, HUVECs were exposed to two different treatment models of high glucose 
at 33 mM concentration. In the first attempt, cells were kept in culture for 48 hrs 
continuously with no interruption. After the incubation period, cells were seeded on growth 
factor reduced extracellular matrix [matrigel] to assess the capacity of cells to develop 
tubules in 3 D matrix, and images were taken after 24 hrs [Figure 48]. HUVECs cultured in 
media supplemented with the LSGS tend to form these capillary like structures when seeded 
on matrigel, because one of the components of the serum supplement is the angiogenic factor 
FGF-β [3 ng/ml], whereas HUVECs in the absence of FGF-β fail to develop capillary like 
formations. Accordingly, untreated HUVECs grown in complete media [+FGF-β] was used 
as the positive control [PC], while cells in serum free media [-FGF-β] was used as negative 
control [NC], and all other treatment conditions were cultured in complete media with serum 
supplement. 
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Figure 48. Tube formation capacity is preserved in HUVECs treated with high glucose [33 mM] for 48 hrs. Matrigel assay was performed to assess the 
capacity of HUVECs to develop capillary like structures when exposed to 33 glucose for 48 hrs continuously, or TG [300 nM, 12 hrs] in the presence or absence of 
PBA. Length of the tubes formed was counted in 5 different blind fields, images are representative of 3 independent experiments [Image J software was used for 
quantification of images taken after 24 hrs]. NC: M200 media without LSGS (FGF-β); PC: M200 media with LSGS (FGF-β). Data are represented as mean± SEM 
and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 vs.k control or indicated groups[n=3].
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As shown above, when HUVECs were treated with TG [300 nM] for 12 hrs then seeded on 
the Matrigel matrix, they failed to form tube-like structures as opposed to its positive control. 
This effect was significantly reversed by adding the ER stress inhibitor PBA [10 mM] 
highlighting the role ER stress in hindering proper endothelial cell migration and proper tube 
formation [P < 0.05]. However, no impact on tube formation capacity was observed when 
HUVECs were incubated with 33 mM glucose for 48 hrs. This is consistent with the results 
in [Figure 34] where HUVECs exposed to glucose treatment with this method, failed to show 
any modification in the mRNA expression levels of key ER stress markers. 
However, when HUVECs were exposed to 33 mM for 5 days with intermittent 8 hrs recovery 
periods followed by the same procedure mentioned above for matrigel assay, a different 
outcome was observed [Figure 49]. Furthermore, CoPP was added to address the role of HO-
1 in endothelial cell tube formation capacity, where as PBA was added to assess the 
involvement of ER stress in the observed effects caused by high glucose treatment.
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Figure 49. Tube formation capacity was inhibited in HUVECs treated with 33 mM for 5 days with intermittent recovery periods [HG], and reversed in the 
presence of CoPP. Matrigel assay was performed on HUVECs after being treated with 33 mM glucose for 5 days with 8 hrs overnight recovery periods in absence 
and presence of PBA or CoPP. Length of the tubes formed was counted in 5 different blind fields [images are a representative of 3 independent experiments]. 
Quantification of images taken after 24 hrs was done by Image J software. NC: M200 media without LSGS (FGF-β); PC: M200 media with LSGS (FGF-β). Data are 
represented as mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.01 vs.  control or indicated 
groups [n=3]. 
	
	
144	
	
HUVECs treated with 33 mM glucose for 5 days with intermittent recovery periods [HG] 
showed a significant reduction in tube-like structures’ formation compared to positive 
controls. When PBA was added [HG+PBA], it attenuated the inhibitory effect of high 
glucose and showed a significant increase in tube-like structures formation compared to HG 
alone [P < 0.05], thus suggesting that the inhibitory effect on tube formation caused by high 
glucose was through ER stress induction. Furthermore, addition of CoPP caused similar 
effect to PBA with significantly increasing tube-like structures formation compared to HG 
alone [P < 0.01], highlighting the protective role of HO-1 in high glucose induced 
impairment of tube formation, and that oxidative stress is a contributing mediator in such 
impairment. 
As aforementioned, angiogenesis is a complex system that under normal physiological 
conditions is kept under control by an intricate balanced interplay between pro-angiogenic 
and anti-angiogenic molecules, and any disturbance between these mediators could lead a 
pathological condition of aberrant angiogenesis which could be either impaired or excessive 
(Tahergorabi and Khazaei 2012). 
VEGF is a key contributor in the formation of new blood vessels, as it can induce the growth 
of pre-existing blood vessels [angiogenesis] or de novo vessels [vasculogenesis], and hence, 
it is a fundamental factor for embryonic development and well as vascular repair. Of all the 
members of VEGF, VEGF-A is the most potent inducer of blood vessel growth known up to 
this date, with relatively high specificity to endothelial cells, where it plays its role in 
angiogenesis via a number cellular mechanisms by stimulating endothelial cells proliferation, 
differentiation and migration, increase in matrix metalloproteinase activity, creation of 
vascular lumen, and increase in vascular permeability working in concert with other 
angiogenic factors (Takahashi and Shibuya 2005). 
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Accordingly, given the importance of this angiogenic factor, it was evaluated in this study 
both at the mRNA and protein expression levels to assess its involvement in high glucose-
induced impaired angiogenesis as well as highlighting its role in the protective mechanism of 
HO-1 in high glucose conditions [Figure 50]. 
 
Figure 50. HUVECs treated with 33 mM glucose for 5 days with intermittent recovery periods [HG] 
caused a significant reduction in VEGF-A expression, whereas induction of HO-1 with CoPP 
significantly increased mRNA and protein expression of VEGF-A both in control cells and those 
exposed to high glucose [33 mM, HG]. [A] Real time qPCR showing mRNA expression levels of VEGF-
A in HUVECs incubated with high glucose [HG] in the presence or absence of CoPP [n=6]. [B] Western 
blot analysis to detect protein expression levels of VEGF-A in HUVECs incubated with high glucose [HG] 
in the presence or absence of CoPP [n=3]. Data represent normalized VEGF-A/β-actin expression. Data 
represents normalized VEGF-A/GAPDH relative expression. In [A] and [B], data are represented as 
mean± SEM and were analyzed by one-way ANOVA, followed with a Tukey's multiple comparison test. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs.  control or indicated groups. 
 
The above figure shows that there was a significant reduction in both mRNA and protein 
expression levels of VEGF-A following exposure of HUVECs to 33 mM glucose for 5 days 
with intermittent recovery periods compared to untreated controls [CTL] [P < 0.05]. 
Importantly, treatment of cells with CoPP significantly elevated both mRNA and protein 
expressions of VEGF-A in HUVECs treated with high glucose [P < 0.05, P < 0.01, 
respectively], which is consistent with the results of the metrigel assay presented above in 
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Figure 49. Of particular note, HUVECs exposed to 5 mM glucose when treated with CoPP, 
they also exhibited significant increase in mRNA and protein expression levels of VEGF-A 
[P < 0.01, P < 0.05, respectively], thus underscoring the role of VEGF in the pro-angiogenic 
mechanism of HO-1. 
 
5.13 HO-1 induction improves NO bio-availability in HUVECs exposed to 
high glucose accounting for improved endothelial function 
Although the mechanisms by which NO promotes angiogenesis are not fully elucidated, it is 
well established in literature that NO exerts its endothelial pro-survival activities by; 1]  
Inhibiting apoptosis; 2] Exerting anti-inflammatory effects;  3] Enhancing endothelial cell 
proliferation by increasing the expression of VEGF and fibroblast growth factor; 4]  
Enhancing endothelial migration  by stimulating endothelial cell podokinesis through 
dissolution of the extracellular matrix via the FGF-β induced upregulation of tissue 
plasminogen activator; 5] Antagonizing anti-angiogenic factors, and 6] Inhibition of 
oxidative stress (Dimmeler, Hermann et al. 1999; Rossig, Fichtlscherer et al. 1999; Dulak, 
Jozkowicz et al. 2000) 
There is consolidated evidence that VEGF stimulates the production of NO through two 
different signalling pathways, both of which converge over activation and phosphorylation of 
eNOS; 1] Phosphoinositide 3-kinase [PI3K] which activates eNOS via Ser/Thr kinase Akt; 2] 
Phospholipase-c/ inositol triphosphate pathway [PLCγ- IP3] which activates eNOS via 
calcium-calmodulin complex [Ca+2/CaM] (Forstermann and Sessa 2012) [Figure 51]. 
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Figure 51. A schematic representation of VEGF-A mediated NO production. Binding of VEGF-A to 
its receptor VEGF-R2 initiate two signalling pathways, namely PLCγ-Ca+2/CaM pathway, and PI3K-Akt 
pathway. Both pathways phosphorylate and activate eNOS at Ser117 activator residues leading to increase 
in NO production. 
 
According to my findings shown above in Figure 50, the addition of CoPP to HUVECs has 
led to significant increase in VEGF-A protein and mRNA levels, both in 33 mM and 5 mM 
glucose media, thus highly indicating the role of HO-1 overexpression in modulation of 
VEGF-A expression. In this capacity, it was of particular interest to investigate the role of 
HO-1 induction in the regulation of NO pathway with special emphasis on one of VEGF-
A/NO activation pathways mentioned above, namely Akt and eNOS [Figure 52]. 
Specifically, I used western blot analysis to assess the phosphorylation status of Akt and 
eNOS on activator residues, namely Ser473 and Ser1177, respectively. Moreover, I 
investigated the effect of exposing HUVECs to 33 mM glucose for 5 days with intermittent 
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recovery periods on this particular pathway, and I also assessed the effect of HO-1 induction 
under high glucose conditions in the presence of CoPP. 
 
Figure 52. Western blot analysis showing increased phosphorylation of Akt [Ser 473] and eNOS 
[Ser1177] in HUVECs treated with CoPP [10 µM, 12 hrs] compared to untreated control [CTL] and 
high glucose [HG]. [A] Basal phosphorylation of Akt. [B] Basal phosphorylation eNOS at Ser1177. [C] 
HO-1 protein expression in HUVECs treated with HG in the presence or absence of CoPP. Signal strength 
was quantified using Odyssey scanner from LI-COR bioscience and data represents normalized 
phosphorylated protein/total protein. Data are represented as mean± SEM and were analyzed by one-way 
ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 vs.  control 
or indicated groups. Blots are representative of 3 independent experiments and shows enhanced signal 
strength of p-eNOS, p-Akt and HO-1 with CoPP treatment. 
 
 
Western blot analysis showed that high glucose treatment [HG] did not affect the basal 
phosphorylation status of both eNOS and Akt compared to untreated controls [CTL]; 
however, HO-1 induction by CoPP caused a significant increase in their basal 
phosphorylation levels indicating an increase in enzymes activity even in the absence of any 
physical (e.g. shear stress) or chemical stimulation (e.g. Bradykinin) of the pathway. 
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Moreover, in order to consolidate the above findings of western blot analysis, NO production 
was investigated using Greiss assay for nitrite quantification, a by-product of NO metabolism 
[Figure 53]. 
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Figure 53. Greiss assay showing a significant increase in nitrite concentration [NO by-product] in 
HUVECs incubated in 5 mM glucose as well as 33 mM glucose for 5 days with 8 hrs intermittent 
recovery periods [HG] only in the presence of CoPP [10 µM, 12 hrs]. Data represents nitrite 
concentrations in conditioned culture media quantified from their spectrophotometric absorbance at 540 
nm. Data are represented as mean± SEM and were analyzed by one-way ANOVA, followed with a 
Tukey's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 vs control or indicated groups [n=4]. 
 
As expected, Greiss assay findings was consistent with western blot analysis, as it showed a 
significantly high nitrite levels when HO-1 was induced in HUVECs by CoPP compared to 
untreated controls and those incubated with high glucose indicating increased NO production. 
Consistent with impaired endothelial function, high glucose treatment modestly, but 
significantly, reduced the production of NO in HUVECs compared to control, which was 
revered in the presence of HO-1 inducer CoPP. 
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Put together, these findings suggest that the cytoprotective role observed in HUVECs against 
high glucose-induced ER stress, is partly due to an increase in the expression of VEGF-A and 
consequent activation of Akt/eNOS/NO cytoprotective pathway. 
 
5.14 Summary of key findings 
The key findings of my PhD work can be summarized as follows: 
• All stressors and inhibitors used in this PhD work were assessed against their dose- and 
time-dependent cytotoxic effects and for each chemical or stressor used, I have 
determined the most optimal conditions of utilization to preserve cell viability above 80 
%. 
• Optimal conditions for the induction of HO-1 using CoPP were determined to preserve 
cell viability. In addition, I ensured that the effects of CoPP are exerted solely through the 
induction and activation of HO-1 enzyme as evidenced by the significant increase in HO-
1 protein expression in western blot analysis as well the increase in indirect bilirubin 
levels in bilirubin colorimetric assay, which was significantly reversed by HO-1 inhibitor 
SnPP. 
• TG treatment of EA.hy 926 cells and HUVECs at the concentration of 300 nM for 12 hrs 
was successful in inducing ER stress response as indicated by increased expression of key 
ER stress markers at both mRNA and protein levels. 
• Continuous high glucose treatment for 48 hrs failed to induce metabolic stress in both 
EA.hy 926 cells [100 mM] and HUVECs [33 mM]. 
• When HUVECs were cultured in high glucose [33 mM] glucose for 5 days with 8 hrs 
overnight recovery periods, ER stress response was strongly induced as shown by the 
increase in mRNA and protein expression of key ER stress markers. This effect was 
completely prevented by HO-1 induction. 
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• In addition to ER stress induction, the intermittent treatment of HUVECs with high 
glucose [33 mM] glucose for 5 days caused an increase in oxidative stress which was 
prevented buy HO-1 induction and chemical chaperones [ER stress inhibitors]. 
• Intermittent high glucose treatment or TG treatment caused a significant increase in the 
phosphorylation of p47phox [Ser345] the regulatory cytosolic subunit of NOX complex in 
HUVECs. To the best of my knowledge, I demonstrate here for the first time that HO-1 
induction by CoPP or alleviation of ER stress by chemical chaperones normalized the 
phosphorylation of p47phox [Ser345] enhanced by TG or high glucose. 
• Exposure of HUVECs to high glucose caused an increase in apoptosis and the activation 
of several pro-apoptotic and pro-inflammatory signals. These effects were prevented 
when HO-1 was induced and in the presence of chemical chaperones aiming at improving 
the ER homeostasis. 
• The abovementioned effects of high glucose are related to metabolic stress responses and 
not to osmotic change in the culture media as indicated by the absence of any significant 
effects when mannitol was added to cells in the same manner as glucose. 
• HUVECs cultured in high glucose [33 mM] glucose for 5 days with intermittent recovery 
periods prior to seeding in Matrigel® matrix showed a significant reduction in tube 
formation capacity, an effect that was prevented by CoPP co-treatment and chemical 
chaperones. 
• HO-1 induction in HUVECs with CoPP was associated with a significant increase in NO 
production and increased phosphorylation of both Akt [Ser 473] and eNOS [Ser 1177] on 
activator residues. However, high glucose did not affect the basal phosphorylation of 
these two enzymes when compared to controls. Consistent with this observation, NO 
production was moderately reduced by high glucose; however, the treatment of cells with 
CoPP significantly increase its production. 
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6 Discussion 
The aim of this study was to investigate the role of HO-1 induction in protecting endothelial 
cells against ER stress-mediated endothelial dysfunction in a diabetes mimicked environment 
in high glucose conditions, an aim that was pursued by assessment of the molecular pathways 
potentially involved [oxidative stress, ER stress-mediated apoptosis and inflammation] and 
their impact on NO bioavailability and angiogenic capacity. In particular, exploring the 
crosstalk between oxidative stress and ER stress in the light of high glucose-induced 
endothelial dysfunction was within the scope of this study. 
The main finding of this project was that induction of HO-1 by CoPP resulted in the 
protection of HUVECs from high glucose-induced ER stress and subsequent endothelial 
dysfunction, featured by the improvement in angiogenic capacity associated with attenuation 
of oxidative stress, ER stress, inflammatory and apoptotic responses. Moreover, the role of 
VEGF-A was investigated to partially assess some of the molecular mechanisms involved in 
the disruption of the capillary forming capacity of HUVECs in response to high glucose 
treatment, and it was observed that its expression was significantly reduced by exposure to 
high glucose, and this anti-angiogenic effect was abolished by HO-1 over-expression. In 
order to further understand the molecular mechanisms involved in the modification in 
angiogenic response of HUVECs with high glucose and HO-1 induction, I investigated the 
activation of Akt/eNOS/NO pathway, however, it was not significantly affected by high 
glucose treatment at the basal level, albeit being significantly upregulated with HO-1 
induction by CoPP. However, NO production was moderately, but significantly, reduced in 
response to high glucose while HO-1 induction prevented this. 
In addition, I highlighted the presence of possible crosstalk between ER stress and oxidative 
stress by demonstrating the attenuation of ER stress in response to HO-1 overexpression. 
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6.1 Intermittent High glucose treatment induces ER stress response and 
oxidative stress in HUVECs 
It is well-established that chronic hyperglycaemia in diabetes mellitus causes endothelial 
dysfunction that is induced by oxidative stress (Giugliano, Ceriello et al. 1996) and ER stress 
(Zhong, Wang et al. 2012). In vitro, endothelial cells as well as different cell types from 
various species exposed in cell culture to high glucose concentrations above 5 mM, have 
been shown to demonstrate altered cell biology, viability and metabolic activity (Kassan, 
Galan et al. 2011). 
HUVECs primary cells and EA.hy926 endothelial cell line were the models of choice that 
were utilized to pursue the aims of this study as their advantages outweigh their 
disadvantages in meeting those aims. HUVECs provide the classical model for studying 
endothelial function both at the physiological and pathophysiological levels as they  represent 
a good study model for normal and abnormal angiogenesis, oxidative stress response, ER 
stress, inflammation and apoptosis-related pathways. In addition, they can be used to model 
several pathological conditions such as cardiovascular complications associated with diabetes 
and to study the protective effects of various pharmacological compounds and approaches. 
These cells have been shown to adequately demonstrate stimulation-dependent angiogenesis 
and key endothelial signalling pathways such as Akt/eNOS and VEGF-R responses. 
Furthermore, HUVECs are highly representative of the in vivo situation providing a more 
comprehensible idea of the actual physiological situation. However, disadvantages still exist 
in this cell model as they have a limited life span and enter into senescence stage after 10 
serial passages, in addition to non-reproducibility of results because HUVECs usually are 
obtained from different donors, and have a relatively high tendency for dedifferentiation with 
high passage numbers. On the other hand, EA.hy926  cells combine several advantages of 
having unlimited life span, high proliferative capacity, relatively consistent phenotypic 
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features across passages, reproducibility of results with the advantages of possessing the 
basic phenotypic features of typical endothelial cells such as the presence of Weibel-Palade 
Bodies, von willebrand factor [vWF] secretion, expression of ICAM, VCAM and E-selectin 
which are upregulated upon activation, and VE-cadherin expression in cellular junctions 
(Bouis, Hospers et al. 2001). However, since these cells were immortalized by fusion with 
adenocarcinoma cell line, their cell biology has been altered to a certain degree, and so 
becoming a less representative in vivo model. Taken together, this is why it was crucial in 
this project to utilize both cell models in order to overcome the disadvantages of each one of 
them. 
HUVECs and EA.hy926  cells were first incubated continuously in high glucose [33 mM for 
HUVECs and 100 mM for EA.hy926] glucose for 48 hrs (constant exposure), which did not 
result in ER stress induction or endothelial dysfunction in contrast to previous reports which 
demonstrated ER stress induction by high glucose treatment in  various cell types using  
lower concentrations and shorter durations than what was used in this project. A previous 
study conducted by Zhong, Li et al., (2012) on rat retinal Muller cell line (rMC-1) showed 
increased protein expression of ER stress marker BiP associated with an increase in the 
phosphorylation of eIF-2α after 24 hrs of incubation with 25 mM glucose. This study also 
showed an increase in ATF-4 and CHOP expression after 72 hrs of incubation with 25 mM 
glucose. Several factors may contribute to the differences observed between these findings 
and mine in this project: the difference in the cell type, glial cells vs. endothelial cells, the 
difference in the species, rat vs. human, and the culture conditions used to maintain the cells 
(DMEM supplemented with 1% FBS and 0.5%  BSA vs. DMEM supplemented with 10% 
FBS and no BSA in my study). 
Additionally, nither HUVECs nor EA.hy926  cells showed any sign of oxidative stress when 
exposed to high glucose using the abovementioned treatment model. This is in contrast to 
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another study conducted on calf aortic endothelial cells which showed  increased ROS 
production with constant 22 mM glucose treatment for 72 hours (Inoguchi, Li et al. 2000). 
Another study conducted by Ceriello, Quagliaro et al., (2002) showed that perfusion of 
isolated rat hearts with 33 mM glucose for 2 hours caused a significant increase of coronary 
O2- production. Such disparity in observations could be attributed to the difference in cell 
types and the experimental models used (in vitro vs ex vivo). 
It is now recognized that both hyperglycaemia at 2 hrs during an oral glucose challenge and 
glucose fluctuations per se are strong predictors of both cardiovascular disease (Bonora and 
Muggeo 2001), and micro-angiopathic complications (Shichiri, Kishikawa et al. 2000). In 
addition, there is growing evidence that acute increase of glucose levels is accompanied by 
oxidative stress generation (Ceriello 1997), which may contribute to the development of 
endothelial dysfunction (Tanaka, Gleason et al. 1999). There is also enough evidence to 
suggest that in vivo glucose fluctuations may be deleterious for endothelial cells and that this 
effect is, at least partly, mediated through oxidative stress. Similar to oxidative stress, 
fluctuations in glucose levels can also affect the onset of ER stress response. Therefore, in 
this study, I proposed an experimental model in which HUVECs were exposed to intermittent 
high glucose (33 mM for 18 hrs alternating with 5 mM for 8 hours for 5 consecutive days), a 
condition that partly mimics what actually happens in vivo in diabetic patients. This model 
was successful in inducing oxidative stress and endothelial dysfunction, which was featured 
by increased ROS production and apoptosis respectively. These findings are consistent with 
another study which showed induction of oxidative stress and development of apoptosis in 
HUVECs when intermittently exposed to 20 mM glucose [20 mM alternating every 24 hrs 
with normal 5 mM] for 14 day which was featured by elevation of oxidative stress markers 
nitrotyrosine and 8-hydroxydeoxyguanosine and increased caspase-3 expression and activity, 
respectively (Quagliaro, Piconi et al. 2003).In addition to the observation of increased ROS 
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production with intermittent exposure to 33 mM of glucose, I also investigated the role of one 
of ROS potential sources, NOX. This was addressed through assessing the phosphorylation 
of the p47phox subunit of  this enzyme complex. Interestingly, there was significant increase in 
phosphorylation of p47phox subunit suggesting an increase in  the activity of the enzyme. This 
observation is in keeping with what Maeda et al., (2015) reported when exposing HUVECs to 
22 mM glucose for 3 days alternating with normal medium [5 mM glucose] every 12 hrs, as 
they have realized a significant elevation in O2- production as well as significant upregulation 
of p22phox component of the NOX. This upregulation was diminished when the cells were 
transfected with p22phox siRNA to knockdown the expression of p22phox. Similarly, 
mitochondria may also be a source of ROS in HUVECs in response to chronic and 
intermittent glucose exposure, however, I did not investigate the potential role of 
mitochondrial dysfunction and its role in ROS production in the present project, and therefore 
it is recommended to directly address its role in future studies. 
Moreover, ER stress induction was observed in HUVECs when the cells were exposed to 33 
mM glucose for 18 hrs alternating with 5 mM glucose for 8 hrs for 5 consecutive days, and 
was featured by increased protein expression of BiP and ATF-4 and increased mRNA 
expression of BiP, ATF-4 and CHOP associated with increased phosphorylation of eIF2α. 
This is in agreement with another study conducted by Zhong, Wang et al., (2012) on 
pericytes from human retinal blood vessels, where ER stress was induced by subjecting these 
cells to 25 mM glucose intermittently for 8 days alternating between 25mM and 5 mM 
glucose. 
The observations in my study and other reports that ER stress and oxidative stress are 
induced by chronic and intermittent exposure of cells to high glucose rather than continuous 
exposure could be due to the fact that the repetitive shift from high glucose to normal glucose 
during glucose fluctuation induced an UPR and purturbations in the redox state inside the 
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cells, resulting in exaggerated expression and activation of the abovementioned ER stress 
markers as well as increased in ROS production. On the other hand, the absence of stress 
induction in HUVECs when treated with high glucose concentration in a continuous fashion 
could be attributed to the downregulation of glucose transporters, thus resulting in the 
decrease of glucose diffusion into the cells and eventually the lack the desired metabolic 
response. Another explanation is that during continuous exposure to high glucose, some 
metabolic variations induced by this constant situation might change or trigger feedback 
regulatory cell controls, partially counteracting the high glucose stress effect, whereas 
intermittent exposure to high glucose might reduce such adaptation, causing more 
pronounced stress induction. 
It is noteworthy that in another report (Felice, Lucchesi et al. 2010), ER stress induction and 
increased ROS production were realized in HUVECs when challenged with high glucose 
concentraions continuously without any interruptions exposure. This discrepancy in findings 
may be because the investigators used HUVECs that were obtained by in house isolation 
from single donor as opposed to the HUVECs utilized in the current project were obtained 
“ready to use” from Gibco pooled from different donors, so this may pose a difference in 
quality of the cells, proliferation potential, and their molecular response to stress in culture. In 
addition, in-house cell isolations are well known to face obstacles of comparing data with 
individual groups or over a long-term study due to the variability among the reagents and the 
procedures used to isolate cells. Nevertheless, there is not enough evidence as to why cells 
behave differently when challenged with intermittent versus constant glucose treatment and it 
is recommended that further work should be conducted in order to directly address this 
inconsistency. 
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6.2 HO-1 induction protects against high glucose-induced oxidative stress 
in HUVECs 
The cytoprotective roles of HO-1 have been studied extensively in recent years and shows a 
promising therapeutic potential against many cellular stressors. In this project I studied the 
role of HO-1 induction in HUVECs using CoPP treatment against high glucose induced 
oxidative stress, and my findngs showed significant reduction in ROS production. This is 
consistent with other reports that used CoPP (Li et al., 2011), or other methods to investigate 
the effect of HO-1 such as using HO-1 inhibitor SnPP with subsequent increase in ROS 
production (Castilho et al., 2012). On the other hand, induction of HO-1 was not necessarily 
met with the same response, as Bansal, Biswas et al., (2014) have shown increased ROS 
production and oxidative damage in response to hypoxia induced HO-1 upregulation. It is 
possible that HO-1 has localized into the mitochondria resulting to mitochondrial dysfunction 
due to interfering with the enzymes of electron transport chain. This is also in contrast to my 
observation that HO-1 induction by CoPP resulted in reduced phosphorylation of p47phox, 
suggesting that inhibition of the NOX activity is potential mechanism for the antioxidant 
effect of HO-1 against high glucose induced oxidative stress in HUVECs. In addition, the  
difference in the concentration of the drug used to induce the HO-1 could result in a different 
metabolic response. As an example, a study conducetd by Balla, Balla et al., (2000) which 
demonstrated the induction of cytoprotective pathways in endothelial cells through the 
induction of HO-1 at low concentrations of hemin, whereas Higdon, Benavides et al., (2012) 
showed an induction of oxidative damage and cell death response pathways with the 
development of endothelial dysfunction at higher concentrations of hemin. These findings 
highlight the importance of variation in concentration of the pharmacological inducer in 
dictating the cellular response, whether cyto-protection or cytotoxicity. 
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6.3 HO-1 induction protects against high glucose-induced ER stress in 
HUVECs 
In order to address the question whether there is a cross talk between ER stress and oxidative 
stress in HUVECs treated with 33 mM of glucose, I addressed two questions: 
1] Does HO-1 induction by CoPP alleviate ER stress? 2] Does the treatment of cells with the 
ER stress inhibitor PBA alleviate oxidative stress? 
According to my findings, ER stress induced in HUVECs in response to 33 mM of glucose 
for 5 days with intermittent exposure was abrogated by CoPP treatment which was associated 
with reduced protein expression of ER stress markers BiP, ATF-4 and reduced 
phosphorylation of eIF2α in addition to suppressed mRNA expression of BiP, ATF-4 and 
CHOP. The effect of CoPP on cell protection is known to be related to increased expression 
of HO-1, one of the antioxidant enzymes responsible for heme degradation by catalyzing its 
oxidation into biliverdin, CO and free iron (Lee, Lee et al. 2011). 
Alternatively, PBA treatment has resulted in a significant reduction of ROS production 
caused by the treatment of cells with 33 mM of glucose, thus suggesting the presence of 
molecular interplay between ER stress and oxidative stress. 
Other studies have tried to investigate the potential existence of interplay between ER stress 
and oxidative stress in a large array of diabetic models both in vivo and in vitro. A recent 
study where human aortic endothelial cells treated with high concentrations of dextrose used 
as diabetic model, reported an elevation of O2- anion, which was abrogated by α tocopherol 
antioxidant treatment, while PBA did not have a significant effect when added to cells alone 
(Mooradian, Onstead-Haas et al. 2016). However, when both drugs were used together there 
was a greater reduction in O2- levels as opposed to both drugs being used separately, 
therefore indicating the presence of synergism which could be interpreted as the ER stress 
reducer [PBA] having a potentiating effect over the antioxidant. Interestingly, the reverse was 
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not true where α tocopherol failed to abolish the effect of dextrose mediated-ER stress, when 
compared to PBA which reduced the expression of ER stress marker BiP and  the 
phosphorylation of eIF2α to control levels. These results are only partially in agreement with 
the findings in the present project, because although they underscore the interplay between 
ER stress and oxidative stress in the context of diabetes, it is an asymmetrical one as only 
PBA has potentiated the effect of antioxidants against oxidative stress but not vice versa, in 
contrast to my findings which highlights some degree of symmetry by demonstrating the 
antagonistic effect of HO-1 against ER stress on one hand, and the antagonistic effect of PBA 
against oxidative stress on the other hand. Nevertheless, since both drugs [CoPP and PBA] 
were not used in combination it is still unclear the nature of such interplay whether it is 
synergistic or additive.  
Indeed, the molecular mechanism[s] involved in the interaction between the two stressors 
was the subject of intensive investigation (Song, Scheuner et al. 2008; Malhotra, Miao et al. 
2008 ). In the present project, I have shown increased CHOP mRNA expression in HUVECs 
in response to 33 mM glucose treatment for 5 days with intermittent 8 hrs recovery periods, 
an effect that was alleviated by PBA treatment, underscoring the role of ER stress in CHOP 
expression mediated by high glucose. However, I did not assess the role of HO-1 
overexpression by CoPP treatment against this effect, nonetheless, I have shown that HO-1 
overexpression has reduced protein expression of ER stress marker ATF-4, and 
phosphorylation of eIF2-α, both of which are upstream markers to CHOP in ER stress 
signalling pathway, thus indicating albeit indirectly the antagonistic effect of HO-1 against 
CHOP. Although there is clear association and hence an interplay between ER stress and 
oxidative stress with the possible involvement of CHOP, yet again a detailed and more clear 
causal relationship remains to be further elucidated and more direct assessment of the effect 
of HO-1 on CHOP is still warranted to support this claim 
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Furthermore, both pharmacological drugs [CoPP and PBA] had salutary effects against 
apoptosis, inflammation, and improved angiogenic capacity when co-treated with high 
glucose, illustrating thus the interaction between ER stress and oxidative stress in the 
pathophysiology behind high glucose-induced endothelial dysfunction presented in this 
HUVECs model. 
Taken together, my findings as well as previous studies indicate that ER stress and oxidative 
stress are a highly inter-related pathophysiological processes which regulate a wide range of 
signalling pathways in the cell, demonstrated by the fact that the two stresses coexist with 
each other and reflected by the multi-functional and multilayered stress responses which 
target both ER stress and oxidative stress. The two cellular stresses profoundly affect normal 
physiology as well as many human pathologies, including metabolic, neurodegenerative, 
inflammatory, and neoplastic disease. However, to the best of my knowledge, this is the first 
study to highlight the alleviatory effect of HO-1 induction in HUVECs in high glucose 
induced ER stress, in addition to underscoring, the interplay between ER stress and oxidative 
stress induced in HUVECs in response to chronic and intermittent treatment with high 
glucose. 
Nevertheless, in spite of these exciting findings, a number of questions still remains: [i] how 
do ER stress and oxidative stress act on components at the molecular and cellular level to 
alter physiology? [ii] how do these stress responses cross-talk with each other in different cell 
types and disease models? and [iii] how can we design compounds and therapies that 
selectively target ER stress and/or oxidative stress in specific tissues/organs? Current 
investigations to tackle these puzzles are hindered by the complex nature of both ER stress 
and oxidative stress. More mechanistic and physiological studies using newly developed 
high-throughput technologies, a real-time in vitro and in vivo imaging system, and novel 
conditional genetic animal models are warranted. 
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6.4 HO-1 induction protects against inflammation in high glucose treated 
HUVECs 
Before I addressed the role of HO-1 induction in protecting HUVECs against high glucose-
induced inflammatory responses, I asked whether my treatment model of HUVECs [33 mM 
for 5 days intermittent with 8 hrs recovery periods] would elicit an inflammatory response in 
the cells, and whether this response is ER stress or oxidative stress related, or both. 
According to my findings, HUVECs subjected to high glucose exhibited a significant 
increase in the phosphorylation of two integral molecules of the inflammatory signal 
transduction pathways IKKα/β and c-Jun, in addition to a significant increase in the 
expression of the pro-inflammatory cytokine IL-6 both at the protein and mRNA levels. 
Moreover, to highlight the role of ER stress and oxidative stress in mediating an 
inflammatory response in HUVECs, cells were treated with TG and H2O2 respectively, which 
significantly increased the phosphorylation and expression of the abovementioned markers 
and this response was diminished by co-treatment with PBA and CoPP, respectively. 
Interestingly, when cells exposed to high glucose were treated with PBA and CoPP, the 
observed modification in the abovementioned target markers was abrogated suggesting the 
following: 1] The inflammatory response induced in HUVECs by 33 mM of glucose was ER 
stress and oxidative stress-mediated; 2] HO-1 induction exerts an anti-inflammatory action 
against high glucose-mediated inflammation. 
These data are in agreement with other published studies which demonstrated that high 
glucose concentrations in vitro induce inflammation in endothelial cells. One study has 
reported a significant increase of IL-6 secretion in HUVECs upon treatment with 30 mM 
glucose for 48 hrs in addition to increased expression of ICAM-1 adhesion molecule 
(Bryland, Wieslander et al. 2012). However, since they did not test the role ER stress in the 
process, the role of its involvement in inflammation can not be confirmed.  
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My findings are also consistent with another report that featured an increase in 
phosphorylation of IκBα, nuclear translocation of NF-κB p65 and increased expression of 
VCAM-1 in HUVECs in response to high glucose (25 mM) treatment at for 48 hrs (Yang, 
Han et al. 2013).  
Furthermore, the anti-inflammatory role of HO-1 overexpression illustrated in the present 
project in HUVECs treated with high glucose, is compatible with a previous study that 
investigated the role of HO-1 overexpression in transgenic diabetic mice and reported 
significant decease in the expression of IL-6 as compared to wild type diabetic mice 
associated with improved cardiac function in echocardiography (Zhao, Zhang et al. 2013). 
According to my findings, treatment of HUVECs with 33 mM of glucose for 5 days with 
intermittent 8 hrs recovery periods elicited an inflammatory process featured by the 
activation of two integral inflammatory signalling pathways: 1] JNK-AP-1 pathway 
represented by increased phosphorylation of c-Jun which is midstream between JNK and AP-
1. 2] IKK- NF-κB pathway represented by the increased phosphorylation of IKK. It is 
expected that downstream inflammatory transcription factors AP-1 and NF-κB are activated 
as a result, however, further and more direct investigation is required to support this claim. 
Interestingly, HO-1 anti-inflammatory role was illustrated in this project by observing an 
abrogation in c-Jun and IKK phosphorylation and hence their inactivation and this suggests 
that HO-1 exerts its anti-inflammatory action in part by antagonizing both of the 
abovementioned pathways. This is a crucial point to highlight especially that there are many 
previous studies trying to investigate the mechanisms of the anti-inflammatory action of HO-
1 both in vitro and in vivo, and to pinpoint which inflammatory markers are potential targets 
for the action of this enzyme. One study conducted by Soares et al., (2004) reported that HO-
1 induction exerted an inhibitory effect on NF-κB activity with the subsequent decrease in the 
expression of downstream effector cytokine IL-1 and adhesion molecules VCAM-1, ICAM-
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1, and E-selectin. More interestingly, they reported no change in IKK phosphorylation levels 
in response to HO-1 overexpression, which is in contrast to my findings, indicating that HO-1 
probably exerts its anti-inflammatory action through an additional pathway independent from 
IKK, which still remains to be elucidated. Moreover, they reported no change in JNK 
activation in response to HO-1, although c-Jun was not tested but this finding implies that c-
Jun was not affected by HO-1 overexpression, which is also inconsistent with my findings in 
the current project. This could be explained by the fact that phosphorylation of IKK requires 
an oxidative step (Kamata, Manabe et al. 2002), and since I showed an increase of ROS 
production in my HUVECs model in response to high glucose, one could speculate that high 
glucose-induced ROS would result in this phosphorylation. Furthermore, we would also 
expect that HO-1 by exerting its antioxidant effect caused the observed reversal in 
phosphorylation and hence the anti-inflammatory effect. With respect to JNK, although 
change in JNK activation has not been reported in response to HO-1 overexpression in the 
abovementioned study, they reported increase in p38 MAPK activation, which we could 
speculate, might have played a role in the molecular mechanism behind the anti-
inflammatory effect of HO-1 observed in their study [Figure 54]. However, more 
investigation is required in order to provide further insight over the molecular mechanism(s) 
involved in the anti-inflammatory role of HO-1 in endothelial cells. 
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Figure 54.  Molecular mechanisms behind the anti-inflammatory role of HO-1.  In the present project, 
I showed a reduction in the phosphorylation of IKK and c-Jun in glucose treated HUVECs [33 mM/5 
days+8hrs intermittent recovery] in response to HO-1 overexpression by CoPP. Since there are reports that 
one of the underlying molecular mechanisms for IKK phosphorylation is oxidative stress, we could 
speculate that HO-1 by counteracting this oxidative state has resulted in reduction in IKK phosphorylation. 
I have also shown HO-1 overexpression to alleviate c-Jun phosphorylation which is downstream to JNK, 
so this suggests that inhibition of JNK by HO-1 is a potential underlying mechanism.  
 
Another study investigating the anti-inflammatory role of HO-1 overexpression in mouse 
brain endothelial cells using CoPP treatment, reported an increase of NF-κB production in 
response to LPS stimulation. An effect that was reversed by pre-treatment with CoPP 
indicating an anti-inflammatory role of HO-1 overexpression, confirmed when this effect was 
abrogated by SnPP co-treatment (Shih and Yang 2010). This study is in keeping with my 
findings in showing the successful anti-inflammatory effect of utilizing CoPP in vitro to 
induce HO-1, however, although the target markers investigated in both projects are different, 
it would be safe to assume they are still congruent with each other as I have demonstrated the 
same effect with high glucose [inducer of inflammation] and HO-1 [anti-inflammatory] albeit 
through featuring a modulation in the phosphorylation of inflammatory marker IKKα/β 
which is upstream to NF-κB. However, if we were to assume that IKK was not modified at 
all, it would be probably due to the activation of two independent inflammatory pathways by 
LPS versus high glucose. 
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Additionally, I demonstrated the attenuating role of HO-1 on the phosphorylation of p47phox 
subunit and thus the potential inhibition in NOX activity associated with reduced ROS 
production which I would expect it to be one of the mechanisms behind the protective roles 
HO-1 plays against high glucose-induced inflammatory responses in HUVECs. However, 
further in depth investigation is required to consolidate this in addition to directly testing the 
biomechanics of HO-1 metabolic byproducts [CO, biliverdin, iron] in the context of high 
glucose-induced stress in endothelial cells. 
Taken together, it is clear that HO-1 exerts its anti-inflammatory action in endothelial cells 
based on a broad spectrum of molecular targets indicating the existence of a highly complex 
and intricate molecular interplay that requires further investigation to provide more insight 
over this mechanism. 
One of the main limitations in the above analysis is that adhesion molecules [e.g. ICAM-1, 
VCAM-1 and Selectins] expression levels have not been investigated which would be helpful 
in providing more insight on the mechanism of high glucose-mediated inflammation and on 
the mechanism behind HO-1 alleviatory role. 
Additionally, although I did not investigate the expression or nuclear translocation of the 
inflammatory transcription factor NF-κB in the present experimental design, I would 
speculate that it has been activated since it falls in-between p-IKKα/β upstream and IL-6 
downstream both of which show significant elevation. However, further and direct 
investigation of inflammatory transcription factors NF-κB and AP-1, and adhesion molecules 
ICAM-1, VCAM-1 and Selectins is still warranted in order to further validate these key 
findings. 
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6.5 Intermittent high glucose treatment [33 mM for 5 days] caused 
apoptosis in HUVECs: Critical role for ER stress and ROS 
My findings show that HUVECs when challenged by high glucose treatment at 33 mM for 5 
days intermittently, they enter into an apoptotice state. This is consistent with other studies 
which showed that chronic exposure of endothelial cells to glucose concentrations > 5.5 mM 
leads to glucose toxicity with the development of endothelial dysfunction, inflammation and 
induction of apoptosis, as the one reported by Kageyama, Yokoo et al., (2011) demonstrated 
in human coronary artery endothelial cells [HCAECs]. Their high glucose treatment also 
showed upregulation in TNF-R1 death receptor as well as elevation in TNF-α concentration 
in cell culture supernatants when measured by ELISA. My findings feature activation of 
inflammatory and apoptotic pathways, as demonstrated by increased activity of key markers 
IKKα/β and c-jun respectively, so we could speculate that TNF-α contributed 
mechanistically in the inflammatory and apoptotic responses observed in HUVECs in 
response to 33 mM glucose treatment for 5 days with intermittent 8 hrs recovery periods, 
however, direct assessment of these molecules is warranted to assert this claim. 
As mentioned earlier in the discussion, due to my observation of increased phosphorylation 
of IKKα/β, I have speculated that the downstream NF-κB was consequently activated and 
translocated to the nucleus for transcriptional activation of inflammatory markers which was 
supported by increased IL-6 protein and mRNA levels, this was also associated with 
increased apoptosis demonstrated by increased percentage of apoptotic cells in flow 
cytometric analysis, increased caspase 3/7 activity in luminescent assay, and by showing 
caspase 3/7 cleavage in western blot analysis. However, in contrast to this, other investigators 
have shown that inhibition of TNF-α induced apoptosis mediated by NF-κB activation 
(Wajant, Pfizenmaier et al. 2003). This disparity could be explained by the fact that while the 
NF-κB pathway negatively regulates the apoptotic program, ongoing apoptosis in turn 
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interferes with the activation of NF-κB through caspase-mediated cleavage of several of the 
components utilized by this pathway including NF-κB itself with its different subunits. 
Noteworthy, in most cases caspase-mediated cleavage results in release of fragments that can 
act in a dominant-negative fashion towards their non-cleaved counterparts. Thus, caspase 
action not only reduces the amount of signalling intermediates necessary to transduce NF-κB 
response, but also creates new peptides that actively interfere with NF-κB activation. 
Another study supporting the hypothesis that high glucose and TNF-α may work in concert 
to induce apoptosis in endothelial cells showed that these cells are more susceptible to TNFα-
induced apoptosis in a high glucose environment by showing a significantly higher 
percentage of cell death in high glucose [33 mM, 24 hrs] environment compared to the 
normal control group [5 mM] (Clyne, Zhu et al. 2008). 
In addition, it is crucially important to note that the abovementioned effects in HUVECs in 
response to 33 mM glucose treatment for 5 days with intermittent 8 hrs recovery periods were 
comparable to those observed with ER stress inducer TG and these effects were abrogated by 
PBA co-treatment in both cell groups challenged by high glucose or TG. This suggests that 
ER stress plays an important role in the pathophysiology behind high glucose-induced 
apoptotic response. This apoptotic response observed in HUVECs with high glucose 
exposure could be induced by TNF-α-ER stress interplay as previous investigators 
demonstrated reported ER stress induction with increased overexpression of ATF-4 and 
CHOP associated with elevation in TNF-α levels both at the protein and mRNA levels. 
Interestingly, the observed effects with TNF-α were abolished by ATF-4/CHOP siRNA  thus 
underscoring the role of ER tress in TNF-α activation (Chen, Gao et al. 2013). 
Taken together, although the findings in the present project as well as many previous studies 
support the role of TNF-α in high glucose induced ER stress, oxidative stress, inflammation 
and apoptosis in different cell models, I did not directly assess the participation of this 
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cytokine in HUVECs, therefore I recommend further direct assessment of TNF-α expression 
and secretion as well as TNF-α receptor silencing to delineate its role in high glucose-
induced stress in HUVECs. 
 
6.6 HO-1 induction in HUVECs protects against high glucose-mediated 
apoptosis: Cross talk between ER stress response and oxidative stress 
I demonstrated that induction of HO-1 by CoPP resulted in the protection of HUVECs from 
high glucose induced apoptotic cell death. In this study, I investigated the effect of HO-1 
induction in HUVECs exposed to 25 mM and 33 mM glucose for 48 hrs, which did not result 
in cell death [data not shown], as previously reported by other investigators (Piro, Anello et 
al. 2002). However, when HUVECs were treated with 33 mM glucose for 5 days with 8 hrs 
intermittent recovery periods, the percentage of cell death significantly increased, which was 
reversed by CoPP treatment. I have also shown there is increased IL-6 cytokine levels in 
response to high glucose concentration which was abolished by HO-1 induction. This is 
consistent with other reports that proposed that high glucose in vitro to have a role in 
apoptosis induced by cytokines (Mellado-Gil and Aguilar-Diosdado 2004). 
Various studies have explored the mechanism(s) by which chronic elevation of glucose 
causes endothelial cell damage, and suggest that oxidative stress induced by chronic exposure 
to high glucose can directly cause damage to endothelial cells mediated by an increased 
intracellular accumulation of ROS. The mechanism(s) of endothelial cells damage by ROS 
may be mediated by oxidizing nucleic acid, proteins, and membrane lipids (Circu and Aw 
2010). Eliminating oxidative stress could therefore have a direct protective effect on 
endothelial cell apoptosis. 
The assessment of O2- production in HUVECs treated with 33 mM glucose for 5 days with 8 
hrs intermittent recovery periods was carried out in the present project using flow-cytometric 
	
	
170	
	
analysis, with the evaluation of the effect of HO-1 up-regulation on this cellular response. 
Apoptosis was confirmed by showing increased caspase-3/7 activity in luminescent assay, 
enhanced cleavage of caspase 3/7 in western blot analysis and increase percentage of 
apoptotic cells in flow cytometry cell death assay. These cellular responses were abolished in 
parallel with the addition of the HO-1 inducer CoPP. The inhibition of HO-1 with SnPP IX 
unmasked the pro-apoptotic effect of chronic and intermittent high glucose and revealed the 
protection conferred by HO-1. HO-1 is an antioxidant enzyme responsible for heme 
degradation, which catalyzes its oxidation into biliverdin, CO and free iron (Maines 1988). 
Thereby, the mechanisms of action of HO-1 can be possibly explained by the elevated level 
of bilirubin, which has an antioxidant property via scavenging of ROS, and the production of 
CO, both of which have an anti-inflammatory effect and inhibit apoptosis (Ferris, Jaffrey et 
al. 1999). 
Moreover, according to my findings, treatment of HUVECs with 33 mM glucose for 5 days 
with intermittent 8 hrs recovery periods, induced ER stress as featured by increased 
expression of key ER stress markers both at the mRNA and protein levels (BiP, ATF-4) and 
phosphorylation/activation of eIF2α. In addition, I also demonstrated elevated mRNA levels 
of ER stress pro-apoptotic marker CHOP in response to high glucose treatment, which 
suggests the involvement of ER stress in high glucose-mediated apoptotic response in 
HUVECs. Although I did not test the effect of HO-1 directly on CHOP, I did demonstrate its 
general protective role over ER stress induction, suggesting that it would also alleviate the 
CHOP response. 
Taken together, my findings as well as most of the abovementioned studies support the claim 
that HO-1 exerts its anti-apoptotic effects likely by alleviating oxidative and ER stress related 
endothelial cell damage. Moreover, there is substantial evidence from previous studies that 
these effects are mainly executed through the metabolic byproducts of HO-1 namely bilirubin 
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and CO, however, one of the main limitations of my analysis is that I have not directly 
investigated the activity of these byproducts except for bilirubin levels following CoPP 
treatment, therefore further investigation is still highly warranted in order to provide deeper 
insight over HO-1 mechanism of action in providing its cytoprotective effects against high 
glucose-induced endothelial cell damage. 
 
6.7 HO-1 induction improves angiogenic capacity in high glucose treated 
HUVECs 
In order to investigate the protective role of HO-1 overexpression in HUVECs against high 
glucose mediated angiogenic impairment, I first examined tube formation capacity of 
HUVECs in response to 33 mM glucose treatment for 48 hours applied constantly as opposed 
to 5 days with 8 hours intermittent recovery periods. 
This was performed by assessing the differentiation capacity of HUVECs into capillary-like 
structure in a 3D extracellular matrix when cells were challenged by high glucose exposure at 
a concentration of 33 mM for 48 hrs. Though some reports demonstrate that high glucose 
incubations [30 mM] for 24 to 48 hrs induces apoptosis and disruption of tube formation 
capacity in HUVECs (Ho, Liu et al. 2000; Baumgartner-Parzer, Wagner et al. 1995), in the 
present study no statistical differences were observed in the tube formation capacity between 
cells incubated in 5 mM glucose or 33 mM glucose for 48 hrs. It may partly be due to the 
medium containing low concentration [2%] of serum used in this study. In support of this 
scenario, Gade et al., (1999) reported that the inhibiting effect of high glucose on endothelial 
cell growth could be observed only at serum concentrations as high as 20% but not when the 
cells were grown in the medium containing 2, 5 or 10% of FBS. Another possible explanation 
could be related to the model of high glucose treatment, where continuous exposure of the 
endothelial cells to 33 mM glucose for 48 hrs may not have been long enough to induce stress 
to the cells and therefore no negative impact on the tube formation capacity was noticed. 
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Additionally, the passage number has to be taken into consideration during analysis, as 
HUVECs in the abovementioned study was used between P4-7 whereas in the present project 
they were used up to P10, and this passage difference could play a role in producing such 
discrepancy due phenotypic modification with advanced passages, which could also explain 
the lack of inhibition of tube formation when HUVECs were treated with 33 mM glucose for 
48 hrs, albeit previously reported in other studies. 
However, when exposing HUVECs to 33 mM glucose for a period of 5 days with intermittent 
recovery periods, there was significant impairment in tube like structure formation in the 
Matrigel assay. Similar data reported by other investigators, showed significant impairment 
of the tube formation by EPCs after 4 days of culture in 25 mM glucose for 4 days (Chen, Lin 
et al. 2007). Although the treatment models are not identical [continuous vs intermittent], 
both resulted in similar impairment, this could be explained by the difference in cell models 
[HUVECs vs EPCs], as the proliferation potential and tube formation capacity are highly 
likely to vary between both models. Furthermore, a recent study supports this claim in 
showing that HUVECs possess a greater angiogenic potential compared to EPCs by 
demonstrating a greater in vitro tube formation capacity (Haug, Torio-Padron et al. 2015), so 
I would expect them to be more resistant to external stressors comapred to EPCs, and this is 
why it may have taken longer duration and higher concentration of glucose to disrupt the 
capillary like structure formation. Other explanations could be due to the difference in 
extracellular matrix used or technical differences in both protocols such as seeding density 
[50,000 vs 10,000], size of wells [24 well vs 96 well plates], or the type of growth factors 
included in the media [FGF-β vs VEGF]. Finally, as mentioned earlier in the discussion, the 
observation of angiogenic impairment in this study with 33 mM glucose treatment for 5 days 
with intermittent recovery periods could be due to the fact that chronic and intermittent 
exposure to high glucose elicited detrimental cellular responses and activated cell death 
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pathways that lead to inhibition of tube formation, a condition which partly mimics what 
actually happens in vivo in the diabetic milieu with respect to glucose fluctuations. 
Some reports have shown the interplay between high glucose and FGF-β mediated by 
increased TNF-α following glucose treatments [> 5mM], to disrupt tube formation capacity 
and angiogenesis (Clyne, Zhu et al. 2008). Accordingly, given that one of the components of 
the serum supplement used to supplement the M200 culture medium in my experiments is 
FGF-β [10 ng/ml], it would be expected that there was some sort of interaction between high 
glucose and FGF-β, thereby it is recommended to conduct a similar experiment in parallel 
with the substituting FGF-β for VEGF in culture media in order to either support or challenge 
this claim. 
Interestingly, other reports have shown that high glucose treatment of human aortic 
endothelial cells caused increased tube formation capacity compared to control levels of 
glucose [5 mM] (Madonna et al., 2016). This inconsistency in the behavior of endothelial 
cells to form tubes in reponse in response to high glucose could be caused by the difference 
in the cell models. One limitation with endothelial cells is that they are not identical, 
demonstrating phenotypic differences that have been identified between large vessel-derived 
endothelial cells, such as HUVECs, and endothelial cells of microvascular origin, such as 
human dermal microvascular endothelial cells, between blood and lymphatic vessels, and 
between arterial and venous endothelial cells. These differences are clearly manifested at the 
structural [e.g. fenestrated vs sinusoidal, density of tight junctions], functional [e.g. 
permeability, leukocyte trafficking], and organ specific levels leading to a broad-spectrum of 
responses to growth factors and inhibitors which vary considerably. Moreover, proliferating 
endothelial cells in culture undergo changes in activation state, karyotype, expression of cell 
surface antigens and growth properties, which further pronounces the discrepancy between 
different endothelial cell types (Jackson and Nguyen 1997).  
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A growing body of evidence suggests the pro-angiogenic effect of HO-1 when studied in an 
array of different endothelial cell models. Recently, it has been reported that HO-1 
upregulation in HUVECs resulted in a significant increase in cellular proliferation and 
formation of tube like structures in Matrigel assay (Kim, Park et al. 2015). This pro-
angiogenic effect was diminished by SnPP treatment confirming the pro-angiogenic effect of 
HO-1. These findings are in agreement with my results, which demonstrate the increased tube 
like structure formation in response to CoPP treatment. 
Moreover, the angiogenic effects of HO-1 upregulation were assessed in an in vivo study by 
measuring the capillary density in ischemic myocardium in a rat model of myocardial 
infarction. This study has reported an increased capillary density and regional myocardial 
blood flow in the peri-infarct myocardium in response to HO-1 induction, and it was shown 
to be mediated by increased VEGF expression and activity, and that these effects were 
abolished when rats were pretreated with SnPP. In vitro tube formation capacity was also 
assessed in this study using human coronary arteriolar endothelial cells in Matrigel assay and 
demonstrated that the tube like structure formation was significantly enhanced with HO-1 
induction and this effect was again diminished after pre-treatment with SnPP (Kaga, Zhan et 
al. 2005). 
Another interesting study which investigated the role of HO-1 in delayed wound healing in 
db/db diabetic dyslipidemic mice, showed significant increase in blood vessel and 
granulation tissue formation which led to enhanced wound healing in db/db mice infected 
with HO-1 adenovirus  compared to the db/db group (Grochot-Przeczek, Lach et al. 2009). 
These findings are consistent with the present study, which showed a significant disruption of 
tube formation by Matrigel assay due to chronic high glucose treatment and this effect was 
abrogated by HO-1 induction with CoPP treatment. 
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Taken together, the findings in  the present project supported by previous reports, highlight 
the significant pro-angiogenic role of HO-1 when tested both in vivo and in vitro in addition 
to underscoring its antagonistic effect on hyperglycaemia mediated impaired tube formation. 
In order to address whether there is a cross talk between oxidative stress and ER stress in the 
pathophysiology behind high glucose-mediated impaired angiogenic capacity, I used the 
chemical chaperone PBA which is known to alleviate ER stress by efficiently aiding protein 
folding. The Matrigel assay shows significant reduction in tube like structure formation in 
response to chronic glucose exposure and this effect was abolished by co-treatment with PBA 
resulting in a significant increase in tube formation to control levels. 
These findings suggests involvement of ER stress in the mpaired tube formation caused by 
high glucose treatment, as well as the existence of a cross talk between ER stress and 
oxidative stress as HO-1 induction by CoPP achieved the same effect as PBA. However, 
since both PBA and CoPP showed increased tube formation capacity, further investigation is 
deemed important to identify the nature of the interaction between them, whether it is an 
additive effect vs synergistic one and whether it is a two way or one-way causal effect. Other 
investigators highlighted the role of ER stress in aberrant angiogenesis in 
diabetes/hyperglycaemia. Bhatta et al., (2015) reported increased expression of ER stress 
markers BiP, ATF-4, p-eIF2α and CHOP in early outgrowth cells, which are a subtype of 
angiogenic progenitor cells, in response to high glucose exposure for 7 days which has been 
abolished by PBA treatment. Furthermore, the migration and colony forming unit capacities 
of these cells were significantly affected with chronic high glucose exposure, which again 
were abrogated by PBA treatment. 
These findings are in accordance to the findings in the present project where chronic 
exposure of HUVECs to high glucose was responsible for the upregulation of several ER 
stress markers in addition to impaired tube formation capacity, which was reversed by PBA 
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treatment. However, it is recommended to broaden the investigation in this area by silencing 
some key ER stress marker genes, and then assess the outcome on tube formation potential 
via Matrigel assay in order to support this observation with PBA treatment. Furthermore, I 
have studied only one step of the angiogenic process which is the capacity of endothelial cells 
to arrange in tube formations and differentiate into capillary like structures mimicking the in 
vivo process which is categorized under differentiation assays. However, in order to 
generalize my findings on angiogenesis it is highly recommended that other steps should be 
investigated as well, hence, endothelial cell proliferation assay by bromodeoxyuridine [BrdU] 
and modified Boyden chamber assays to assess endothelial cell migration are essential to 
support the observed effects of HO-1 on angiogenesis. 
 
6.8 HO-1 induction increases NO production and activates p-Akt/p-eNOS 
pathway in HUVECs 
After demonstrating the pro-angiogenic role of HO-1 overexpression in improving the tube 
formation capacity of HUVECs when subjected to high glucose in culture media, it became 
pivotal to investigate some of the potential molecular mechanisms and signal transduction 
pathways behind such improvement in endothelial function. In particular, I investigated the 
involvement of Akt/eNOS/NO cascade in this condition through assessment of Akt and 
eNOS protein phosphorylation, and NO production in culture media. Interestingly, my 
findings are in line with a previous study conducted on HUVECs that showed increased 
Akt/eNOS phosphorylation and NO production in response to HO-1 induction (Liu, Wang et 
al. 2015). However, they also demonstrated reduced Akt/eNOS phosphorylation and NO in 
HUVECs due to high glucose compared to controls, which is in contrast with the findings in 
the present project in that regards, as there was no statistically significant difference observed 
between control and high glucose conditions. This inconsistency could be attributed to the 
nature of the medium used to culture the cells as they used endothelial growth medium 
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supplemented with 10% FBS as opposed to M200 medium supplemented with LSGS [+2 % 
FBS] used in the present project. Furthermore, serum might interfere with protein 
phosphorylation in culture media as well as influence the purity of protein harvested from 
cells. Additionally, higher FBS concentration might also interfere with gene and protein 
expression of cells as well, which would alter their phenotype. Equally important to note, 
Akt/eNOS phosphorylation and NO production were diminished by biliverdin reductase 
knockdown, which indicates the direct effect of unconjugated bilirubin [by-product of HO-1] 
in the activation of this pathway. This is partially in agreement with the findings in this 
project as I demonstrated an increase in unconjugated bilirubin in response to CoPP treatment 
that has been reversed by HO-1 inhibitor [SnPP]. Taken together this underscores the 
activation of Akt/eNOS/NO pathway in response to CoPP treatment in HUVECs. 
However,  my findings show lack of any significant change in the basal phosphorylation of 
eNOS Ser1177 and Akt, despite the reduction of NO production in HUVECs in response to 
intermittent exposure to high concentration of glucose, which is in keeping with a previous 
study which reported no statistically significant difference in the phosphorylation of eNOS 
ser1177 or in NO production in HUVECs that have been challenged with intermittent 22 mM 
glucose for 3 days when compared to control (Maeda, Hayashi et al. 2015). This finding may 
suggest that the deleterious effects of glucose fluctuation observed in the endothelial cell 
model in the current project, cannot be solely ascribed to a substantial alteration in eNOS 
activation which under physiological conditions, is the primary source of NO as it is 
constitutively expressed within the endothelial cell. In contrast, other investigators have 
shown increased expression of inducible nitric oxide synthase [iNOS] by high glucose in 
endothelial cells, an isoform only induced under inflammatory stimuli with the consequent 
increase in NO production; however, the glucose concentration used was higher [> 33 mM] 
than those in my findings (Zhang, Fu et al. 2014), and inducers of iNOS, such as 
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lipopolysaccharides, were simultaneously used. Another study has shown no induction of 
iNOS by high glucose in the cultured endothelium (Guo, Chen et al. 2000). 
One possible explanation for the moderate yet significant alteration in NO production levels 
in HUVECs in response to high glucose treatments in the present project, is that there was in 
fact a marked increase in NO caused by induction of iNOS due to the inflammatory response 
induced by high glucose, but this increase was masked by the scavenger effect of increased 
ROS in the highly oxidative state caused by high glucose [previously discussed], generating 
ONOO-  instead. Hence, direct assessment of iNOS and ONOO-  is highly recommended to 
validate or invalidate this claim. 
It is noteworthy that sometimes in order to observe molecular modification in response to 
cellular stressors, cells must be subjected to specific stimuli such as bradykinin to increase 
basal phosphorylation levels of eNOS Ser1177 and Akt, at which point any significant 
alteration in their phosphorylation due to intermittent and high glucose treatments would be 
easily observed, however, in the present project, no bradykinin was used to stimulate the 
cells, which could explain the low basal phosphorylation levels of these two markers,  and 
hence it is highly recommended to conduct further experiments with the use of bradykinin to 
further assess the effect of intermittent and high glucose treatment of HUVECs on eNOS 
Ser1177 and Akt phosphorylation. Moreover, the medium I used to grow the HUVECs is 
lacking insulin like growth factor-1 [IGF-1], so it could be possible that both high glucose 
treated cells and control cells lack significant phosphorylation of eNOS and Akt given the 
absence of a powerful activator of Akt like IGF-1, which may also explain the low basal 
phosphorylation levels of  eNOS Ser1177 and Akt. 
Contrary to the above reports, other investigators have demonstrated significant elevation in 
eNOS phosphorylation and activity associated with increase in NO production in response to 
high glucose exposure. Hamuro and colleagues showed that HAECs treated with 30 mM 
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glucose for 36 hrs, which showed elevation in eNOS phosphorylation in addition to increase 
in NO production. 
Interestingly, they also reported impaired angiogenesis, which was presented by inhibition of 
endothelial cell migration, and improved by using eNOS inhibitor l-NAME, indicating the 
inhibitory effect of NO on endothelial cell migration and angiogenesis (Hamuro, Polan et al. 
2002). From earlier published reports, there was a controversy on whether NO has a positive 
or negative effect on endothelial cell migration and tube formation capacity. Increasing levels 
of NO have been shown in earlier studies to inhibit endothelial cell migration and tube 
formations (Gade, Andrades et al. 1997). In contrast, NO has also been shown to augment 
endothelial cell migration and tube formation (Murohara, Witzenbichler et al. 1999). This 
discrepancy in the results may be due to differences in endothelial cell types used, which as 
highlighted previously could play an important role in the differences in endothelial cell 
responses to various stimuli, or due to differences in the experimental conditions followed. 
Alternatively, different methods used to estimate cell migration/tube formations may be 
critical in the interpretation of results. For example, with respect to cell migration, results 
obtained from Boyden chamber method mainly reflect cell taxis, while wound healing 
method and phagokinetic track method reflect cell kinesis, it is possible that taxis and kinesis 
are regulated by different and independent mechanisms at molecular level. 
On the other hand, with respect to tube formation capacity, the differences in outcomes could 
be attributed to the type of Matrigel used whether it was regular Matrigel as opposed to 
growth factor reduced as it is well known the non-growth factor reduced has the tendency to 
stimulate gross tube formation, which could lead to skewed results. Technical differences 
may also contribute to the disparities in these reports such as well size, cell-loading density, 
and the Matrigel density used to construct the 3D matrix. 
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A previous study investigating the causal relationship between HO-1 and NO in endothelial 
cells, reported that the cytoprotective effects of NO in bovine pulmonary artery endothelial 
cells were directly linked to HO-1 overexpression by activating soluble guanylate 
cyclase/cGMP pathway, and HO-1 inhibitor SnPP abrogated these affects (Polte, Abate et al. 
2000). These findings together with the findings in this project underscore the existence of a 
molecular link between HO-1 and NO, which further consolidates the role of NO in the 
molecular mechanism for the cytoprotective role of HO-1 against the impairment of 
angiogenesis and endothelial dysfunction induced by high glucose. 
Moreover, in vivo studies conducted on diabetic dyslipidemic db/db mice further indicate that 
the cytoprotective effects of HO-1 induction against hyperglycaemia-mediated endothelial 
dysfunction are afforded by increase in NO production and increased phosphorylation of 
Akt/eNOS (Liu, Wang et al. 2015). 
In an attempt to expand the scope of my understanding of the molecular mechanisms 
involved in the improvement of tube formation capacity in response to HO-1 overexpression, 
VEGF- A expression in HUVECs was investigated. According to my findings, VEGF-A 
expression increased in response to HO-1 overexpression by CoPP, both at the mRNA and 
protein levels. These findings are in accordance with a previous report showing in mouse 
aortic endothelial cells, an increase in VEGF expression both at the protein and mRNA levels 
in wild type cells in response to HO-1 induction by hemin (Cisowski, Loboda et al. 2005). 
This effect was significantly diminished in HO-1 knockout [HO-1-/-] cells which supports the 
role of HO-1 overexpression in the molecular regulation of VEGF. 
Moreover, other investigators reported an increase in VEGF-A expression in human 
microvascular endothelial cells in response to CoPP treatment which was reversed by SnPP 
treatment indicating that VEGF-A expression was dependent on HO-1 expression (Loboda, 
Jazwa et al. 2005). 
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To emphasize the two-way relationship between HO-1 and VEGF-A, an interesting study 
conducted by Bussolati et al., (2004) on HUVECs and human microvascular endothelial cells 
reported increased HO-1 protein and mRNA expression in response to VEGF treatment for 
24 hrs. In addition, there was also an increase in the angiogenic capacity in Matrigel assay 
under VEGF treatment, which was reversed by SnPP highly indicating that the pro-
angiogenic effects carried out by VEGF are driven by HO-1. These findings put together, 
suggest the existence of a positive feedback mechanism between HO-1 and VEGF-A and 
interdependence between both molecules in promoting angiogenesis. 
My findings show an increase in VEGF expression associated with the activation of 
Akt/eNOS/NO pathway and increase in angiogenic capacity in HUVECs in response to HO-1 
induction, this is partially in keeping with a previous study, which reported VEGF-A 
treatment of HUVECs resulted in increased phosphorylation of Akt-Ser 473 leading to its 
activation. Moreover, improved angiogenesis on Matrigel assay was also observed, and 
interestingly this effect was abrogated by Akt siRNA treatment (Karali, Bellou et al. 2014). 
This underscores a possible molecular mechanism behind the HO-1-mediated increase in 
HUVECs tube formation capacity, where HO-1 might exert its pro-angiogenic action through 
VEGF-Akt-NO interaction. 
NO has been reported as a regulator of VEGF expression whether exogenous NO (Kim, Jung 
et al. 2000) or endogenous NO (Kimura and Esumi 2003); as such, we could speculate that 
the increase in VEGF-A expression that was observed in HUVECs in my study in response to 
HO-1 overexpression could be directly related to the increase in NO production; however, 
direct assessment of this causal relationship could be further validated by using NOS 
inhibitors such as L-NAME. 
In summary, my findings highlight the role of VEGF-A and NO for HO-1 to promote 
angiogenesis; however, although I have shown an increase in VEGF-A protein and mRNA 
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expression and NO production in response to CoPP, I would highly recommend using HO-1 
inhibitor or HO-1 siRNA transfection to support these findings. Moreover, claiming that 
VEGF-A contributes to the pro-angiogenic activity of HO-1 practically means that VEGF-A 
exerts an autocrine action on HUVECs, so I would also recommend measuring or quantifying 
VEGF-A in culture media, and VEGF-R2 siRNA transfection to confirm its role. 
Noteworthy, one significant limitation in the above analysis is the passage number of 
HUVECs as they were utilized up to passage 10, especially that HUVECs primary cells may 
lose their VEGF receptor expression with high passage numbers, which therefore warrants 
further investigation to identify cell surface VEGF receptors expression in HUVECs 
especially in advanced passages. Finally, further in depth investigation is recommended in 
order to completely understand the causal relationship between HO-1 and VEGF-A in 
promoting angiogenesis in HUVECs model in the context of hyperglycaemia. 
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7 Limitations of the study 
Although this project was carefully designed, I am still aware of its limitations and 
shortcomings. These limitations can be categorized into 3 different levels: 
 
7.1 Test subject 
Virtually one endothelial cell model was used to convey my hypothesis which is HUVECs 
primary endothelial cells. Despite how interesting the findings may be; it is recommended 
that more endothelial cell models be utilized for the purpose of reproducibility. In addition, in 
vivo projects are warranted to provide a broader generalization of the results. 
 
7.2 Study design 
• Although I used SnPP which is a HO-1 inhibitor to confirm the effects observed are 
actually due to HO-1 activity, there are early reports (Zakhary, Gaine et al. 1996) 
showing that it weakly inhibits eNOS and soluble guanylate cyclase which may result in 
skewed results, for that purpose it would be advisable to include another technical 
intervention to confirm the findings, like silencing HO-1 by SiRNA. 
• Although I demonstrated that ER stress, oxidative stress, apoptosis and inflammatory 
responses are induced in HUVECs in response to high glucose treatment in addition to 
showing impaired endothelial function, it is still recommended to establish a more 
detailed molecular link between the abovementioned stress responses and the endothelial 
dysfunction observed by inhibiting or gene silencing of key markers in these stress 
pathways. 
• Although I used chemical chaperones to show the involvement of ER stress, there is still 
controversy surrounding the mechanism of action and molecular interaction of PBA and 
TUDCA, and there are several other cellular factors could be at play when observing a 
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response, thus it highly recommended to use other approaches to assess ER stress such as 
gene scilencing key ER stress markers. 
• Passage number: Although it is generally acceptable in literature to use HUVECs primary 
cells in culture up to passage number 10, there are still some concerns that these cells 
might undergo morphological and behavioral changes, and differentiate into different 
sub-population of cells with different phenotype, which could lead to skewed results. For 
that purpose, it is recommended to conduct some cell identification assays like FACS 
sorting, especially for passage number 7 to 10. 
 
7.3 Statistics 
The sample size in some of the experiments in this project was n= 3 independent 
experiments, although this sample size gives a valid statistical significance, it is still 
warranted to increase the sample size to raise the bar for statistical significance. 
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8 Conclusions and future directions 
A) Conclusions 
This project posed three main questions: 
1) Does HO-1 overexpression play a protective role against high glucose induced 
endothelial dysfunction? 
2) Does this protective mechanism involve alleviation of ER stress pathway? 
3) Is there a molecular interplay between oxidative stress and ER stress in this 
endothelial dysfunction? 
To answer these questions: 
1) I used HUVECs as my model of choice for endothelial cells and subjected them to a high 
concentration of glucose [33 mM for 5 days with intermittent recovery periods of 8 hrs 
with normal glucose concentration, 5 mM] to induce endothelial dysfunction featured by 
increased cell death and impaired angiogenesis presented here by a lack of tube 
formation potential when cultured in 3D extracellular matrix. These effects were 
abrogated with HO-1 overexpression by using CoPP employed here as my 
pharmacological inducer of choice. 
2) For the second question, I demonstrated increased expression of key ER stress markers 
both at the mRNA and protein levels in response to the high glucose treatment, which 
was reversed with HO-1 overexpression. 
3) Finally, in answering the second question I also answered the third posed question, 
where the alleviatory role of HO-1 induction against ER stress illustrates the presence of 
a cross talk between oxidative stress and ER stress, since the primary well-established 
role of HO-1 is having an antioxidant property mainly through its metabolic byproducts. 
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This work contributes to current literature in underscoring the critical cytoprotective role HO-
1 plays in endothelial cells [HUVECs] when challenged by high concentrations of glucose 
[33 mM, 5 days] in culture medium. I have specifically demonstrated that HO-1 
overexpression by the pharmacological inducer CoPP results in the attenuation of oxidative 
stress, apoptosis and inflammatory response, in addition to enhancing the capacity of 
endothelial cells to form capillary like structures, which is one of the key features and 
important steps of angiogenesis. To the best of my knowledge, this the first study that 
highlights the possible antagonistic role of HO-1 against ER stress in the context of high 
glucose-induced dysfunction in endothelial cells. Moreover, my work also highlights the 
potential existence of a molecular interplay between ER stress and oxidative stress in 
promoting endothelial dysfunction observed in response to high concentrations of glucose. 
Finally, both HO-1 induction by CoPP and ER stress alleviation by PBA resulted in reduced 
p-p47phox expression, which may be a new mechanism for blocking NOX with the 
consequent abrogation of oxidative stress. 
The findings in this project brings us one step closer to understanding the molecular 
mechanisms behind the cytoprotective role of HO-1 in diabetic cardiovascular complications; 
nevertheless, it still remains compulsory for further investigations to be implemented on more 
variations of endothelial cell models in addition to in vivo studies in order to generalize 
comprehensively the findings in this project. 
 
B) Future directions 
I demonstrated in this project increased ROS production in HUVECs when treated with 33 
mM glucose for 5 days with 8 hrs intermittent recovery periods, which was associated with 
increased p-p47phox expression, the regulatory subunit of NOX enzyme  highlighting the 
crucial role this enzyme plays in this oxidative response. However, it is highly recommended 
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to investigate other subunits of this enzymes (gp91phox, p67phox, and p22phox) to assess whether 
they play a part as well in this process. In adddtion, it is crucial to identify the exact 
mechanism and Ser/Thr kinase involved in Ser345 phosphorylation in p47phox subunit of 
NOX in response to high and intermittent glucose treatment. 
Moreover, a cytoprotective role of HO-1 induction by CoPP was observed againset high 
glucose induced ER stress by demonstrating inhibition of integral ER stress markers 
expression, and against apoptosis by demonstrating reduction in caspase 3/7 activities 
associated with cell death inhibition. Therefore, it is essential to investigate the direct role of 
HO-1 expression against ER stress pro-apoptotic marker CHOP to assess whether the anti-
apoptotic effect of HO-1 is ER stress related or an independent molecular mechanism. 
It is noteworthy that future studies should focus on the mechanism of cytoprotective action of 
HO-1 in endothelial cells against high glucose induced endothelial dysfunction and metabolic 
perturbations, by directly investigating the role of HO-1 metabolic by products, particularly 
CO and bilirubin. 
Furthermore, in order to consolidate the pro-angiogenc effects of HO-1 expression in 
HUVECs, it is fundamental to investigate different steps of the angiogenic process in 
addition to differentiation and tube formation capacity, such as endothelial cell migration and 
proliferation using modified Boyden chamber and bromodeoxyuridine [BrdU] assays, 
respectively. 
Finally, I have demonstrated increased VEGF-A expression and NO production in response 
to HO-1 induction by CoPP, however, I highly recommend that future investigations would 
put more focus on the molecular link and the causal relationship between NO and VEGF-A, 
and to asses their role in promoting the angiogenic process observed with HO-1 induction, 
whether by silencing VEGF-A or inhibition of eNOS using l -NAME. 
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